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Abstract 
The development of any drug product is always guided by the goal of designing a 
product which complies with defined specifications at release and that is able to maintain 
its physic-chemical properties and stability within acceptable limits during its shelf-life. 
Therefore, the compliance with the principles of Quality, Safety and Efficacy depends on a 
meticulous and planned pharmaceutical development work. 
The present work focused on the formulation of a stable Nicorandil oral tablet 
dosage form, through a careful evaluation and choice of the Drug Substance, the 
excipients and selection of an optimized manufacturing process. 
Critical factors affecting Nicorandil stability were discussed and evaluated under a 
risk management strategy considering their importance to the stability of the drug product. 
Selection of excipients was done through a DS/excipients compatibility studies and 
single and total impurities were quantified by HPLC analytical technique, to select those 
who showed better chemical stability. 
Development of the formulation aimed to produce 10mg Nicorandil tablets, by direct 
compression of a homogeneous powder mixture and was conducted along four trials. 
Finished product pharmaceutical performance and chemical stability after a three 
months short term stability study, in ICH conditions, was evaluated and compared with a 
reference drug product. 
Statistical evaluation of the multiple parameters suggests that, in this period, there 
are no significant differences between test and reference, either in pharmaceutical 
performance or chemical stability. 
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Resumo 
O desenvolvimento de qualquer medicamento deve ser orientado para a obtenção 
de um produto que cumpra com as especificações definidas à data do fabrico e que 
mantenha as suas propriedades físico-químicas e de estabilidade dentro de limites 
aceitáveis durante o seu ciclo de vida. Por isso o cumprimento dos princípios de 
Qualidade, Segurança e Eficácia depende de um meticuloso planeamento do 
desenvolvimento farmacêutico. 
O trabalho apresentado teve como objetivo o desenvolvimento de uma formulação 
estável de comprimidos de Nicorandil, através de uma criteriosa caraterização da 
substância ativa, de uma escolha fundamentada de excipientes e de um processo 
otimizado de fabrico. 
Os fatores críticos que afetam a estabilidade do Nicorandil foram discutidos e 
avaliados no âmbito de uma análise de risco, considerando a sua relevância para a 
estabilidade do produto acabado. 
A seleção de excipientes foi feita recorrendo a estudos de compatibilidade destes 
com a substância ativa, usando a quantificação das impurezas individuais e totais 
recorrendo à técnica analítica de HPLC, para selecionar os que indiciavam melhor 
compatibilidade. 
O desenvolvimento da formulação teve como objetivo a produção de comprimidos 
contendo 10mg de Nicorandil, por compressão direta de uma mistura de pós homogénea 
e é constituído por 4 etapas. 
A avaliação dos comprimidos incidiu sobre o desempenho farmacêutico e sobre a 
estabilidade química após um estudo de estabilidade abreviado de 3 meses em 
condições ICH. Os resultados desta avaliação foram comparados com um produto de 
referência. 
A avaliação estatística dos dados gerados sugere que, neste período de tempo, não 
existem diferenças significativas entre o produto teste e o de referência, quer a nível de 
desempenho farmacêutico, quer a nível da estabilidade. 
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1. Theory and review of the literature 
Solid oral dosage forms and especially tablets for oral administration, are the most 
common pharmaceutical dosage form (1). Virtually ubiquitous, oral tablets, despite its 
apparent simplicity, demand a careful research and development process until being 
launched into market. Tablets, as well as any drug product, go through a design process 
until it assumes its final shape. This design process is called pharmaceutical 
development. 
The purpose of the pharmaceutical development is to demonstrate, through the 
compilation of scientific evidences, that the achievement of a specific formulation of the 
dosage form, composed by the drug substance (DS) and specific excipients and its 
manufacturing processes, robust and suitable for the intended use (2). 
The information and knowledge gained from pharmaceutical development studies 
include a variable number of test formulations with different compositions and 
manufacturing process trials using different process parameters. All of this data provide 
scientific knowledge to support the establishment of the design space, specifications, and 
manufacturing controls. Concerning the pharmaceutical development, two major 
sequential stages have an important role in drug development: pre-formulation, where the 
DS is studied and tested and the formulation, where the dosage forms is defined. 
1.1. Pre-formulation and formulation 
The development of any drug product requires an extensive chemical and physical 
characterization of the DS and excipients, which is the basis to set a proper strategy for 
the development process (3). The purpose of pre-formulation and formulation is to gather 
knowledge on the DS, excipients, manufacturing process and finished drug product to 
demonstrate the desired pharmaceutical performance, has predictable therapeutic 
response and stability of the final drug product throughout its life cycle. In other words, it 
means it has to demonstrate the necessary quality, safety and efficacy properties and still 
be able to be manufactured at an industrial scale. 
Pre-formulation is the first stage where the DS properties are investigated and 
where those which can have an impact on the formulation design are identified and 
studied, such as: crystallinity, solubility, chemical and physical stability and polymorphism 
(4). 
In this stage it is also necessary to evaluate and select adequate excipients to 
ensure an optimal performance of the drug product. Although, selecting excipients is not a 
straightforward process, since it must be demonstrated that they are chemical and 
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physically compatible with the DS. This issue is of utmost importance since it is directly 
related to the stability and quality of the final drug product (5, 6). 
1.2. Stability of drug products 
DS and drug product stability is an issue of major importance since it is a well-
recognized cause of poor drug product quality, safety and efficacy (7-9). 
A drug product can only remain in market while its quality profile comply with 
pharmacopoeial standards and manufacturer specifications, which have been previously 
approved by regulatory agencies. These specifications allow the establishment of the 
shelf-life period (10). 
Stability of drug products is directly related to patient safety. It is mandatory to 
present enough evidences of drug product stability to regulatory authorities to achieve 
market authorization. On the other hand, stability of the drug product is also related to 
economic success. 
Ultimately, instability of DS and drug products will cause many adverse reactions on 
patients due to the presence of degradation products and/or low efficacy, due to loss of 
potency. From the regulatory point of view, patient safety is the reason why DS and drug 
product stability are highly regulated through international standards and guidelines which 
helps to guarantee the necessary quality standards of the DS and drug product prior to 
market entry. 
By last, if a drug product with stability issues enters market it will most likely be 
subject to product recalls, bad publicity, low expiry date and high costs, either direct or 
indirect, to pharmaceutical companies. 
Eventually, every single drug product will chemically and physically change along its 
lifecycle, since chemical and physical interactions are unavoidable. Therefore, developing 
a drug product must take into consideration strategies to guarantee product stability and 
compliance with specifications as long as possible. 
A drug product is a complex system formed by molecules of DS and excipients. 
These molecules have specific structures and organic groups that will dictate the physical 
and chemical properties of the raw materials that they originate but also the properties of 
the finished drug product. 
These interactions are also influenced by external factors such as temperature, 
humidity, light or oxygen, manufacturing process, packaging material and transport and 
storage conditions. 
The main consequence associated with drug product stability is the increased level 
of toxicity that degradation products bring to the patients and therefore pharmaceutical 
Development of oral tablets containing Nicorandil  
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companies are bound to perform and report stability studies on their drug products (8, 9, 
11). These stability studies are performed initially during the pharmaceutical development 
stage but also along the product life time, while it remains on market. 
The initial stabilities studies will serve to propose an expiry date, or in other words to 
define the time during which the drug product complies with its critical quality attributes 
and is within the defined specifications. On the other hand, follow up stability studies and 
long term studies will serve to monitor and support the previously defined expire date. 
When addressing the stability of drug products it is necessary to specify that this can 
be chemical, physical and microbiological stability (9). 
Chemical stability is of major importance and can be evaluated and quantified 
through analytical procedures using different techniques. Identity, assay and impurity 
levels are mandatory parameters to be evaluated, since these parameters are the ones 
that can change under several factors, as already mentioned, but also due to interactions 
between DS (if more than one are present in the drug product) and between DS and 
excipients. 
Many chemical reactions are promoted due to catalysts substances present in the 
excipients, water molecules or micro-environmental pH. These chemical reactions can 
cause DS degradation, through mechanisms such as hydrolysis, oxidation, reduction, 
decarboxylation, ring cleavage, polymerization, polymorphic changes and photolysis, only 
to mention a few common examples (9). All of these potential degradation pathways lead 
to the appearance of degradation products related to a potential increase in product 
toxicity. This is why it is also necessary to achieve an adequate knowledge of the 
degradation process and to identify the degradation products formed (11). 
Other factors that influence the chemical stability are, for example, temperature, 
light, oxygen and excipients present on the formulation of the drug product, among others. 
Mechanical strengths like pressure/compaction forces, milling and grinding may also 
affect chemical as well as physical stability of the DS and drug products (9). 
Physical stability is related to the physical properties of the DS and excipients or 
alterations on these along drug product shelf life. Physical stability is related to drug 
product properties that affect its efficacy, such as solubility, dissolution, disintegration, 
resistance to crushing, friability, water content, polymorphic changes and 
crystalline/amorphous transitions (7, 12). Bioavailability is, therefore, dependent on this 
type of stability, since these properties are related to the in vivo performance of the drug 
product. 
Microbiological stability, although less critical in solid oral dosage forms than in other 
pharmaceutical forms, such as liquids or semi solids, must be monitored along the long 
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term stability study to ensure that proper limits, defined by compendial specifications, are 
respected. 
International guidelines are the standard information source to properly conduct a 
stability study which is essential to demonstrate that a product remains within allowed 
impurity levels. It is generally accepted by regulatory agencies a decrease up to 95% of 
the labelled DS amount during shelf life of a drug product, although, shelf life is mainly 
dictated by the level of degradation products (13). The International Conference on 
Harmonization, through its impurity guidelines (10, 14), specifies the reporting, 
identification, and qualification thresholds for impurities in drug products. A limit between 
0.1% - 1% of total and single degradation products is usually the interval in which the 
identification or qualification is mandatory (13). 
The stability assessment of drug products can be done using several strategies. 
Since it is not practical to perform an on-going (or long term) stability evaluation during 
product development, it became necessary to speed up testing times through accelerated 
stability studies in standardized conditions. These studies are often carried out both on the 
DS and drug products at temperatures from 25ºC up to 40°C, under relative humidity 
conditions from 60% to 75% (15, 16) and during a defined period of time. These type of 
studies are also known as isothermal stress testing (IST) (17). 
ICH long term, intermediate and accelerated conditions for these studies are defined 
in international guidelines and are 25ºC/60%RH, 30ºC/65%RH and 40ºC/75%RH (16). 
Although the prediction of shelf life can be based on studies under accelerated 
conditions, data at the recommended storage temperature are generally required to 
support the actual shelf life of marketed products and to confirm the results of the 
accelerated stability process (16), however, the use of statistics applied to the real time 
data should allow extension of shelf-life (18). A simple extrapolation can be done to 
predict shelf-life by considering that the shelf life determined at 40°C/75%RH is about 
one-fourth of that at room temperature. 
1.2.1. Solid state stability 
Solid state reactions are more complex and take longer than reactions which take 
place in solution state because in the solid state there are less number of molecular 
contacts between drug and excipient molecules and there are also multiple phase 
reactions which makes reactions in the solid state more difficult to interpret (19). 
These type of reactions can also be studied through the increase of temperature 
and humidity. Higher values of these two factors accelerate the speed at which 
degradation reactions take place, which on its turn increase the amount of degradation 
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products. Such strategy allows the quantification of these products on shorter time, which 
otherwise would take unpractical time to appear. The purpose of these studies is to have 
an indication of stability through data extrapolation, assuming that the degradation 
mechanism at higher temperatures and relative humidity levels is the same as that at 
25°C. 
1.2.2. Temperature 
Isothermal stress testing or degradation of samples at constant higher temperatures 
is kind of stress condition commonly used for compatibility studies (13, 20). It is based on 
the assumption that the kinetics of degradation reactions follows Arrhenius kinetics, which 
states the reaction rate dependence on temperature (13). However, this need not to be 
the case and a non-linear Arrhenius plot may be an indication of change of degradation 
mechanism as the temperature is increased. 
Extrapolation of shelf life is based on the assumption that a solid-state reaction 
follows Arrhenius kinetics and that an activation energy determined at higher 
temperatures can be used to calculate the rate and shelf life at room temperature. The 
assumption is valid if the reaction at higher temperatures also occurs at room temperature 
and follows the same degradation pathway and no irrelevant degradation products are 
formed meanwhile (18). 
A shift in the primary degradation processes is often indicated by the appearance of 
additional impurity peaks in the HPLC analysis or changes in the retention factor (Rf) 
values that are an indication of interaction or decomposition. Some authors state that if no 
interaction is observed at 50 to 60ºC, especially in the presence of moisture and air, none 
can be expected at lower temperatures (21). 
Therefore, usually more than one stressed condition is chosen to determine if the 
degradation reactions observed at elevated temperatures might be the ones which have 
such high activation energies that they occur only under pharmaceutically irrelevant 
conditions. 
1.2.3. Water Content and Hygroscopicity 
Moisture present in dosage forms may come from several sources: bulk active 
pharmaceutical ingredient (API), excipients, manufacturing processes and environmental 
conditions (9). The mechanisms of water interaction in solid state are related to the water 
molecule characteristics. Water is a molecule with particular characteristics thanks to the 
hydrogen bonds it can form with other molecules. Hydrogen bond is a type of electrostatic 
force that rules water properties in its physical states and also its interactions with solids.  
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Its small size, low weight, low density, high dielectric constant and ability to form 
hydrogen bonds make it a perfect plasticizer, or in other words, a molecular mobility 
increaser. 
The presence of water, or moisture, in a solid can promote reactions like hydrolysis 
and also increases solid state reactions rates due to its plasticizing properties (12) 
providing the molecular mobility required for reactions to occur between the two solid 
components (9, 12). 
Interaction with water happens at the surface of solids (adsorption) or when water 
penetrates a solid structure (absorption). These interactions with solids depend on the 
affinity of the solid for water, the temperature, air relative humidity and the area of the 
solid exposed (12, 19). 
Since water molecules are mobile and are rapidly attracted to charged areas with 
polar groups they will reduce the hydrogen bonds present, increasing the free volume by a 
dilution effect, decreasing viscosity and the Glass Transition Temperature (Tg), which is, 
as mentioned before, correlated to chemical reactivity. Water behaves as a reactant in the 
chemical reactions but also as a reaction media by adsorbing at the surface of the DS 
which causes its solubilisation and degradation. 
To evaluate the effect of water with a solid it is common to incorporate it directly in a 
sample of DS or a combination of the DS and one or more excipients (preparation of a 
slurry or suspension) or through a closed system with controlled relative humidity (climate 
chambers, for example) (5). 
Each of these methods has advantages and disadvantages. While the slurry 
experiments provides useful information for simulation and rapid assessment of aqueous 
sensitivity of the DS, they often do not simulate conditions in solid dosage forms, which 
could be important to interpret data retrospectively or during investigational compatibility 
studies (5). 
Moreover, the same amount of water in the air results in lower relative humidity at 
elevated temperatures. In contrast, incubation of samples under controlled humidity 
conditions ensures consistent maintenance of equilibrium moisture levels in the solid 
system, thus enabling investigation of degradation reactions where water acts as a 
medium or only to increase the molecular mobility of reacting species. 
In addition, storage of samples in constant humidity chambers (e.g., open-dish) can 
lead to increased induction times, thereby increasing the complexity of reaction kinetics as 
compared to water added as a slurry. 
The presence of water in raw materials can happen in two distinct ways. Water may 
be chemically bound or unbound. In the first case water is not available to interact 
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chemically. On the second case, however, water is available to react with other organic 
groups. 
Total moisture content is normally given by analytical techniques that do not 
distinguish between bound or unbound water, like Karl-Fischer test, for example. 
Unbound water, on the other hand can be determined by the water activity 
parameter or equilibrium relative humidity, which shows only the water that is free to 
interact. 
Water present in a crystal structure as a hydrate is held in place by hydrogen bonds 
and is not normally available for reaction, although, imperfections on the crystal lattice 
structure may also be naturally present or being caused by external factors and, in these 
areas of disorder, high rates of reactivity can be found. These imperfection or damaged 
areas of the crystal lattice represent amorphous regions which have higher free energy 
and as such have increased reactivity, especially when water concentrates on them.  
So it is also important to keep in mind that all solid state reactions also have a 
solution state reaction component. In molecules of DS or excipients that have some 
crystallization water (chemically bound water molecules incorporated in the crystal 
structure), mechanical processes such as grinding release these water molecules which 
become available to participate in degradation reactions, in other words, hydrolysis 
involve adsorbed water rather than chemically bound water. 
Excipients that preferentially bind to water equilibrate more slowly to higher levels of 
mobile water and consequently show greater chemical compatibility with a moisture-
sensitive drug (22). 
Some strategies to protect moisture sensitive products involve the control of 
environmental conditions inside manufacturing areas, film coating with moisture barrier 
products, selection of excipients that minimize contact with moisture and the selection of 
adequate packaging material with the ability to act as a barrier to moisture. 
Not all packaging materials are adequate to protect moisture-sensitive DS (e.g. 
Nicorandil). Water can still reach the drug product inside its primary packaging material by 
vapour transmission through the polymeric films, hence the need to consider the final 
primary packaging material since the early stage of the pharmaceutical development. 
1.2.4. Mechanical Stress 
Many pharmaceutical solids exist in a thermodynamically stable crystal form but can 
also contain metastable regions of amorphous material which may be induced during 
manufacture (23). It has been described that the molecular mobility of the amorphous 
regions of solids will be important in the determination of its physical stability (24). 
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Mechanical stress is often an unavoidable part of drug product manufacturing 
process, e.g., milling, grinding or sieving. These mechanical stresses may lead to the 
formation of amorphous pockets of drug or crystal defects in the crystalline drug molecule 
or to the increase of the intimacy and surface area of contact between the drug and the 
excipients in the mixture. Thus, mechanical stresses may lead to increased rates of 
degradation reactions (25). 
In amorphous solids or in amorphous regions of a crystalline solid, the net effect of 
water sorption is to lower the glass transition temperature (Tg), having a plasticizing effect 
in the material, promoting an increased molecular mobility and therefore inducing a higher 
chemical reactivity. The accelerated degradation rates are associated with the significantly 
lower activation energy for reaction in the amorphous state when compared to the 
crystalline state. Simulation of mechanical stresses in compatibility studies is often 
recommended when dealing with sensitive DS. 
The two major factors that need to be addressed on a Nicorandil formulation are the 
integrity of its crystalline structure and excipients moisture level. Typically, DS in the form 
of crystalline solids are more stable because they are in their form thermodynamically 
more stable, they have lower ground state free energy and consequently require higher 
energy of activation for the reaction to occur, which in practical terms means that 
degradation reactions take longer to evolve. 
While crystals are characterized by an organized molecular structure, the 
amorphous state does not have any type of molecular organization. Consequently, the 
amorphous state generally exhibit higher chemical instability, faster dissolution rate and 
greater hygroscopicity, which makes them more likely to degrade. 
When crystalline solids are processed under mechanical or thermal stress, such as 
milling or compaction, total or partial loss of crystallinity might happen with the consequent 
increased instability. 
Most solid state instabilities preferentially occur and start in the disordered non-
crystalline region of the solid. One key process in the amorphous state reactivity is the 
motion of molecules over a timescale, above or below its glass transition temperature 
(Tg). 
Motion is usually described as function of temperature, viscosity and molecular size 
and can take place in seconds, at and above Tg or months to years, bellow Tg. This is 
especially important because, molecules must collide with enough energy for reactions to 
take place and in the crystalline structure that mobility is less than in the amorphous state. 
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When crystalline solids are processed by mechanical means, there is a higher 
probability that fractures in the crystalline structure can happen, which create disordered 
regions where enhanced molecular mobility will occur. 
It is, therefore, crucial to keep the crystal structure of Nicorandil as intact as possible 
which is a major challenge since its particles and crystal structure are easily damaged by 
mechanical stress. 
2. DS / Excipients compatibility 
Excipients should not be regarded as inert materials. In fact, the choice of the 
excipients to include in a formulation must be justified (6, 20). 
An excipient is any substance other than active drug substance which has been 
appropriately evaluated for safety and is included in a drug delivery system to protect, 
support or enhance stability, or enhance any other attribute of the overall safety and 
effectiveness of the drug product during storage or use (26, 27). In the last decades, 
excipient manufacturers became increasingly aware of the demands of pharmaceutical 
industry to ensure that the patients are provided with a drug product compliant with the 
intended dosage consistent and safely (28) which is intimately related to eh choice of 
excipients. 
The technological evolution of today’s excipients, allow pharmaceutical companies 
many options to choose from, when developing a drug product of high quality, effective 
and safe helping to place on the market. The choice of excipients is of utmost importance 
to formulation scientists and this choice will dictate the future quality attributes of the drug 
product (20). 
Excipients and their concentration in a formulation are selected based not only on 
their functionality, but also on the compatibility between the drug substance and 
excipients. The choice of excipients for the compatibility study should be done considering 
factors such as the DS nature and its impurities, excipients and their impurities, 
degradation mechanisms and process conditions of the drug product. 
Incompatibilities will be visible in the form of changes in physical, chemical, 
microbiological or therapeutic properties of the dosage form, caused by undesirable drug 
substance interaction with one or more components of a formulation or even changes in 
the excipients. The most common indications of incompatibility are alterations in the 
colour or appearance of the drug product, changes in the mechanical properties (e.g. 
tablet hardness, dissolution performance, physical form conversion) and increase in 
degradation products (28, 29). 
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The rationale behind excipients choice and concentration should be based on 
compatibility studies which are conducted to predict the potential incompatibility of the 
drug and the excipients in the final dosage form. When developing a drug product with a 
low stability DS strategies to mitigate such instability can be adopted. 
A typical drug product development starts with some early pre-formulation studies to 
characterize the candidate drug and to determine which properties will be relevant during 
the development of the drug product.  
Pre-formulation data from solubility, stressed stability, excipient compatibility, and 
other pre-formulation studies may influence the selection of the formulation dosage form 
and excipients. The results may also influence the choice of manufacturing process. The 
pre-formulation data should also help to identify the critical material attributes and critical 
process parameters for each process step. 
Thus, methodical, carefully planned and executed compatibility studies can lead to 
savings in terms of resources and time delays associated with stability issues arising 
during late stage product development. The results from these studies can also be useful 
in determining the causes of stability issues if they happen at later stages in development. 
Design of compatibility studies involves the use of mixtures of DS with one or more 
excipients. 
These mixtures may be incubated at different stress conditions in the form of 
physical mixtures per se or after compaction. Often water is added in these systems to 
evaluate its role in accelerating drug–excipient interactions. 
The role of excipients in drug stability is widely known (9) and these effects can be 
the stabilisation or destabilization of formulations. Excipients can interact in formulations 
either playing as reactants or as catalysts. Additionally they can also provide moisture or 
change the microenvironment of pH. Excipients can be a source of moisture in a tablet 
matrix due to its high water content although it is often difficult to interpret the effect of 
moisture source from an excipient. A typical example is the effect of colloidal silica that 
can entrap water turning it unavailable to react but at the same time has been described 
as a degradation promoter in some drugs due to increased hydrolysis rate (9). 
The surface acidity can also be a factor that promotes increased degradation. This 
is caused by the carboxylic groups on the solid surface, for example. Microcrystalline 
cellulose is an example of an excipient that shows both higher acidity and high moisture 
level. 
Thus, compatibility studies involving grinding and compaction are helpful for 
moisture sensitive and low melting compounds, and also for DSs for which milling is 
envisaged for particle size reduction. Presence of water often accelerates degradation 
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kinetics. In addition, sorbed moisture can accelerate isomerisation and/or crystallization 
processes. 
One of the important goals of pre-formulation compatibility testing is to determine 
the feasibility of processing conditions, such as wet granulation and the moisture 
resistance need for packages. 
The selection of accelerated environmental storage conditions for compatibility 
testing is based on the nature of the API, and the expected stresses during the storage of 
the finished dosage form. These include storage at elevated temperatures, higher 
humidity, and exposure to UV irradiation, peroxides, etc. While the International Council 
on Harmonization (ICH) and the regulatory authorities provide guidelines on the selection 
of accelerated storage conditions for the finished dosage form for confirmatory stability 
studies based on the target label storage requirements, the selection of accelerated 
conditions for compatibility studies is at the formulator’s discretion. 
Prior to the start of the work a general literature review of Nicorandil was done. 
Topics searched were related to chemistry, degradation and impurities, pharmacological 
information, analytical information and formulation. 
3. Risk Management 
A risk management methodology is briefly addressed in this work. Regarding the 
risk methodology implemented and according to ICH Q9 Quality Risk Management (30), 
risk is defined as “the combination of the probability of occurrence of harm and the 
severity of that harm”. During pharmaceutical products development, risk is present at 
different levels, areas and depends on many factors. 
Quality risk management is a tool that ensures high quality standards of the drug 
product throughout its lifecycle since it increases product knowledge that allows the 
profiling of the risk at different stages of the development. Such strategies allow the 
identification and control of potential quality issues that can arise during development, 
manufacturing and commercialization of the drug product. 
This process is called risk assessment and consists of the identification and 
classification of hazards and the analysis and evaluation of risks associated with exposure 
to those hazards. 
Quality risk assessment begins by stating the problems associated with a given 
product and the steps that potentially can compromise product quality. 
An example of a typical risk classification system can be found in Table 1. 
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Table 1. Risk ranking system 
Low Broadly acceptable risk. No further investigation is needed. 
Medium Risk is acceptable. Further investigation may be needed to reduce the risk. 
High Risk is unacceptable. Further investigation is needed to reduce the risk. 
The risk assessment tool links material attributes and critical process parameters 
(CPP) to drug product Critical Quality Attributes (CQA’s) to correlate and evaluate the 
potential impact that each parameter will have on them. CQA’s are physical, chemical, 
biological or microbiological properties that should be within an appropriate limit, range or 
distribution, to ensure the desired product quality. CQAs are generally associated with the 
drug substance, excipients, intermediates (in-process materials) and drug product (2). 
Additionally, (CPP) are process parameter whose variability has an impact on a critical 
quality attribute and therefore should be monitored or controlled to ensure the process 
produces the desired quality. 
Risk assessment is typically performed early in the pharmaceutical development 
process and is updated during development when materials, process and product 
knowledge is obtained. 
Despite being a useful tool that helps to support scientifically strong product 
dossiers to regulatory authorities it is not always appropriate or necessary to use a formal 
risk management process. The use of informal risk management processes (using 
empirical tools and/or internal procedures) can also be considered acceptable. 
Prior to the start of the development process it was necessary to define the target 
profile so that a risk assessment and risk management strategies could be defined (31). 
Generally, a Target Product Profile (TPP), defines the product attributes and it is 
often expressed primarily in clinical terms, but should also include the pharmaceutical, 
technical, regulatory and commercial/marketing attributes required of the product. The 
TPP is based on the ideal product characteristics, which are considered to be desirable. 
For the product development process the Quality Target Product Profile (30) (QTPP) 
was selected based on the reference product characteristics, as it relates to the quality, 
safety and efficacy, as well as on the DS characteristics. QTPP is a prospective summary 
of the quality characteristics of a drug product that ideally will be achieved to ensure the 
desired quality, taking into account safety and efficacy of the drug product. 
For the purpose of this work, the potential critical quality attributes (CQAs) were 
evaluated considering the DS, excipients and drug product characteristics that can have 
an impact on drug product quality. Once identified it was possible to evaluated and control 
these characteristics. 
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Additionally, product and process design should be stated as early as possible, 
while identifying critical parameters and process monitoring and control helps to correctly 
guide product development. 
The selection of an adequate manufacturing process was based on all the 
information gathered and supported by a risk assessment used during all stages of the 
development to identify potential high risk formulation and process parameters so that a 
control strategy could be implemented. 
Based on the development layout a range of formulation and process variables were 
defined as robustness limits inside which variations are accepted without compromising 
quality safety and efficacy of the drug product. 
These CQA are considered priorities in the risk assessment evaluation. For this 
product, assay, degradation products, dissolution, content uniformity (CU), water content 
and hardness of tablets are identified as CQA’s that have the potential to be impacted by 
the formulation and/or process variables can influence product stability. 
Quality attributes that are not considered critical, such as tablets physical attributes, 
will be evaluated according to compendial standards and reference product 
characteristics. 
4. Nicorandil 
4.1. Background 
Nicorandil is a DS produced for the first time in 1984 by Chugai Pharmaceutical 
Co®. Ltd. Japan (32), company that still owns the marketing rights for Nicorandil. Chugai 
Pharmaceutical has licensed its production to companies such as Merck® and Sanofi-
Aventis® under the names of Dancor®, Ikorel® and Sigmart®, among other brand names. 
Nicorandil market sales represent several millions of euros in the last 5 to 10 years in 
Japan and across 11 countries throughout Asia and Europe. 
Nicorandil became a widely used anti-angina therapeutic agent since its launch in 
Japan in 1984 and in Europe in 1994. Ever since and after years of clinical experience 
worldwide, the safety record of Nicorandil continues to give physicians a reliable source of 
solutions to treat this major patient group (33) increasing the importance of this DS in the 
treatment of cardiovascular diseases due to the minimum effects on the dynamics of 
cardiovascular circulation and on cardiac functions (34). When administered twice-daily 
the dosage of Nicorandil ensures 24 hours control (35) and provides an effective and 
tolerable therapy for patients with angina, either as monotherapy in up to 80% of patients 
(36) but also in combination with other anti-angina therapies, without interactions or an 
increase in adverse reactions (37).  
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Nicorandil is a nitrate derivative of nicotinamide (nicotinamide ester) that has a dual 
mechanism of pharmacological action (38) and belongs to a group of medicines called 
vasodilators. 
Nicorandil widens the coronary blood vessels to increase the blood supply to the 
heart hence relieving angina effects. This effect is caused by its nitrate group which 
promotes venous relaxation through stimulation of guanylate cyclase (39). 
Another effect of Nicorandil is the widening of systemic blood vessels. This means 
that the total pumping effort of the heart is reduced (40). This effect is done through the 
opening of potassium channels caused by the nicotinamide ring (41). The combined 
action improves coronary blood flow to post-stenotic regions, reduces preload and after 
load and improves the oxygen balance in the myocardium. 
This characteristically pharmacological action makes Nicorandil suitable for the 
prevention and long term treatment of chronic stable angina pectoris and reduction of the 
risk of acute coronary syndromes in patients with chronic stable angina. 
The common initial oral dose is 10mg twice daily, increased as necessary to a 
maximum of 30mg twice daily. Bioavailability is about 75% to 80%. Nicorandil is rapidly 
and well absorbed from the gastro intestinal tract but food can decrease the rate of 
absorption. First-pass metabolism is not significant and Nicorandil molecule is only slightly 
bound to plasma proteins. 
Maximum plasma concentrations are achieved in 30 to 60 minutes after intake and 
are directly related to the dosage intake. Metabolism occurs mainly by de-nitration of the 
molecule through its side chain. A second degradation mechanism occurs through 
production of N-(2-hydroxyethyl)-nicotinamide eventually forming nicotinic acid. 
Further metabolisation of these products leads to the formation of water and vitamin 
B complex substances. Less than 20% of an administered dose is excreted in the urine as 
metabolites. Less than 2% of the dose is excreted via the biliary route and 10% of the 
dose can be found in plasma but is rapidly eliminated. The main phase of elimination has 
a half-life of about 1 hour. 
4.2. Reaction and Degradation Mechanisms 
Nicorandil molecule represents a challenge for the formulation scientist due to its 
properties which are dictated by its tridimensional molecular structure (42), crystalline 
lattice and composition in organic groups, which turns it in a stable molecule when 
unprocessed (43) but highly unstable once it is processed and included in a drug product 
formulation (44, 45). 
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Nicorandil molecule, as highlighted on Figure 1, has four organic groups: a pyridine 
ring (#1), an amide group (#2), a secondary amine group (#3) and a nitrate group (#4). 
 
Figure 1. Nicorandil organic groups 
The molecular structure of Nicorandil does not present chiral carbon atoms or 
isomerism and according to current knowledge it has no known polymorphs. 
Nicorandil molecule adopts a folded conformation, which is stabilized by 
intramolecular Van der Walls contacts between the carbonyl group oxygen atom and the 
nitrogen atom in the nitro group. Intermolecular hydrogen bonds and short contacts are 
observed (42). 
Besides the molecular folded conformation, Nicorandil is arranged in a crystalline 
pattern so that the Nitrogen atoms of the pyridine rings are close together with the atoms 
of C-CH2ONO2 neighboring group, at a distance 0.3367 nm, less than the sum of the van 
der Waals radii of C and N (0.3484 nm) (42). Plot atoms approaching Nitrogen and 
Carbon atoms can be regarded as the reaction center.  
This molecular structure and conformation, as illustrated in Figure 2 (adapted from 
reference 32), determines its major degradation pathway and the presence of substituents 
strongly influences its reactivity. 
 
Figure 2. Crystalline packing view of Nicorandil  
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Nicorandil, as a nitrate ester, mainly decomposes through a hydrolysis reaction 
which starts in the nitro ester bond (46). Besides this, the electron withdrawing functional 
group close to the ester bond which makes it a candidate for nucleophilic attack by 
hydroxide ions. This explains its strong degradation in presence of water or high relative 
humidity environments. 
Since amide bonds (also present in Nicorandil molecule) are less susceptible to 
hydrolysis than ester bonds (because the carbonyl carbon of the amide bond is less 
electrophilic due to the double bond of the Carbon-Nitrogen) and the leaving group, (an 
amine) is a poor leaving group, the first cleavage, occurs in the ester bond, releasing this 
way, the nitrate ion. 
These degradation reactions in aqueous solution follows a first order kinetic reaction 
either in alkaline or acid environment although it is faster in alkaline pH originating an 
intermediate product with an UV absorption spectra near 335nm (47). There are several 
known degradation products identified (Figure 3). 
 
Figure 3. Nicorandil main degradation products 
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The hydrolysis reaction of Nicorandil starts by the formation of an intermediate 
molecule (3-(4,5-dihydro-2-oxazolyl) pyridine)) (48) (Figure 4). 
 
Figure 4. Hydrolysis reaction of Nicorandil 
This reaction has been further elucidated (47) and explains the formation of the 
Nitrate ion (Figure 5). 
 
Figure 5. Hydrolysis of Nicorandil and Nitrate formation 
Along with the formation of the intermediate molecule (II), the nitrate ion is also 
formed. This reaction evolves into the formation of one of the major degradation products, 
N-(2-hydroxyethyl) nicotinamide, when the intermediate compound reacts with water 
(Figure 6). 
 
Figure 6. Intermediate compound formation 
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From this intermediate compound (III) nicotinic acid (V) and N-(2-hydroxyethyl) 
nicotinamide (IV) are formed, depending on conditions (47) (Figure 7). 
 
Figure 7. Degradation reactions sequence from intermediate compound 
Besides these known degradation impurities, Nicorandil has been described in a 
research paper as a molecule that participates in solid state quaternization polymerization 
reactions (49). 
The proposed structure for the dimer formed through this reaction is shown on 
Figure 8. 
 
Figure 8. Nicorandil dimer 
Further polymerization is possible through the additional bonds between Nicorandil 
molecules, forming additional degradation products. Nicorandil molecules can form 
dimers, trimers and tetramers, which have been described as degradation products in 
British Pharmacopoeia (2014) Nicorandil tablets monograph (revised). 
The polymerization reaction forms polymeric compounds between 40ºC and 70ºC 
which are soluble in water and insoluble in organic solvents. 
The general polymerization reaction is shown on Figure 9 (adapted from reference 
34). 
 
Figure 9. Nicorandil polymerization reaction 
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It has been described that this degradation is not as strong in acidic environments 
as it is in alkaline environments (41, 43, 46, 50), probably due to the low pKa of 
Nicorandil. 
Another factor that is associated with increased degradation is the damage induced 
on the crystal lattice of Nicorandil. Such damage can be induced by common operations 
associated with the manufacture of solid dosage forms such as milling, grinding or 
tableting.  
The disruption of the crystalline conformation is linked with a change in the free 
energy at the surface of the crystalline structure (surface energy) which means that more 
energy is available to participate or initiate degradation reactions (9, 51, 52). 
4.3. Critical Drug Substance attributes 
Considering the previous information and bibliographic search, DS attributes were 
selected and discussed regarding their critic level (Table 2). 
Table 2. Critical Drug Substance attributes assessement 
DS attributes Justification Is it a CQA? 
Particle size 
distribution 
Particle size distribution is a critical attribute since it can negatively influence 
blend homogeneity, solubility, dissolution and content uniformity of tablets. 
Yes 
Hygroscopicity 
Hygroscopicity is a property related to product stability since Nicorandil is 
sensitive to high moisture levels. Hygroscopic materials adsorb moisture from the 
environment into the formulation increasing the water molecules amounts 
available for reaction. Since Nicorandil is not hygroscopic this parameter is not 
considered a CQA. 
No 
Solubility 
Nicorandil is referred in manufacturer’s CoA as sparingly soluble. Solubility is a 
critical attribute since it can negatively affect dissolution and assay, therefore this 
parameter must be evaluated. 
Yes 
Water content 
Water content is a critical attribute since high levels of water on the components 
and drug product might induce higher degradation rates. Since Nicorandil 
presents low water content this parameter is not a CQA. 
No 
Chemical stability 
Nicorandil is an unstable molecule when processed and blended with other 
substances. Formulation development must be designed considering the factors 
that can promote degradation of Nicorandil. 
Yes 
Flowability 
Flow properties of the components of a formulation obtained by direct 
compression are always critical attributes and require further testing. 
Yes 
Polymorphism 
Nicorandil has no known polymorphs, therefore this parameter is not considered 
critical. 
No 
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5. Reference Product 
The reference drug product (RP) marketed is an uncoated, white, round, with 
faceted edges, weighing approximately 100mg and 200mg oral tablet with a label 
indication of 10mg and 20mg of Nicorandi, respectively. 
According to the public literature (53) the qualitative and quantitative formulation of 
the RP is described in Table 3. 
Table 3. Qualitative and quantitative composition of Reference Product 
Qualitative formulation Quantitative formulation 
Nicorandil 10% 
Mannitol 76% 
Corn starch 1% 
Croscarmellose sodium 5% 
Stearic acid 8% 
Nicorandil RP has a shelf life of 18 months when stored in a dry place below 25ºC 
and each blister strip should be used within 30 days of opening. Primary packaging is 
composed of hard tempered aluminium foil/ (Polyamide/aluminium/PVC) blister strips 
containing 10 tablets. Each tablet inside the blister is linked to a round disk with a 
desiccant agent (silica gel) placed on one side of the blister, as can be seen on Figure 10. 
 
Figure 10. Primary packaging material of Nicorandil 10mg reference product 
This type of design allows the control of moisture inside each blister pocket although 
once one tablet is removed all other will be exposed to air due to the communication 
channels linking each pocket. A detailed physical and chemical characterization of the RP 
is described in the pre-formulation section. 
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6. Patent landscape 
The pharmaceutical industry is prolific in generating intellectual property. The 
protection of such intellectual property is done through patents. A patent is an exclusive 
right granted for an invention (intellectual property) and lasts generally for a period of 
twenty years. Patents are territorial rights and only applicable in the country or groups of 
countries in which a patent has been filled or granted in accordance with the law of that 
country or according to the patent treaty established between groups of countries (54). 
Patents can be issued, for example, over DS, drug products or manufacturing processes. 
Patents are a valuable source of information not only to avoid infringement of third parties 
intellectual property but also because it describes previous work which is helpful to guide 
alternative, novelty approaches to formulate a drug product. 
With the purpose to collect support information to the present work on Nicorandil 
formulations and stability, a patent search was conducted and the selected documents 
studied are described on Table 4. 
Table 4. List of patents selected for evaluation 
Office Number Title Date 
USPTO 4,200,640 
Nitric Esther of N-(2-hydroxyethyl) Nicotinamide 
and Pharmaceutical Use. 
29 Apr 1980 
USPTO 4,803,213 
Method For Production of Stable 
Nicorandil Preparation. 
07 Feb 1989 
USPTO 4,822,808 
Method For Production of Stable 
Nicorandil Preparation. 
18 Apr 1989 
EPO 0 574 221 B1 
Pharmaceutical Stable 
Formulations of Nicorandil. 
15 Dec 1993 
EPO 1 001 773 B1 
Oral Solid Pharmaceutical Compositions Containing 
Nicorandil For a Modulated Release and the 
Process for their Preparation. 
06 Feb 2002 
Nicorandil synthesis is disclosed in patent USPTO 4,200,640. Additionally, this 
patent also proposes a few formulations for solid oral dosage forms containing Nicorandil 
to support that this compound can be formulated into different pharmaceutical 
formulations. 
Some examples of Nicorandil formulations proposed are described on Table 5. 
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Table 5. Examples of Nicorandil formulations described on patents 
Sublingual tablet (5mm diameter) Tablet for internal use (7mm diameter) 
Nicorandil 10% Nicorandil 10% 
Lactose  39% Lactose  44.5% 
Mannitol 50% Corn starch  20% 
Magnesium stearate  0.6% Crystalline cellulose  25% 
  Magnesium stearate  0.5% 
Total 50mg Total  100mg 
Hard capsules, 250mg (capsule number 3) Granules (1mm granules) 
Nicorandil 10% Nicorandil 10mg 
Lactose  88% Lactose  12710mg 
Magnesium stearate  2% Corn starch paste  280mg 
Total 200mg Total (per wrapper) 1000mg 
Specific advantageous use of excipients are described in other patens such as 
patent USPO 4,803,213 (also published as EPO 0 185 347 B1). In this patent the use of 
organic dibasic acids, namely, fumaric acid, oxalic acid, tartaric acid among others, are 
associated with increased stability of Nicorandil molecule, mainly against hydrolysis. The 
use of micronized sugar such as mannitol, lactose, glucose, maltose among others is also 
referred as a strategy to protect against compression forces. 
Stability improvement of Nicorandil, through the use of specific excipients and the 
recognition of the lack of stability of Nicorandil when exposed to humidity or compression 
forces are described in other patents such as Patent number 4,822,808 (USPO) (also 
published as EPO 0 230 932 B1). Besides the excipients mentioned in other patents the 
use of aliphatic saturated acids like lauric acid, miristic acid, stearic acid, among others, 
are also described as having stabilizing effect on Nicorandil. 
The instability of Nicorandil when compressed and the establishment of a direct 
relationship between higher compression forces and the decrease of assay is common to 
patents listed on Table 4. The protection of Nicorandil crystals against deformation and 
destruction has become in this way the purpose of the patents. 
Additionally, moisture is identified as a source for Nicorandil degradation and it is 
mentioned the relative stability of unprocessed Nicorandil against the instability of the 
same when exposed to even low relative humidity conditions. This has been addressed 
again on patent USPO 5,580,576 also published as EPO 0 574 221 A1 which specifies 
that the instability can happen even in the presence of low level moisture at room 
temperature and that three main factors are identified as degradation promoters: 
increased moisture level, increased temperature and storage time. Details are disclosed 
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regarding degradation, which is said to be progressive and caused by the hydrolysis of the 
ester bond that links to the nitrate group. This cleavage releases nitric acid that 
immediately decomposes into the nitrate molecule and N-(2-hydroyethyl)-nicotinamide. 
Patent EPO 1 001 773 B1 proposes the use of glyceride of a saturated fatty acid 
with more than 18 carbon atoms, which has a protective action against crystalline 
structure deformation under compression forces. This component is specified as glyceryl 
behenate. Despite being a patent which also aims to describe a release modification 
formulation it describes the immediate release quantitative composition of the reference 
product. 
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1. General aims 
The main purposes of this work were to develop a stable oral tablet containing 
Nicorandil and to study the effect of formulation variables and manufacturing process on 
the stability of the finished product. 
2. Specific Aims 
The specific aims are defined by the drug product quality target product profile 
(TPP) (Table 6). These specific aims are based on the profile characteristics of the drug 
product available on market worldwide. Some of the parameters were considered Critical 
Quality Attributes taking into account the influence that they could have on the stability of 
the DS. 
Table 6. Target Product Profile proposal for the finished product 
Parameter TPP Justification 
Is it a 
CQA? 
Dosage form and 
route of administration 
Oral tablet 
Same dosage form and  
route of administration as RP.  
No 
Dosage design Immediate release Equivalent type of DS release as the RP. No 
Dosage strength 10mg Same strength as RP. No 
Assay 100% w/w label claim 
Assay affects safety and efficacy. Formulation and 
process variables can affect assay therefore this is 
considered a CQA of the drug product. 
Yes 
Impurity level 
Total impurities on the drug 
product to be quantified after 
a 3 month stability study and 
at least comparable to the 
RP in the same conditions. 
Known impurities: NMT 0.5% 
Unknown impurities: NMT 
0.2% 
Degradation products affects safety and efficacy. 
Formulation and process variables can affect the 
formation of degradation products, therefore this is 
considered a CQA of the drug product. 
Limits defined are based on international guidelines 
(10) and consider the maximum daily dose intake of 
Nicorandil. 
Yes 
Dissolution 
Very fast dissolution profile 
(Q +5%) > 85%, 15min. 
Dissolution is critical to ensure therapeutic effect. 
Formulation and process variables can affect 
dissolution performance, therefore, considering the 
immediate release target profile this is considered a 
CQA of the drug product. 
Yes 
Water content As low as possible 
Water content can affect degradation rate and 
hence stability of the drug product, therefore this is 
considered a CQA of the drug product. 
Yes 
Hardness 
(Resistance to 
crushing) 
As low as possible 
maintaining minimum 
compendial standards for 
oral tablet dosage form. 
Proposed specification is  
20N – 60N 
Hardness affects safety and efficacy as it is related 
to increased product instability, therefore this is 
considered a CQA of the drug product. 
Yes 
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Table 6. Target Product Profile proposal for the finished product (cont.) 
Parameter Target proposal Justification 
Is it a 
CQA? 
Tablet shape Round, biconvex 
Size and shape are not critical attributes. 
Tablets dimensions chosen are similar to the RP. 
No 
Tablet 
dimensions 
7 mm 
Score and 
embossing 
None 
Score and embossing are not critical attributes. Tablet divisibility is 
possible in the 10mg strength although such purpose falls outside 
the scope of this work. 
No 
Colour and 
appearance 
White 
Color and appearance are not critical attributes although they are 
a long term stability indicator of physical incompatibilities and 
should be evaluated. 
No 
Weight 100mg 
Tablet weight can affect safety and efficacy since it is related to 
the uniformity of dosage unit. Weight is similar to the 10mg 
strenght tablet of the RP. Since it is a compendial routine test for 
tablets it is not considered a critical attribute for the scope of this 
work but must be neverthless evaluated. 
No 
Friability NMT 1.0% w/w 
Compendial routine test for tablets. Since tablet hardness is a 
critical quality attribute, friability must be monitored to avoid loss of 
structural integrity of tablets during handling and transport. 
Requires close monitoring. 
No 
Disintegration 
Tablets should 
disintegrate in more 
than 20s and less 
than 10 minutes 
Compendial routine test for tablets. Disintegration time has an 
impact on dissolution profile and hence on efficacy and 
bioequivalence of the drug product. Requires close monitoring. 
No 
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1. Materials 
1.1. Reagents 
All reagents used were of Analytical Purpose (AP) grade or HPLC grade. The 
method of preparation is the following: 
Mobile phase A for HPLC analysis: prepared with Water (u.p.):THF:TEA:TFA 
(989:3:5:3, v/v). Also used as a solvent for the preparation of samples for HPLC analysis. 
Mobile phase B for HPLC analysis: prepared with Water (u.p.):THF:TEA:TFA 
(979:8:5:8, v/v). 
THF: tetrahydrofuran; TEA: triethylamine; TFA: trifluoroacetic acid. (all from Merck®) 
HCl 0,1N: Served as dissolution media and was prepared by diluting 8.28mℓ of 
fuming HCL 37% per 1 liter of water R1. Confirmation of pH was done using a calibrated 
pH meter. 
0.05 M Phosphate buffer solution pH 4.5: Used as buffer solution in dissolution 
media and solubility testing. Prepared according to Ph. Eur. 4.4.3 by dissolving 6.80g of 
potassium dihydrogen phosphate R (Merck®) in 1000.0 mℓ of water R. The pH of the 
solution is 4.5. 
Phosphate buffer solution pH 7.0 R1: Used as buffer solution in dissolution media 
and solubility testing. Prepared according to Ph. Eur. 4.4.3 by mixing 250mℓ of 0.2M 
potassium dihydrogen phosphate R (Merck®) and 148.2 mℓ of an 8 g/l solution of sodium 
hydroxide R (Merck®). Adjust the pH if necessary. Dilute to 1000 mℓ with water R. 
1.2. Excipients 
Excipients that were used during pre-formulation and formulation studies are listed 
in Table 7. These are identified by their chemical name, brand names and supplier. 
  
                                               
1
 Water R. See Ph. Eur. for definition and specification. 
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Table 7. List of excipients used during development 
Non-proprietary name Brand name and grade Supplier 
Isomalt GalenIQ
®
 721 Beneo Palatinit
®
 
Pregelatinized Starch Starch 1500
® 
LM Colorcon
®
 
Sodium starch glycolate Vivastar
®
 PSF JRS Pharma
®
 
Sodium alginate Keltone
®
 FMC Biopolymer
 ®
 
Stearic acid Dub Microlub
®
 50 Stearinerie Dubois
®
 
Microcristalline cellulose Avicel
®
 PH102 FMC Biopolymer
 ®
 
Anhydrous Colloidal Silicon dioxide Aerosil
®
 / Syloid
®
 AL1-FP Evonik 
®
 / Grace
®
 
Mannitol, fine powder Pearlitol C25
®
 Roquette Pharma
®
 
Mannitol, coarse grade Pearlitol SD 200
®
 Roquette Pharma
®
 
Croscarmellose sodium AcDiSol
®
 FMC Biopolymer
 ®
 
Crospovidone Kollidon CL
®
 BASF
®
 
Sample preparation for compatibility studies 
Binary and composite mixtures of Nicorandil with excipients were prepared by 
weighing separately each component into 5mℓ glass vials or petri dishes where they were 
mixed together with rotation movements and the use of a spatula. Components were 
added in a 1:1 proportion. With the purpose of evaluating the effect of compression on the 
compatibility with excipients, Nicorandil was compressed with each excipient in a 
hydraulic press with 0,5 ton force and 5 ton force during 30s or 5min. Compacts were 
pulverized using mortar and pestle and the resulting powder was prepared according to 
the method described in the sample preparation for HPLC. Samples were prepared once 
and replicates were taken from the source mixture and analyzed. 
Pre-formulation and Formulation development studies 
In Table 8 a list of the equipment used can be found. All equipment used were 
calibrated by a certified entity. Analytical scales were verified regarding response in the 
working range before each use. All equipment responses were considered adequate at 
the time of usage. 
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Table 8. Equipment used 
Equipment Manufacturer 
pH meter inoLab pH Level 2P WTW 
Analytical balances 
(range: 0 – 210g; sensitivity: 0,01mg) 
Mettler Toledo XS205 
Module AR402 motor drive adapted with a universal gear 
and double cone mixer 
Erweka
®
 
Purelab Ultra Elga 
(ultra pure water source) 
Enkrott
®
 
Heating/ Drying oven Memmert
®
 
Vacuum heating oven Heraeus
®
 Instruments Vacutherm 
Pellet press and dies for FTIR 
Specadie System 
Specac
®
 
Climate chambers 
(25ºC/60%; 30ºC/65%; 40ºC/75%) 
Fitoclima® D1200 Pharma 
Votsch® 
HPLC systems 
VWR Hitachi Elite Lachrom and Shimadzu 
LC2010C systems with column oven (set 
up at 25ºC) and photodiode array detector 
2. Methods 
Pre-formulation and formulation studies must be necessarily supported by analytical 
methods to evaluate the performance and characteristics of the test products along the 
way. 
Analytical methods must be developed and validated to demonstrate that such 
methods are adequate for its purpose and that the results obtained are reliable and 
reproducible on the working range defined. Method validation are mandatory according to 
cGMP and extensively documented through international guidelines (55, 56). 
Several parameters are commonly determined during analytical method 
development and validation: selectivity/specificity, linearity in the working range, precision 
(repeatability, intermediate precision and reproducibility), accuracy, stability of solutions, 
definition of the detection and quantification limits. 
The present work used dissolution, UV and HPLC methods developed and validated 
in-house according to international guidelines (ICH) and the acceptance criteria used to 
evaluate method validation can be consulted in the Annex section. Calculation formulas 
used in the quantification are described in the Annex section. Whenever Ph. Eur. is 
referred as compendial source, version 7.0 is to be considered. 
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2.1. Statistical analysis 
Statistical analysis was done using IBM Corp. SPSS Statistics version 22.0. 
Dissolution tests were compared by one-way ANOVA and Tukey HSD post-hoc 
tests. For each sample group, a normality test was determined using the Shapiro-Wilk 
statistic and to determine the homogeneity of variance a Levene’s test was used. A value 
of p<0.05 was considered significant for all tests. 
Stability assessment was done by evaluating multiple variables associated with the 
chemical and physical stability of the dosage form. The chosen statistical tool for this type 
of data analysis was the cluster analysis (57). A Two Step clustering technique based on 
the between groups linkage clustering method was used (58). Criterion for the clustering 
was the Schwarz’s Bayesian Criterion (BIC) and the number of clusters was determined 
automatically. Measurement between data intervals was done using the squared 
Euclidean distance. Samples were automatically standardized by the software (Figure 11). 
 
Figure 11. Clustering evaluation parameters 
2.2. Solubility 
Solubility, in pharmaceutical terms, is the maximum amount of a DS that can be 
dissolved in a solvent in a given condition (59). The solubility of a DS is one of the most 
important properties that needs to be assessed early in the development process. 
The bioavailability of an orally administered drug depends primarily on its solubility 
in the gastrointestinal tract and its permeability across cell membranes. This forms the 
basis of the biopharmaceutical classification system (BCS) (60, 61) which can be used to 
establish in vitro / in vivo correlations between drug products. The solubility determination 
also supports analytical method development since a DS needs to be in the solution state 
to be quantifiable and provides information on the formulation development if there is the 
need use manufacturing processes or excipients that can improve solubility. 
Solubility of Nicorandil in purified water was determined according to the Ph. Eur. 
Section 5.11. – Characters section in monographs. Solubility test is done in several 
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sequential steps. The first step consists in weighing 100mg of the Nicorandil in a 
stoppered tube adding 0.1mℓ of the solvent. This solution is then shake vigorously for 
1min and placed in a constant temperature at 25.0 ± 0.5ºC for 15min. If the DS is 
completely dissolved it is considered very soluble (S>100mg/0.1mℓ). In the case of the DS 
is not completely dissolved the dissolution procedure is repeated by adding to the sample 
more 0.9mℓ (total 1mℓ) more of the solvent. This procedure is repeated in sequence with 
additional volumes of 10, 30, 100, 1000 and 10000mℓ until all DS is dissolved. 
According to the total volume added the DS is classified in terms of solubility 
according to Figure 12. 
 
Figure 12. Solubility classification according to Ph. Eur. 
2.3. Dissolution 
Dissolution is the dynamic process by which DS is dissolved in a defined solvent 
and it is characterized by the rate at which it dissolves versus time. In vitro dissolution 
testing serves many purposes: it guides the formulation and product development process 
toward optimization; to assess BA/BE studies; to monitor drug product performance during 
stability testing or quality control release, for example. One of the requirements to conduct 
an appropriate dissolution test is to use a sufficient volume of dissolution medium, which 
should be able to dissolve the expected amount of drug released from a drug product. 
2.3.1. Sink conditions evaluation 
According to the Ph. Eur. sink conditions are met for a DS when 3 to 10 times its 
solubilization volume are above the saturation volume. Nicorandil sink conditions were 
assessed in three dissolution media covering the relevant physiological pH of the GIT (pH 
ranging from 1.1 to 7.0) and considering that Nicorandil is a sparingly soluble DS, 
therefore, a dissolution volume of 900mℓ is preferred. 
Considering that the highest strength marketed is 20mg, maximum concentration in 
a 900mℓ dissolution vessel would be 0.0222mg/mℓ. Assuming that five times this 
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concentration is enough to demonstrate sink conditions, then if more than 0.111mg/mℓ 
can be dissolved in the buffer solutions then sink conditions can be demonstrated. 
Sink conditions testing was done in duplicate by weighing approximately 5.8mg of 
Nicorandil into a 50mℓ volumetric flask. To demonstrate solubility, samples were analysed 
in UV spectrophotometry against a standard solution after proper dilution (final 
concentration: 0.022mg/mℓ). Standard solution was prepared by accurately weighing 
approximately 22.2mg of Nicorandil into a 200mℓ volumetric flask and diluting 4mℓ of this 
solution into a 20mℓ volumetric flask (final concentration: 0.022mg/mℓ). The results are 
presented in Table 9. 
Table 9. Nicorandil sink conditions assessment 
Dissolution media tested 
Calculated solubility 
(mg/mℓ) 
Working concentration 
/ max solubility ratio 
HCl 0.1N 0.1176 (+ 0.03) 18.7% 
Phosphate buffer pH 4.5 (Ph. Eur.) 0.1152 (+ 0.03) 19.1% 
Phosphate buffer pH 7.0 (0.025M) (Ph. Eur.) 0.1174 (+ 0.03) 18.7% 
Results indicate that the working concentration is less than 20% of the calculated 
solubility in all dissolution media tested which means that sink conditions are met and that 
Nicorandil can be solubilized at least five times, its highest marketed strength (20mg) in 
900mℓ dissolution volume. 
Under the Biopharmaceutical Classification System (BCS), Nicorandil can be 
considered as a Class 1 DS since it is highly permeable and highly soluble according to 
the BCS standards which state that when more than the highest strength is soluble in 
250mℓ or less the DS is considered highly soluble. In this case it has been demonstrated 
that Nicorandil solubility is more than 20mg/250mℓ = 0.08mg/mℓ. 
2.3.2. Dissolution conditions 
The selection of the dissolution medium considered that as an immediate release 
formulation Nicorandil must be quickly dissolved in the gastric fluids so that it can be 
promptly ready for absorption. A suitable dissolution media for this purpose is HCl 0.1N. 
Experimental dissolution was carried out in a calibrated Varian VK 7000 with Cary 
50 spectrophotometer complying with Ph. Eur. (2.9.3) specifications (apparatus 2). Initial 
equipment set up considers 900 mℓ of HCl 0.1 N (pH 1.1 + 0.05) in each of the six 
dissolution vessels. The temperature of the media was 37.0  0.5ºC. At the start of the 
test one tablet is weighed and placed in each dissolution vessel under 50 rpm stirring rate. 
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Dissolution samples were collected automatically and analyzed by UV 
spectrophotometry at 262nm wavelength in 1.0cm quartz cells, against a reference 
standard, at the beginning of the dissolution test (blank measurement) and at 5 minutes 
interval until 30minutes. 
Reference standard was prepared by weighing accurately 22.4mg approximately of 
Nicorandil working standard into a 200mℓ volumetric flask and dissolving with HCl 0.1N. 
Afterwards 2.0mℓ are diluted in a 20mℓ volumetric flask. Concentration of the final 
reference solution is 0.011mg/mℓ. 
2.4. Ultraviolet spectroscopy 
UV method is a fast and simple method that can be used in DS quantification and 
identification. The first step that needs to be taken when choosing UV analysis is to select 
a suitable wavelength showing an adequate absorbance range, at which Nicorandil can 
be quantified, this can be done by tracing a spectra of the DS solution along the UV range 
and evaluating the existing peaks. 
A standard solution of Nicorandil was prepared at the concentration of 0.022mg/mℓ 
in three dissolution media/buffers: HCl 0.1N, phosphate buffer pH 4.5 (Ph. Eur.) and 
0.025M phosphate buffer pH 7.0 (Ph. Eur.) and analysed in UV using 1cm quartz cells. 
Nicorandil DS solution presents a maximum absorbance peak around 262nm as can be 
seen in Figure 13, which is suitable for the quantification of Nicorandil based on UV 
spectrophotometry. 
 
Figure 13. Nicorandil UV spectra in different pH 
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2.5. Mixture homogeneity 
Ensuring mixture homogeneity is essential to obtain tablets with the correct amount 
of DS. During transport or manipulation of the blend or during filling of the die in the 
compression process, powder blend might de-mix and tablet weight usually tends to vary. 
However, these variations can be small and not easy to detect. The blending process 
must be robust enough to achieve blend homogeneity and this can be demonstrated 
through sampling representative samples on the powder blend and test them for DS 
assay. 
Blend homogeneity was performed using an in-house UV analytical method. This 
method is intended to be able to quantify Nicorandil DS in a sample of powder mixture in 
an accurate, robust and reproducible way. Sample are prepared by weighing accurately a 
quantity equivalent to 40 mg of Nicorandil DS (approx. 400 mg of final mixture) into a 
200mℓ volumetric flask. Add HCl 0.1N and sonicate for at least 15 minutes. After filling up 
to volume the solution is filtered through a 0.45μm membrane filter (GHP) and 2mℓ of the 
solution are diluted in a 20mℓ volumetric flask with solvent. Final concentration of the 
solution is 0.02mg/mℓ of Nicorandil. 
Sample is analysed by UV spectrophotometry at 262nm against the solvent. Assay 
results should be between 95% and 105% and RSD should be no higher than 5% while 
individual values fall inside the average result ± 10%. 
2.6. Uniformity of dosage units 
Uniformity of dosage units was assessed by an in-house UV method which served 
to calculate the individual assay content of 10 tablets according to Ph. Eur. (2.9.40) using 
Shimadzu UV 160A Spectrophotometer. 
Sample are prepared by introducing a tablet into a 100mℓ volumetric flask, adding 
HCl 0.1N and sonicating for at least 15 minutes. After filling up to volume the solution is 
filtered through a 0.45μm membrane filter (GHP) and 2mℓ of the solution are diluted in a 
20mℓ volumetric flask with solvent. Final concentration of the solution is 0.02mg/mℓ of 
Nicorandil. Sample is analysed by UV spectrophotometry at 262nm against the solvent. 
2.7. HPLC 
HPLC is considered an established standard technique in most pre-formulation and 
formulation studies with the advantage of combining sensitivity, efficiency and reliability 
(4). HPLC methods are used to assess the degradation of substances in the solid or 
solution state and its kinetics. Additionally, if degradations products can be identified, or 
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standards are used, it is possible to identify the degradation products of the reactions and 
hence to elucidate the degradation mechanism.  
HPLC analysis was performed according to Ph. Eur. (2.2.29) and in-house standard 
operating procedures. The chromatographic conditions are the following: the column used 
was a Gemini C-18 (5 μm), 150 x 3.0 mm Phenomenex. Sample injection volume was 
10µl using an auto sampler. Flow was 1.0 mℓ/min. Detection was made at UV 254nm 
(assay and impurities) and at 215nm (nitrate only). Run time was 90 min. 
Assay standard solution were prepared by accurately weighing 20mg approximately 
of Nicorandil working standard and diluting into a 20mℓ volumetric flask using solvent 
(concentration = 1.00 mg /mℓ). Impurity standard solution was prepared by diluting 1mℓ of 
the assay standard solution into a 200mℓ volumetric flask (concentration = 0.005mg/mℓ). 
Test solutions were prepared by accurately weighing approximately 200mg of 
powdered tablets (the equivalent to 20mg of Nicorandil) and dissolving with solvent in a 
20mℓ volumetric flask (concentration = 0.02mg/mℓ). Samples were placed in an 
ultrasounds bath during 15min and after they were filled up with the remaining volume and 
filtered through 0.45 μm membrane filter (GHP) into a HPLC vial. 
All HPLC analysis were preceded by a system suitability defined test according to 
in-house criteria in which two different impurity standards were injected in triplicate and 
two different assay standards were injected in duplicate. Ratio between response factor of 
standard 1 and response factor of standard 2 must be between 99% and 101%. RSD 
between samples must be NMT 0.85% for assay runs and 5% for impurity runs. For every 
6 sample injections standard is injected (assay or impurity). Recovery result must be 
between 99.0% and 101.0%. Additionally retention time of sample must be equal to 
retention time of Nicorandil standard + 0.05%. 
2.8. Water content (Karl Fischer) 
Karl Fischer titration is a widely used analytical method for quantifying water content 
in a variety of products (62). The fundamental principle behind it is based on the Bunsen 
Reaction between iodine and sulphur dioxide in an aqueous medium. 
Total water of samples was determined by Karl-Fischer titration method using a 787 
KF Titrino, Metrohm® equipment, according to Ph. Eur. (2.5.12) Method A. This method 
indicates the total water (bound and unbound) contained on a sample. The water 
contained in the sample is extracted from the powder mixture or tablets (previously 
grounded with mortar and pestle) by the Methanol R (Merck®) and quantified by 
potentiometry using Hydranal® (Sigma Aldrich®) as the titration agent. 
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The determination of total water in Nicorandil samples was done using an in-house 
Karl Fischer method, which was previously validated with a system suitability test. For the 
water determination aproximately 300mg of sample is accurately weighed and introduced 
in the extraction medium. Double measurements were performed.  
2.9. Apparent Volume 
The test for apparent volume is intended to determine the apparent volumes, before 
and after settling and the apparent densities of a powder. Powder density was determined 
using a calibrated tapped volume-meter SVM 102 Erweka®. Test. Test execution followed 
Ph. Eur. (2.9.15) procedure. Approximately 100g of powder were poured into a 250mℓ 
graduated cylinder ensuring that at least 200cm3 were filled. Bulk volume (V0) was 
measured at the start of the test. A series of taps were done sequentially: 10 taps (V10), 
490 (V500), 750 (V1250), 1250 (V2500) on a total of 2500 taps performed. Results were 
recorded at each measurement by reading the height of the surface of the powder in the 
graduated cylinder. When necessary surface of the powder is gently levelled with a 
spatula. Results are expressed in terms of apparent volumes before settling or bulk 
density: g/V0mℓ and after 1250 taps, tapped density: g/V2500. 
2.10. Flowability and Powder flow 
The test for flowability is intended to determine the ability of a sample of powder to 
flow vertically through an orifice. Powder flowability was determined using a calibrated 
Erweka® Granulate Tester Type GT equipment, according to the procedures defined in 
Ph. Eur. (2.9.16). Approximately 100g of powder were accurately weighed and transferred 
into a dry funnel. Upon test start the bottom end of the funnel is opened and the powder 
flows into a container. The time that the amount of powder takes to be transferred into the 
contained is measured by the equipment using a laser beam. Three determinations were 
performed. 
The flowability result is expressed as the mean in seconds related to 100 g of 
sample and as a plot of the mass versus the flow time. 
Although the powder flow evaluation depends on the methodology used, the 
evaluation performed along the pre-formulation and formulation studies followed the 
method recommended by the Ph. Eur. (2.9.36), using the Compressibility Index and the 
Hausner ratio which are calculated using both the bulk volume and the tapped volume of a 
powder. Compressibility index and the closely related Hausner ratio are simple, fast and 
popular methods of predicting powder flow characteristics (63). 
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The compressibility index has been proposed as an indirect measure of bulk 
density, size and shape, surface area, moisture content, and cohesiveness of materials 
because all of these can influence the observed compressibility index. Formulas and 
classification tables can be verified in the Annexes. 
2.11. Particle size distribution 
2.11.1. Analytical Sieving 
Sieving is one of the oldest methods of classifying powders and granules by particle 
size distribution (64). The analytical sieving method is a method to estimate the particle 
size distribution of dry powders by sieving. The particle size determined by this method is 
shown as the size of a minimum sieve opening through which the particle passes. This 
test was performed using an Analytical sieve shaker Type AS 200 control “g”, Retsch® 
according to the procedure defined in Ph. Eur. (2.9.38). The sieves used comply with ISO 
3310-1 standard and had the mesh size (micra) of: 90, 125, 180, 250, 355, 500, 710, 
1000, placed vertically with the smallest mesh size on the bottom. Base of the column of 
sieves is a round container that fits the sieve column. 
Previously to the test each sieve is weighed empty. Approximately 100g of powder 
sample was accurately weighed and transferred to the top of the sieves column (1000 
micra sieve). Sieves were placed on the equipment which then started a vibrational 
motion during 10min with an amplitude of 1.5mm. At the end of the test each sieve was 
weighed again including the recipient at the base of the column. The values of the 
difference in mass indicate the amount of particles at each sieve which were used to plot 
the particle size distribution. 
2.11.2. Laser diffraction 
Particle size analysis of Nicorandil by laser diffraction was performed using a 
Malvern® Mastersizer 2000 using the sample wet dispersion method. The method 
complies with Ph. Eur. 2.9.31. 
Samples were prepared by adding the DS into a beaker with some drops of silicone 
oil (Tegiloxan®3) until all sample was wetted. Afterwards sample is homogenized by 
magnetic stirring and while maintaining stirring an amount is collected from the beaker 
and placed on the equipment until an obscuration between 8% and 12% is achieved. 
Samples were prepared in triplicate. At least two measurements were made for each 
sample. 
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2.12. Physical characterization of tablet 
Tablet characterization also refers to the confirmation of weight and dimensions. 
Weight is directly related to dosage strength. A tablet is designed to contain a specific 
amount of DS, therefore the weight of the tablet must be routinely checked to ensure that 
the dosage form contains the proper amount of drug. Variations on tablet weight can 
compromise efficacy of the drug product. 
Thickness is an indicator of tablet hardness and is a function of the die fill and 
compression force. At a constant die fill, the hardness values increase and thickness 
decreases as additional compression force is applied. 
Weight, thickness, diameter and hardness of tablets was done using a calibrated 
Erweka Multicheck® 5.39i by measuring 10 tablets. Weight acceptance complies when the 
standard deviation is not higher than 5% of the average mass value. 
2.12.1. Friability 
Friability is another measurement of the mechanical resistance of tablets (65). This 
test is intended to determine the friability of uncoated tablets, the phenomenon whereby 
tablet surfaces are damaged and/or show evidence of lamination or breakage when 
subjected to mechanical shock or attrition. Testing was done using a calibrated Erweka® 
T4 according to Ph. Eur. (2.9.7) standards. This test is performed by adding approximately 
6,5g of tablets into the drum and setting it to roll 100 times during 4 min (25 rotations per 
minute). The friability is expressed as the loss of mass and it is calculated as a 
percentage of the initial mass. Uncoated tablets that lose not more than 1.0% of their 
weight are generally considered acceptable (66). 
2.12.2. Disintegration 
Immediate release tablets should be readily disintegrated in the stomach so that the 
DS it contains can become fully available in the body fluids for dissolution and absorption 
(66). Disintegration test was done using a calibrated Erweka® ZT3-2 type A equipment 
according to the Ph. Eur. (2.9.1) standards. Testing was done using 6 tablets, one per 
each tube of the basket, adding a disk and suspending it in the beaker containing purified 
water at 37ºC + 1ºC where it will submerge and start vertical oscillations. Results are 
expressed in a time period that takes for the first and last tablet to lose its structural form 
without leaving residues in the mesh of the basket. 
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2.12.3. Resistance to crushing 
Hardness is defined as the resistance of a solid to deformation and it is primarily 
related to its plasticity (21, 65). Tablets require a certain amount of strength, or hardness 
and resistance to friability, to withstand mechanical shocks of handling in manufacture, 
packaging, shipping and to comply with the necessary requisites for consumer 
acceptance. Hardness of tablets was measured by the force needed to disrupt them by 
crushing using a calibrated Erweka Multicheck® 5.39i according to the Ph. Eur. (2.9.8) 
standards. 
Ten tablets were placed on the measuring unit between two jaws jaws facing each 
other, one of which moves towards the other. The flat surfaces of the jaws are 
perpendicular to the direction of movement. The crushing surfaces of the jaws are flat and 
larger than the zone of contact with the tablet. The apparatus is calibrated using a system 
with a precision of 1 newton. Ten tablets were measured and the average result is 
expressed in Newton. 
2.13. Optical microscopy 
Particle characterization by optical microscopy was done following the Ph. Eur. 
(2.9.37). Samples were prepared by placing a small amount of DS powder in a dry 
lamella. Samples were observed at 100x, 400x and 1000x magnification. 1000x was done 
using immersion oil. 
2.14. Powder X-Ray Diffraction 
A common analytical technique for the characterization of solid forms is powder x-
ray diffraction (PXRD) (67). This technique is the most preferred and common method due 
to its specificity, simplicity and non-destructive nature (68). The data can be represented 
as a two-dimensional pattern plotted as peak counts (X axis) versus 2θ angle (Y axis). A 
typical PXRD diffractogram presents several sharp and straight peaks with different sizes 
which are characteristic of a crystalline structure. On the other hand an amorphous 
material lacks such a pattern. 
PXRD pattern of samples were recorded at room temperature on an ENRAF–
NONIUS FR590 powder diffractometer (equipped with a CPS120 detector by INEL) and 
data were collected for 30 min using Debye–Scherrer geometry. Copper Kα1 radiation was 
used (k = 1.5406 A˚) monochromatized using a curved crystal quartz (2θM = 26.64º). 
Sample preparation was performed by filling Glass capillaries with 1.0 mm diameter with 
powdered Nicorandil. The samples were mounted on a rotating holder. 
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1. Pre-formulation studies 
1.1. DS characterization 
Two major sources of information regarding chemical and physical parameters and 
other properties of the DS are the manufacturer’s Certificate of Analysis (CoA) and 
compendial sources such as the major Pharmacopoeias. The information contained in 
these references are the first information available on DS and contains important 
information that can be used as a start point for pre-formulation studies. 
Nicorandil is the international non-proprietary name for N-[2-(nitroxy)-ethyl]-3-
pyridinecarboxamide (chemical name) or N-(2-hydroxyethyl)-nicotinamide nitrate ester 
and is a DS described in the Japanese Pharmacopoeia (69). Its molecular formula is 
C8H9N3O4 and has a relative molecular weight of 211.18. Nicorandil is a DS that is freely 
soluble in methanol, ethanol (99.5%) and glacial acetic acid. It is soluble in acetic 
anhydride, sparingly soluble in water and slightly soluble in ether. It is poorly soluble in 
ethyl ether or benzene. 
Nicorandil melts and decomposes between 89° and 94°C and has an absorption 
coefficient E1% (1cm, max 262 nm, H2O) of 161-175 AU. The pH of 1% aqueous solution 
is 5.7 - 5.8 and its pKa is 3.18. 
Nicorandil is a non-hygroscopic substance, stable in the crystalline form when 
stored at about 5°C (+ 3°C) in a well-closed container (69), although it is not stable at 
room temperature or in presence of humidity. When in aqueous solution it is highly 
unstable at room temperature. 
Nicorandil is a white to off white crystalline powder with a soft consistency. It is 
possible to observe lumps and aggregates (Figure 14) which can reach approximately 6 to 
8cm in their maximum length, although can be easily scattered. 
There are also hard, small size aggregates, not larger than a couple of millimetres 
which are difficult to scatter, even using manual or mechanical sieving. 
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Figure 14. Bulk appearance of Nicorandil 
A common operation in the pharmaceutical industry, used in the manufacture of 
solid formulations, is powder sieving. When trying to sieve Nicorandil by hand through a 
mesh size of 0.500mm and 0.710mm to scatter the large and small aggregates, it was 
noticed that bulk powder was difficult to pass through both meshes. Without the aid of 
mechanical aids it might be difficult to sieve bulk powder to scatter aggregates, probably 
due to Nicorandil particle characteristics. These large and small aggregates are an 
indication that an adequate powder blend homogeneity through dry blending operations 
might be difficult to achieve. 
To further evaluate particle morphology microscopic visualization was performed. 
Three Nicorandil batches (#1, #2 and #3) were observed using an optical microscope 
according to the method described in the Materials and Methods section (optical 
microscopy). 
Figure 15 and Figure 16 show representative images of Nicorandil particles from 
three batches at different magnifications. 
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Figure 15. Nicorandil optical microscopy. Batches #1 and #2 
 
Figure 16. Nicorandil optical microscopy. Batch #3 
Particles can be described, generally, as short columnar particles while a small part 
are plate shaped. There is batch variability regarding particle characteristics since other 
particle shapes are observed in batches #2 and #3. In these cases particles have acicular 
shape and a major portion are short columnar particles. 
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Particles are translucent with sharp edges and have a smooth surface, although with 
defects, such as cracks. Images also show the microscopic particle agglomeration that 
can be observed on the small hard clusters. 
The effect of grinding on the particles can also be observed. Particles lose their form 
and appear to be smashed and this behaviour is suggestive of a brittle crystal. 
Birefringence, which is an indication of crystallinity, was also observed. 
1.1.1. Solubility 
Solubility was determined in duplicate samples. In both cases it was necessary to 
add up to 10mℓ of purified water to 100mg of powdered Nicorandil to achieve complete 
solubilisation. Nicorandil is therefore considered sparingly soluble in water. 
1.1.2. Apparent density 
Nicorandil apparent density was determined and evaluated (Hausner ratio and 
Compressibility Index), according to Ph. Eur., in five batches, as described in the 
Materials and Methods section. The average and standard deviation results (   ) of five 
batches are shown in Table 10. 
Table 10. Apparent density results of Nicorandil 
Parameter Batch #1 Batch #2 Batch #3 Batch #4 Batch #5 
Bulk density (g/mℓ) 0.263 (+ 0.01) 0.422 (+ 0.01) 0.435 (+ 0.01) 0.304 (+ 0.01) 0.247 (+ 0.01) 
Tapped density (g/mℓ) 0.381 (+ 0.01) 0.530 (+ 0.01) 0.550 (+ 0.01) 0.358 (+ 0.01) 0.314 (+ 0.01) 
Hausner ratio 1.45 1.26 1.26 1.18 1.27 
Compressibility Index 30.97% 20.33% 20.87% 14.9 21.32 
Powder flow evaluation 
Ph. Eur. (2.9.36) 
“Poor” “Passable” “Passable” “Fair” “Passable” 
Interpretation of powder flow took into account that this powder forms lumps which 
create large empty spaces inside the glass tube. Even though classified as Poor and 
Passable, according to the results shown, Nicorandil seems to have bad flow properties. 
1.1.3. Flowability 
In all five batches tested Nicorandil did not flow freely through the 25 mm nozzles. It 
requires constant mechanical aid to maintain powder flow, thus flow through 15mm and 
10mm nozzles was not performed, as it was assumed that powder would not flow through 
a smaller hopper. In two batches (#4 and #5) powder did not flow through 25mm nozzle. 
Results express the average time and standard deviation results (   ) that powder 
takes to go through the hopper and are indicated on Table 11.  
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Table 11. Flowability results of Nicorandil. 
Time (s) / 100gr 
Nozzle: 25 mm 
Batch #1 Batch #2 Batch #3 Batch #4 Batch #5 
N 3 3 3 3 3 
   4.9 s ( 0.38) 7.9 s ( 0.67) 9.5 s ( 0.90) 
Does not flow Does not flow 
RSD (%) 7.76 % 11.24 % 9.48% 
Minimum 4.6 s 7.5 s 8.6 s 
Maximum 5.3 s 8.7 s 10.4 s 
Figure 17 illustrates the flow patterns (25mm nozzle) of bulk Nicorandil. Mass of 
powder is indicated in the Y axis (m [gr]) and time in the X axis (t(s)). Three batches are 
indicated (batches #1, #2 and #3, from left to right), those in which powder flow could be 
recorded. Results show the irregular flow which was started and kept by the use 
mechanical aids. 
 
Figure 17. Nicorandil flow pattern 
Results of apparent density and powder flow suggest that the difficult powder flow of 
Nicorandil, despite being present in a 10% ratio, must be compensated during formulation 
with an adequate ratio of excipients with good flow properties since powder flow can 
influence blend homogeneity, which is a critical issue during formulation, especially in a 
powder blend for direct compression, that can have a large impact on finished product 
quality attributes. 
1.1.4. Water content 
Nicorandil has a low water content. Results of Karl Fischer from the Certificate of 
Analysis indicate an average water content level by Karl Fischer titration method of 0.06% 
(n=8 + 0.03) with a test specification of NMT 0.1%. 
Development of oral tablets containing Nicorandil 
Results and Discussion  
 
 
54 
1.1.5. Particle size distribution 
Nicorandil particle size distribution was determined by laser diffraction method 
according with the procedure described in Materials and Methods section. Considering the 
results of powder density, flowability results and particle characteristics, particle size 
distribution by analytical sieving was not possible to perform, so to obtain an accurate 
result fo r the particle size distribution this method was used. 
The values obtained on three representative batches of Nicorandil are summarized 
on Table 12. 
Table 12. PSD results of Nicorandil by laser diffraction 
 
Fraction Batch #1 
d10 10.36 µm 
d50 38.78 µm 
d90 89.04 µm 
 
Fraction Batch #2 
d10 9.56 µm 
d50 25.69 µm 
d90 52.01 µm 
 
Fraction Batch #3 
d10 7.38 µm 
d50 23.28 µm 
d90 52.72 µm 
Particle size distribution shown refers to three batches used during pharmaceutical 
development. For comparison purposes additional batches were tested regarding particle 
size and the results are described in Table 13 (values in micra). 
From a total of nine batches tested it is possible to observe that Nicorandil particle 
size distribution has a high batch to batch variation. 
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On average, 90% of the particle sizes are below 90µm approximately, although 
higher values go up to 198.6 micron and as low as 43.0 micron. The average size of the 
particles is 29.7µm and 10% of the particles are not larger than 9.3µm. 
Table 13. Nicorandil particle size distribution 
Fractions (µm) d10 d50 d90 
Average (n=9) 9.3 (+4.5) 29.7 (+11.1) 90.3 (+49.2) 
min 2.6 16.0 43.0 
max 14.8 53.3 198.6 
1.1.6. Assay and impurity content by HPLC 
On Table 14, assay and impurities results obtained by HPLC analysis are 
summarized. This data is representative of nine DS batches analysed and has been 
compiled for comparison purposes. From each batch two samples were prepared and 
analysed (see sample preparation for HPLC in Materials and Methods section). 
Table 14. Assay and impurities results of Nicorandil 
Parameter Result 
Assay 100.06% (+ 0.97%) 
Related substances  
Nitrate 0.0673% (+ 0.01%) 
N-(2-hydroxyethyl)-Nicotinamide 0.0453% (+ 0.02%) 
Imp. A 0.0205% (+ 0.01%) 
Imp. B 0.0205% (+ 0.01%) 
Imp C 0.0028% (+ 0.00%) 
Single unknown impurity 0.0108% (+ 0.00%) 
 Total impurities 0.17% (+ 0.03%) 
 
Known impurities standards were analysed and their peaks identified as shown on 
Figure 18. For comparison purposes a blank and an excipients solution chromatograms 
were added. It is possible to observe that Nitrate (#1) impurity elutes around 4min and is 
detected and quantified at 215nm (see HPLC method description in materials and 
methods section). 
Next known impurity that elutes is nicotinic acid (#2) around 5min), followed by N-(2-
hydroxyethyl)-nicotinamide (#3) around 7min and 2-aminoethylnicotinate (Impurity A) (#4) 
around 9min. Impurity #5, methyl-nicotinate, is a synthesis impurity that elutes around 
23min. Nicorandil peak (#6) elutes around 28min and in the gradient phase of the analysis 
polymeric impurities start to elute, first, impurity B (dimer) (#7) around 42min and later 
impurity C (#8), around 53min. 
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Figure 18. Known impurities chromatogram 
1.1.7. Powder X-Ray Diffraction 
Nicorandil was analysed using a powder X-Ray diffraction technique to determine its 
crystalline X-Ray pattern. This information would be used to assess mechanical stress 
effect on crystalline structure during formulation development and short term stability 
study. Figure 19. Nicorandil PXRD diffractogram  
This comparison serves to identify characteristic peaks and to evaluate the 
diffractogram pattern of unprocessed Nicorandil. 
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Figure 19. Nicorandil PXRD diffractogram 
Theoretical models matches the diffractogram obtained on Nicorandil sample. No 
extra peaks have been found and no peaks are missing. The results are compatible with a 
crystalline powder. 
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1.2. Risk assessment of DS attributes 
The first part of the risk assessment focused on the DS attributes which were 
considered critical (Table 2). Risk assessment is performed to evaluate the impact that 
each attribute can have on the drug product CQA’s defined in the Aims of the Study 
section. The risk assessment is summarized on Table 15. 
Table 15. Summary of risk assessment related to DS attributes 
Drug Product 
CQAs 
Drug Substance Attributes 
Particle Size 
Distribution 
Solubility 
Chemical 
Stability 
Flowability 
Assay Medium Low High Medium 
Degradation products Medium Low High Low 
Dissolution Medium Medium High Medium 
Water content Low Low High Low 
Hardness Low Low High Low 
A rationale for the classification of each level is presented on Table 16. This 
rationale is based on a correlation between DS attributes and their potential effect on the 
drug product’s CQA’s. 
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Table 16. Risk assessment rationale on Drug Substance attributes 
DS 
Attributes 
Drug Product 
CQA’s 
Rationale 
Risk 
evaluation 
Particle Size 
Distribution 
Assay 
Small particle size may result in segregation of DS particles with 
consequences on powder homogeneity and hence assay failure on the 
dosage form. Nicorandil DS forms large lumps and microscopic 
aggregates that are difficult to scatter. Proper mechanical action upon 
DS while preparing blend mixture can bypass homogeneity issues. 
The risk is 
medium 
Degradation 
Products 
PSD alone is not expected to have any impact on the degradation 
products of the DS, although during manufacturing it might be 
necessary to use mechanical sieving or milling process to promote 
powder blend homogeneity which can introduce mechanical stress 
enough to disrupt the crystal lattice and hence accelerate the 
degradation reaction. Milling and particle reduction of Nicorandil should 
be evaluated to assess its influence on DS and drug product stability. 
The risk is 
medium. 
Dissolution 
Solubility testing done on Nicorandil indicate that it is soluble in the pH 
range of the GIT. Sink conditions are also observed. According to BCS 
standards Nicorandil is highly soluble. Reference product tablets have 
a very fast profile with more than 90% of DS dissolved at 15min. As 
long as PSD does not suffer major changes, dissolution should not be 
compromised. 
The risk is 
medium. 
Water content This CQA is not related to PSD of the DS. 
The risk is 
low. 
Hardness 
Resistance to crushing can be influenced by PSD since wider values 
can alter the way particles are compacted on tablet matrix. Although, 
10% Nicorandil on the formulation is not expected to have a relevant 
impact on compaction properties of the mixture particles. 
The risk is 
low. 
Solubility 
Assay 
Nicorandil solubility in water has been established as sparingly soluble 
although solubility in buffer solutions on the pH range from 1.0 to 7.0 
comply with sink conditions and is highly soluble according to BCS 
standards, therefore assay determination should not be compromised 
by DS solubility. 
The risk is 
low. 
Degradation 
Products 
Nicorandil solubility is not directly related to degradation rate. 
The risk is 
low. 
Dissolution 
Nicorandil solubility in water has been established as sparingly soluble 
although solubility in buffer solutions on the pH range from 1.0 to 7.0 
comply with sink conditions and is highly soluble according to BCS 
standards, therefore dissolution profile should not be compromised by 
DS solubility. 
The risk is 
medium. 
Water content 
Nicorandil solubility is not expected to have an impact on the drug 
product water content. 
The risk is 
low. 
Hardness 
Nicorandil solubility, an intrinsic property of the DS, is not related to 
tablet hardness, a physical attribute of the drug product. 
The risk is 
low. 
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Table 16. Risk assessment rationale on DS attributes (cont.) 
DS 
Attributes 
Drug Product 
CQA’s 
Rationale 
Risk 
evaluation 
Chemical 
Stability 
Assay 
Based on available bibliography and supplier information, Nicorandil 
is sensitive to humidity, heat and mechanical stress, therefore DS 
chemical stability can seriously affect assay and degradation products 
levels on the finished drug product. These CQA’s must be carefully 
studied and monitored. 
The risk is 
high. Degradation 
Products 
Dissolution 
Dissolution is affected by DS particle size distribution, formulation 
composition and DS solubility. As mentioned for assay CQA, 
chemical stability can ultimately lower content and therefore so will 
the percentage of total DS dissolved.  
The risk is 
high. 
Water content 
Water content is a major factor of drug product instability. This CQA 
must be carefully studied and monitored. 
The risk is 
high. 
Hardness 
High compression forces is a factor that promotes instability of the DS 
on the drug product. This CQA must be carefully studied and 
monitored. 
The risk is 
high. 
Flow 
Properties 
Assay 
DS flow properties can ultimately influence assay, although DS is at 
10% ratio on the formulation which lowers the impact when compared 
with other components present in higher amounts. An optimized 
blending process lowers the risk associated with this CQA. 
The risk is 
medium. 
Degradation 
Products 
DS flow properties are not directly related to drug product impurity 
level. 
The risk is low. 
Dissolution 
DS flow properties are not directly related to dissolution profile or to 
an extent that requires further evaluation. 
The risk is 
medium. 
Water content 
DS flow properties are not directly related to drug product water 
content. 
The risk is low. 
Hardness 
DS flow properties are not directly related to tablet hardness or to an 
extent that requires further evaluation. 
The risk is low. 
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1.3. Reference product characterization 
The RP characterization was done with the purpose of gathering enough information 
to guide the development of the test formulation and to set pharmaceutical performance 
targets. The characterization of the RP included the following tests: 
 Appearance 
 Average weight 
 Hardness 
 Disintegration 
 Water Content (Karl Fischer) 
 Dissolution 
 Assay 
 Related Substances 
From the RP batches available, two 10 mg batches of RP were randomly selected 
for characterization: Dancor batch 5459920 and Adancor batch 5437234. 
Summary of results is shown Table 17. 
Table 17. RP characterization results 
Trade Name Dancor Adancor 
Batch 54599 20 54372 34 
Appearance 6mm round, flat, white tablets 
Scores and 
embossing 
double scored, EM and 73 embossing, 
on opposite faces 
Average Weight (n=10) 99.3 mg 99.5 mg 
Resistance to crushing (n=10) 52 N 50 N 
Disintegration 
First: 2min 10s 
Last: 2min 30s 
First: 2min 35s 
Last: 3min 15s 
Water content (KF) 0.12% 0.10% 
Dissolution (n=6, 15 min) 94.5% (0.91% RSD) 95.5% (2.22% RSD) 
Dissolution (n=6, 30 min) 94.5% (0.93% RSD) 95.5% (2.25% RSD) 
Dissolution testing was done on the RP 10mg tablets using the in house dissolution 
method as described in the Materials and Methods section. 
Dissolution profile can be described as very fast, with more than 90% release at 
10min. Figure 20 shows the n=6 average dissolution profiles of two RP batches. 
Development of oral tablets containing Nicorandil 
Results and Discussion  
 
 
62 
 
Figure 20. RP 10mg average dissolution profile 
HPLC assay and impurity results are summarized in Table 18. 
Table 18. Reference Product assay and impurity results 
Trade Name Dancor Adancor 
Batch 5459920 5437234 
Assay (n=2) 95.9% (+ 1.35) 95.6% (+ 0.81) 
Related substances (n=2)  
Nitrate 0.5888% (+ 0.01) 0.5391% (+ 0.00) 
Nicotinic Acid 0.0016% (+ 0.00) ND 
N-2-hydroxyethyl-nicotinamide 0.0167% (+ 0.00) 0.0174% (+ 0.00) 
Impurity A (2-aminoethyl nicotinate) 0.0869% (+ 0.01) 0.0820% (+ 0.00) 
Impurity B (Dimer) 0.3705% (+ 0.00) 0.3660% (+ 0.00) 
Impurity C (Trimer) 0.1021% (+ 0.00) 0.1245% (+ 0.00) 
Single unknown impurity 0.0441% (+ 0.00) 0.0329% (+ 0.00) 
Total impurities 1.37% 1.30% 
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1.4. Excipients Screening 
A first selection of excipients was made based on bibliographic data related with 
their physical and chemical properties to discard those prone to react with the organic 
groups of Nicorandil and hence accelerate decomposition process, for example, 
excipients containing crystalline water, that be discarded from a possible formulation., or 
those which characteristics would not be adequate for the target immediate release solid 
oral dosage form. 
An initial screening was based on previous studies published (70-75) on the 
development of oral dosage forms of Nicorandil. Most of the papers found were related 
with the development of modified release formulations instead of immediate release, 
which is the aim of the present study. 
On Table 19 there is a compilation of the excipients previously used in formulations 
of Nicorandil found on literature. It describes excipient functionality, references to the 
studies in which they were used, application of such excipients and decision on whether to 
use for further studies and corresponding data that justifies such decision. 
Excipients identified as “potential candidate” refer to excipients that might be 
advantageous to the stability of the formulation and were selected for additional studies. 
Excipients excluded are those that by their characteristics do not seem to be appropriate, 
due to either their organic groups that can be a source of degradation or by other 
characteristics that were not considered preferential. 
Table 19. Excipients considered to be used in a Nicorandil formulation 
Excipient 
Common 
function 
References Decision Justification 
Isomalt Diluent/filler 
Potential 
candidate 
Can be 
tested 
Non hygroscopic excipient suitable for fast disintegrating 
tablets on direct compression formulations. Chemically 
stable, low reactivity and low hygroscopicity. 
Sodium starch 
glycolate 
Disintegrant 
(2 - 8%) 
Potential 
candidate 
Can be 
tested 
Very hygroscopic excipient although on a fast disintegration 
tablet might be necessary to achieve an adequate dissolution 
rate. 
Crospovidone 
Disintegrant 
(2% - 5%) 
Potential 
candidate 
Can be 
tested 
Hygroscopic excipient although on a fast disintegration tablet 
might be necessary to achieve an adequate dissolution rate. 
Microcrystalline 
Cellulose 
Diluent 
Disintegrant 
(74) 
Can be 
tested 
Excipient widely used in direct compression formulations with 
several grades and particle sizes available. 
Mannitol 
Diluent/filler 
(10% - 90%) 
(72, 75) 
Can be 
tested 
Non hygroscopic excipient. It has been used in previous 
works on Nicorandil formulations (51). 
Pre-gelified 
Starch 
Tablet binder in 
direct 
compression 
formulations 
Tablet disintegrant 
(2% - 10%) 
(75) 
Can be 
tested 
Hygroscopic excipient with high water content although has 
low water activity (76, 77) therefore, it will equilibrate slower 
when exposed to moisture conditions and may, preferentially, 
bind the moisture, preventing interaction of water with other 
components acting as moisture scavenger (78). 
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Table 19. Excipients considered to be used in a Nicorandil formulation (continue) 
Excipient Function References Decision Justification 
Croscarmellose 
sodium 
Disintegrant 
(0.5% - 5.0%) 
(75) 
Can be 
tested 
Hygroscopic excipient. Its efficacy might be reduced when 
used with other hygroscopic excipients in a tablet formulation. 
Spray dried 
Lactose 
Reducing sugar (73) Excluded 
As a reducing sugar it will likely react with the secondary 
amine group present in Nicorandil. 
Sodium 
bicarbonate 
Alkalizing agent (73) Excluded 
Sodium bicarbonate is an alkalizing excipients and higher pH 
on a solid matrix has been described as a factor that 
increases degradation rate of Nicorandil. 
HPMC 
(K4M, K15, 
K100M, K200M) 
Binder 
Film coating 
Matrix for 
ER/MR 
(70, 72-74) Excluded 
Hydroxypropyl methylcellulose is an excipient used in oral 
products, primarily a tablet binder, in film-coating and as a 
matrix for use in extended-release tablet formulations hence it 
is not suitable for a fast dissolution profile on an immediate 
release solid dosage form obtained by direct compression. 
Cutina HR
®
 
ER/MR agent 
lubricant 
(72) Excluded 
This excipient forms a matrix that delays Nicorandil 
dissolution hence it is not suitable for an immediate release 
formulation. 
Ethyl cellulose ER/MR agent (70) Excluded 
The main use of ethyl cellulose in oral formulations is as a 
hydrophobic coating agent for tablets and granules. This 
excipient forms a matrix that delays Nicorandil dissolution 
hence it is not suitable for an immediate release formulation. 
Chitosan ER/MR agent (71) Excluded 
Chitosan is a multipurpose excipient in solid oral formulations 
that include controlled drug delivery applications, 
mucoadhesive and rapid release dosage forms. Although, this 
excipient forms a matrix that delays Nicorandil dissolution 
hence it is not suitable for an immediate release formulation, 
besides it has reactive hydroxyl and amino groups and is 
hygroscopic. 
Sodium alginate 
Tablet 
disintegrant and 
binder 
(71, 74) 
Can be 
tested 
This excipient is used as a lubricant and has been referred as 
a possible improvement on Nicorandil stability due to its 
compaction properties. 
Eudragit
®
 L101, 
Eudragit
®
 RSPO 
Film coating 
Matrix for 
ER/MR 
(70, 72, 73) Excluded 
Eudragit
®
 are a class of excipients known as 
polymethacrylates which are primarily used in oral capsule 
and tablet formulations as film-coating agents, enteric 
coatings and sustained release formulations. This excipient is 
not suitable for an immediate release solid dosage form 
obtained by direct compression. 
ER/MR: extended release/modified release 
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Table 19. Excipients considered to be used in a Nicorandil formulation (continue) 
Excipient Function References Decision Justification 
Dibasic calcium 
phosphate 
Diluent (70) Excluded 
The surface of milled anhydrous dibasic calcium phosphate is 
alkaline (2) and consequently it should not be used with drugs 
that are sensitive to alkaline pH. 
Glyceyl 
Behenate 
Lubricant 
(1.0% - 3.0%) 
Potential 
candidate 
Can be 
tested 
Glyceryl dibehenate is a mixture of diacylglycerols, mainly 
dibehenoylglycerol, and variable quantities of mono- and 
triacylglycerols. It is an excipient that has been described (79) 
has having good binding properties, it does not affect tablet 
hardness and is unaffected by mixing or production 
parameters. 
Colloidal silica 
dioxide  
Glidant 
(0.1% - 1.0%) 
(70, 72-74) 
Can be 
tested 
Used in solid oral dosage forms mainly as glidant to improve 
flow properties of powder. Hygroscopic excipient although due 
to its affinity to water it can act as a moisture scavenger. 
Fumaric acid Acidic agent. (72, 74, 80) Excluded 
Fumaric acid has been described as compatible with Nicorandil 
although this excipient has been used on two conditions: 2ºC-
8ºC and 25ºC/60% RH: These results do not guarantee that at 
higher temperatures or humidity this compatibility with 
Nicorandil is maintained. Patent information refers a stable 
Nicorandil formulation using fumaric acid. Since this excipient 
has already been used it is not going to be considered for 
further studies. 
Magnesium 
stearate 
Lubricant (70, 74) Excluded 
The presence of a metallic cation might act as a catalyst on 
degradation reactions. 
Calcium 
stearate 
Lubricant (75) Excluded 
Calcium stearate is a mixture of calcium salts of different fatty 
acids consisting mainly of stearic acid and palmitic acid with 
minor proportions of other fatty acids. It contains calcium oxide 
which might be a factor that promotes Nicorandil degradation. 
Since there are other alternatives, Calcium stearate is not a 
preferred lubricant. 
Stearic acid Lubricant (72, 74, 75) 
Can be 
tested 
Stearic acid is a preferred lubricant and one of the excipients 
that can have a stabilization effect on Nicorandil by protecting 
the crystalline structure under compression forces. This 
excipient is also present in the reference product and described 
in Nicorandil patent although it is mentioned the use of a non-
micronized grade. Selected stearic acid for compatibility studies 
was a micronized grade. 
Talc 
Glidant, diluent, 
lubricant 
(72) Excluded 
Talc is not a preferred lubricant since lubricants based on long 
aliphatic fat acid chains have been described as having a 
stabilisation effect on Nicorandil crystalline structure. 
The information contained on Table 19 helped to select groups of excipients 
according to their functional class that might be advantageous for a solid oral formulation 
containing Nicorandil. 
To achieve a dissolution profile similar to the reference product, which is an 
immediate release formulation, a fast disintegration must be ensured, hence disintegrant 
class excipients must be added to the formulation such as sodium starch glycolate, 
croscarmellose sodium and crospovidone. 
An excipient with glidant properties such as anhydrous colloidal silica might be used 
to improve powder flowability if necessary due to the poor flow properties of Nicorandil. 
Regarding lubricants, glyceryl behenate and stearic acid were considered for 
compatibility testing. 
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1.5. Compatibility Studies 
Compatibility studies of Nicorandil with selected excipients was done using High 
Pressure Liquid Chromatography to assess chemical incompatibility with excipients 
through the quantification of single and total impurity levels. Compatibility studies were 
done using binary mixtures on a ratio of 1:1 of Nicorandil with excipients and further 
studies were performed using combinations of excipients with Nicorandil. 
Before starting the compatibility studies it was necessary to evaluate the effect of 
selected degradation conditions on Nicorandil DS alone to establish the single (known and 
unknown) and total amount of impurities across different conditions.  
The choice of these conditions is important since Nicorandil molecule, as mentioned 
before, is sensitive to both temperature, humidity and compression forces. 
It is important to evaluate which are the adequate degradation conditions otherwise 
it might be possible that too harsh conditions will cause the appearance of degradation 
products that will not appear during product shelf life. Several published studies, including 
patents, refer a wide range of temperature and humidity conditions used during Nicorandil 
degradation studies (45, 51, 80). 
For the compatibility studies performed in this work maximum temperature selected 
for degradation studies was 60ºC since it seems that for higher temperatures degradation 
of Nicorandil is no longer relevant except for forced degradation studies. Regarding 
humidity a wider values range was evaluated, starting with 0% relative humidity (vacuum 
chamber until 80% RH. 
Nicorandil samples were prepared by weighing approximately 100mg of DS directly 
into glass vials that are then placed in the degradation chambers in the different 
conditions tested (Table 20) for 8 hours. Conditions #1, #2 and #3 were used since they 
are ICH degradation conditions for long term, intermediate and accelerated stability 
studies correspondingly and samples were placed in open vials in climate chambers. 
Condition #4 was used to evaluate temperature alone, sample was placed inside a 
closed vial in a vacuum oven. Condition #5 was prepared to evaluate the effect of low 
moisture and higher temperature. Sample was placed in a closed container with desiccant 
(silica gel) and humidity was monitored using a calibrated Temperature and Humidity 
dataloger. Condition #6 was obtained by placing an open vial in a desiccator with a 
saturated salt solution of potassium chloride. Condition #7 was obtained by adding 10% of 
purified water (w/w) to the Nicorandil sample and placing it into a sealed vial. 
For comparison purposes the HPLC results of non-degraded Nicorandil was added. 
Details on temperature and humidity used as well as results are shown on table Table 20. 
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1.5.1. Degradation conditions of Nicorandil 
Table 20. Degradation conditions of Nicorandil 
Condition #1 #2 #3 #4 #5 #6 #7 
DS 
Standard 
(control) 
Temperature 25ºC 30ºC 40ºC 60ºC 60ºC 60ºC 60ºC 
Relative humidity 60% 65% 75% 0% 40% 80% 
Water 
added 
Assay (n ≥ 2) 
101.08% 
(+ 0.13%) 
101.54% 
(+ 0.50%) 
102.24% 
(+ 1.52%) 
100.46% 
(+ 0.16%) 
100.32% 
(+ 0.04%) 
96.57% 
(+ 0.10%) 
67.21% 
(+ 2.02%) 
100.60% 
(+ 0.43%) 
Impurities (n ≥ 2)  
Known 
Nitrate 
0.0642% 
(+ 0.01%) 
0.0571% 
(+ 0.00%) 
0.0642% 
(+ 0.01%) 
0.1523% 
(+ 0.02%) 
0.1849% 
(+ 0.08%) 
0.5649% 
(+ 0.10%) 
5.9907% 
(+ 0.50%) 
0.0673% 
(+ 0.01%) 
A 
0.0433% 
(+ 0.01%) 
0.0439% 
(+ 0.00%) 
0.0499% 
(+ 0.01%) 
0.0337% 
(+ 0.01%) 
0.1643% 
(+ 0.12%) 
0.5602% 
(+ 0.05%) 
5.1487% 
(+ 0.03%) 
0.0453% 
(+ 0.02%) 
B 
0.0218% 
(+ 0.01%) 
0.0236% 
(+ 0.01%) 
0.0206% 
(+ 0.00%) 
0.1328% 
(+ 0.03%) 
0.0807% 
(+ 0.02%) 
0.8748% 
(+ 0.25%) 
11.0327% 
(+ 0.51%) 
0.0205% 
(+ 0.01%) 
C 
0.0025% 
(+ 0.00%) 
0.0063% 
(+ 0.00%) 
0.0080% 
(+ 0.02%) 
0.0425% 
(+ 0.02%) 
0.0278% 
(+ 0.00%) 
0.1184% 
(+ 0.20%) 
3.1804% 
(+ 0.22%) 
0.0028% 
(+ 0.00%) 
Unkn. 
1 
0.0150% 
(+ 0.00%) 
0.0138% 
(+ 0.00%) 
0.0166% 
(+ 0.01%) 
0.0225% 
(+ 0.01%) 
0.0357% 
(+ 0.01%) 
0.1835% 
(+ 0.25%) 
3.2489% 
(+ 0.31%) 
0.0107% 
(+ 0.00%) 
2 
0.0099% 
(+ 0.00%) 
0.0091% 
(+ 0.01%) 
0.0110% 
(+ 0.00%) 
0.0145% 
(+ 0.00%) 
0.0195% 
(+ 0.00%) 
0.0386% 
(+ 0.10%) 
1.5887% 
(+ 0.14%) 
0.0075% 
(+ 0.01%) 
3 <0.01% <0.01% <0.01% 
0.0158% 
(+ 0.01%) 
0.0151% 
(+ 0.00%) 
<0.01% 
(+ 0.10%) 
1.3863% 
(+ 0.15%) 
<0.01% 
(+ 0.01%) 
Total impurities 
0.16% 
(+ 0.01%) 
0.17% 
(+ 0.01%) 
0.19% 
(+ 0.03%) 
0.43% 
(+ 0.10%) 
0.56% 
(+ 0.23%) 
2.38% 
(+ 0.28%) 
32.27% 
(+ 0.88%) 
0.17% 
(+ 0.03%) 
The results obtained seem to indicate that in the ICH degradation conditions there is 
not a clear indication of degradation in the time period tested (8h). Although when 
temperature and humidity rises, Nicorandil starts to degrade faster. The effect of 
temperature alone can be evaluated in condition #4. At high temperature only degradation 
rate is higher than condition #3 (40ºC/75% RH) which is a sign of the important role of 
temperature has on Nicorandil degradation rate. Additionally, it is possible to observe that 
impurities B and C are associated with a temperature increase (condition #4) rather than 
humidity increase (values in bold) On the other hand, impurity A is more related to 
humidity increase (condition #5) rather than on temperature increase (value on bold). 
At the same temperature (60ºC) but increasing the relative humidity, there is an 
indication that degradation increases judging by the result of total impurities increases. 
Still keeping the temperature at 60ºC but doubling the relative humidity level (condition 
#6), increase in total impurities is notorious with approximately 4.5 times folds jump, which 
might suggest that temperature and humidity can have a synergistic effect on the 
degradation of Nicorandil (values in bold). 
The addition of water to Nicorandil sample (condition #7) caused an extensive 
degradation and results here is no relevance in evaluating these results, since impurities 
generated are so high that the variations in their profile are unlikely to be significant. 
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On Figure 21 and Figure 22 it is possible to observe the impurity peaks in conditions 
#5 and #6. 
 
Figure 21. Nicorandil degradation chromatogram (condition 5) 
 
Figure 22. Nicorandil degradation chromatogram (conditon 6) 
Despite being relatively stable at regular temperature and humidity conditions, for 
example 25ºC/60%, when left unprocessed (not in the presence of excipients or subjected 
to mechanical stress (45), there is a range of temperature and humidity were Nicorandil 
degrades with pharmaceutical relevance. For higher temperature and humidity, the 
degradation seems to be so extent that has little significance for the evaluation of 
excipients compatibility. Considering these results the degradation conditions might need 
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to be adapted depending on the excipient tested, nevertheless conditions 25ºC/60%, 
40ºC/75% and 60ºC/80% at least for 8h, seems to be appropriated degradation 
conditions. 
Besides the evaluation of the degradation conditions on Nicorandil, it seems to be 
relevant to evaluate also the how the DS behaves under mechanical stress (grinding, 
milling and compaction forces). The purpose of these tests was to simulate the effects that 
the DS would go through during the manufacture of the final dosage form. 
1.5.2. Evaluation of mechanical stress on Nicorandil 
A mechanical process to reduce the large and small particle aggregates present on 
Nicorandil bulk powder will likely be necessary to ensure blend homogeneity. Two 
processes can be used to this end, sieving using an oscillating bar mechanism to force 
the powder blend through a mesh or a milling process using a rotating mill in blade 
configuration. Mechanical processing has been described, as previously mentioned, as 
source of impurity increase due to the damage of the crystalline structure caused by 
impact forces which, on its turn, causes more entropy in the structure and more free 
energy available to be used in degradation reactions. 
To evaluate the effect of both types of mechanical stressing that can potentially can 
be used during manufaturing, Nicorandil was milled and sieved. These two types or 
particle reduction methods have been selected since they are common techniques used in 
the production of pharmaceutical dosage forms. On the other hand, the purpose was also 
to compare the effect of an attrition method (sieving) with a cutting method on the 
crystallin structure. 
Milling trials were done using an Frewitt Hammerwitt at a rotor speed of 60000 rpm 
(blade configuration) and sieving was done using an oscillating bar sieve attached to an 
Erweka AR402 module at a speed of 134rpm. Mesh sizes used in both experiments were 
0.50mm. Total impurities and assay results (average n≥3) are shown on Table 21. 
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Table 21. Effect of milling and sieving on the impurity profile of Nicorandil 
Compression force Milling Sieving 
Before degradation 
Assay 
99.52% 
(+ 1.10%) 
99.05% 
(+ 2.16%) 
Total impurities 
0.23% 
(+ 0.25%) 
0.20% 
(+ 0.07%) 
Impurity A 
0.1499% 
(+ 0.15%) 
0.0586% 
(+ 0.03%) 
Impurity B 
0.0142% 
(+ 0.01%) 
0.0113% 
(+ 0.01%) 
Impurity C 
0.0015% 
(+ 0.00%) 
0.0000% 
(+ 0.00%) 
After degradation 
60ºC / 80% RH 
(time = 8h) 
Assay 
95.48% 
(+ 8.28%) 
96.38% 
(+ 4.09%) 
Impurity A 
0.1489% 
(+ 0.09%) 
0.2022% 
(+ 0.12%) 
Impurity B 
0.0989% 
(+ 0.09%) 
0.1960% 
(+ 0.12%) 
Impurity C 
0.0284% 
(+ 0.02%) 
0.0347% 
(+ 0.04%) 
Total impurities 
0.63% 
(+ 0.43%) 
1.13% 
(+ 0.81%) 
Samples were analysed before being degraded at 60ºC and 80%RH and after. The 
total impurity level seems to be higher when an oscillating bar sieving process is used 
probably due to a higher friction done on the Nicorandil bulk powder that might cause a 
higher structural damage. 
On Figure 23 and Figure 23a, a PXRD difractogram of Nicorandil samples sieved 
and milled is represented along with Nicorandil DS (not processed). 
 
Figure 23. Nicorandil difractogram of sievied and milled samples  
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Figure 23a. Detailed view of identified area of figure 22 
Generally, diffractograms match at every peak which means that amorphization is 
not detected. There is although a change on the milled sample (points 1 and 2) with the 
appearance of two extra peaks. This might be due to a contaminant during sample 
preparation. Considering the total diffractogram and the consistency of the remaining 
peaks it is unlikely the occurrence of a change on the crystalline structure. 
By comparing in detail the peak shape (Figure 22a), it is possible to observe that for 
the processed samples the peaks are slightly wider that the unprocessed samples which 
means that more fracture sites (smaller crystalline grain) are present, which is coherent 
with the induced mechanical stress. 
1.5.3. Evaluation of compaction on Nicorandil 
To assess the impact on Nicorandil crystalline structure of the compaction forces 
during tableting, a compression test was done on Nicorandil. This test was evaluate by the 
total impurities level after a degradation stage. Samples were prepared by compacting the 
DS on a press using diferent compaction pressures and different times of compression. 
Samples were divided in two compression forces: 0.5 ton, applied during 30s and 2min 
and 5 ton applied during 30s and 2min. Assay and impurities results were quantified and 
are presented on Table 22. 
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Table 22. Assay and impurity results after compaction test 
Compression force 0.5ton 5ton 
Time 30seg 2min 30seg 2min 
T0 
Assay 
100.64% 
(+ 0.43%) 
101.19% 
(+ 0.20%) 
98.81% 
(+ 0.15%) 
101.96% 
(+ 0.30%) 
Nitrate 
0.0553% 
(+ 0.01%) 
0.0532% 
(+ 0.01%) 
0.0655% 
(+ 0.01%) 
0.0611% 
(+ 0.01%) 
A 
0.0371% 
(+ 0.02%) 
0.0368% 
(+ 0.02%) 
0.0390% 
(+ 0.02%) 
0.0414% 
(+ 0.02%) 
B 
0.0309% 
(+ 0.01%) 
0.0317% 
(+ 0.01%) 
0.0587% 
(+ 0.01%) 
ND 
C 
0.0027% 
(+ 0.00%) 
0.0000% 
(+ 0.00%) 
ND ND 
Total impurities 
0.17% 
(+ 0.03%) 
0.16% 
(+ 0.03%) 
0.16% 
(+ 0.03%) 
0.14% 
(+ 0.03%) 
60ºC/80% 
Assay 
100.65% 
(+ 0.54%) 
94.77% 
(+ 0.24%) 
97.92% 
(+ 0.30%) 
91.20% 
(+ 0.65%) 
Nitrate 
0.2302% 
(+ 0.14%) 
1.2964% 
(+ 0.18%) 
0.3268% 
(+ 0.10%) 
2.8520% 
(+ 0.29%) 
A 
0.1357% 
(+ 0.02%) 
0.6663% 
(+ 0.08%) 
0.1509% 
(+ 0.10%) 
1.4356% 
(+ 0.10%) 
B 
0.2308% 
(+ 0.25%) 
1.9264% 
(+ 0.14%) 
0.4497% 
(+ 0.10%) 
3.0725% 
(+ 0.35%) 
C 
0.0709% 
(+ 0.07%) 
0.6112% 
(+ 0.10%) 
0.1186% 
(+ 0.10%) 
1.02664% 
(+ 0.80%) 
Total impurities 
0.81% 
(+ 0.59%) 
5.68% 
(+ 0.98%) 
1.28% 
(+ 0.40%) 
9.37% 
(+ 0.32%) 
T0 
(after 24h) 
Assay 
100.94% 
(+ 0.50%) 
100.61% 
(+ 0.34%) 
101.23% 
(+ 0.70%) 
101.30% 
(+ 0.46%) 
Nitrate 
0.0616% 
(+ 0.01%) 
0.0829% 
(+ 0.01%) 
0.0673% 
(+ 0.01%) 
0.0674% 
(+ 0.01%) 
A 
0.0417% 
(+ 0.01%) 
0.0475% 
(+ 0.01%) 
0.0585% 
(+ 0.01%) 
0.0517% 
(+ 0.01%) 
B 
0.0390% 
(+ 0.01%) 
0.0379% 
(+ 0.01%) 
0.0063% 
(+ 0.00%) 
ND 
C 
0.0060% 
(+ 0.00%) 
0.0058% 
(+ 0.00%) 
ND ND 
Total impurities 
0.16% 
(+ 0.02%) 
0.22% 
(+ 0.05%) 
0.17% 
(+ 0.03%) 
0.17% 
(+ 0.03%) 
60ºC/80% 
(after 24h) 
Assay 
84.04% 
(0.67%) 
81.62% 
(+ 0.45%) 
77.81% 
(+ 1.20%) 
76.42% 
(+ 0.72%) 
Nitrate 
3.1024% 
(0.52%) 
4.5200% 
(+ 0.47%) 
5.4474% 
(+ 0.74%) 
4.4171% 
(+ 0.66%) 
A 
1.9669% 
(0.46%) 
2.9236% 
(+ 057%) 
3.5438% 
(+ 0.67%) 
2.8382% 
(+ 0.54%) 
B 4.9767% 
(0.16%) 
7.2743% 
(+ 0.15%) 
9.0404% 
(+ 1.35%) 
7.1503% 
(+ 0.17%) 
C 
1.5257% 
(0.14%) 
2.2027% 
(+ 0.10%) 
2.9277% 
(+ 0.09%) 
2.1982% 
(+ 0.14%) 
Total impurities 
15.26% 
(0.65%) 
22.06% 
(+ 0.28) 
27.95% 
(+ 1.31%) 
21.54% 
(+ 0.69%) 
ND: Not detected 
Results suggest that the increase on compression force induced the appearance of 
more impurities with the simultaneous decrease in assay results. A second degradation 
test was performed 24h after the first test. Results show higher impurities levels and lower 
assay results which is suggestive of a higher degradation rate than the one occurred in 
the first degradation test.  
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1.5.4. Binary mixtures with Nicorandil 
The selected excipients from the initial screening were used to prepare binary 
mixture with Nicorandil by blending on a 1:1 ratio. These samples were also compressed 
into round compacts to compare degradation rates under similar conditions as observed in 
tablets. Samples were prepared according to the sample preparation method described 
the Materials and Methods section. 
1.5.5. Evaluation of disintegrants 
Compatibility of Nicorandil with disintegrants was assessed and results are 
presented on Table 23 
Table 23. Binary mixtures of Nicorandil with disintegrants 
Nicorandil 
binary mixtures 
SSG PSF 
SSG PSF 
compressed 
AcDiSol 
AcDiSol 
compressed 
Kollidon CL 
Kollidon CL 
compressed 
T0 
Assay 
98.42% 
(+ 0.20%) 
92.88% 
(+ 0.22%) 
97.84% 
(+ 0.05%) 
104.66% 
(+ 0.08%) 
98.98% 
(+ 1.12%) 
103.60% 
(+ 1.55%) 
Total 
Impurities 
0.16% 
(+ 0.02%) 
0.15% 
(+ 0.03%) 
0.16% 
(+ 0.02%) 
0.16% 
(+ 0.01%) 
0.17% 
(+ 0.06%) 
0.21% 
(+ 0.05%) 
25ºC / 60% 
(T= 8h) 
Assay 
99.85% 
(+ 0.18%) 
102.50% 
(+ 1.12%) 
100.60% 
(+ 0.41%) 
98.90% 
(+ 0.62%) 
98.39% 
(+ 0.40%) 
93.84% 
(+ 0.82%) 
Total 
Impurities 
0.16% 
(+ 0.01%) 
0.16% 
(+ 0.02%) 
0.16% 
(+ 0.02%) 
0.17% 
(+ 0.01%) 
0.18% 
(+ 0.01%) 
0.18% 
(+ 0.02%) 
25ºC / 60% 
(T= 1W) 
Assay 
100.94% 
(+ 0.16%) 
100.35% 
(+ 0.14%) 
104.26% 
(+ 1.80%) 
95.11% 
(+ 0.45%) 
104.78% 
(+ 0.64%) 
104.72% 
(+ 0.98%) 
Total 
Impurities 
0.17% 
(+ 0.01%) 
0.18% 
(+ 0.01%) 
0.13% 
(+ 0.02%) 
0.15% 
(+ 0.00%) 
0.76% 
(+ 0.01%) 
0.72% 
(+ 0.06%) 
40ºC / 75% 
(T= 8h) 
Assay 
106.73% 
(+ 0.20%) 
99.85% 
(+ 0.22%) 
100.59% 
(+ 0.10%) 
99.20% 
(+ 0.30%) 
100.20% 
(+ 0.15%) 
100.67% 
(+ 0.34%) 
Total 
Impurities 
0.31% 
(+ 0.01%) 
0.35% 
(+ 0.01%) 
0.27% 
(+ 0.01%) 
0.40% 
(+ 0.02%) 
1.50% 
(+ 0.12%) 
1.48% 
(+ 0.15%) 
60ºC / 75% 
(T= 8h) 
Assay 
79.79% 
(+ 1.14%) 
73.85% 
(+ 1.23%) 
71.20% 
(+ 0.96%) 
76.00% 
(+ 0.88%) 
65.38% 
(+ 0.20%) 
72.55% 
(+ 0.20%) 
Total 
Impurities 
23.47% 
(+ 0.08%) 
29.20% 
(+ 0.05%) 
23.11% 
(+ 0.12%) 
25.80% 
(+ 0.03%) 
33.45% 
(+ 1.66%) 
26.81% 
(+ 1.43%) 
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1.5.6. Evaluation of glidants 
Two types of anhydrous silica have been used in compatibility studies with 
Nicorandil, a colloidal grade of silica (type 1) and a granular grade (type 2). Both binary 
mixture were analyzed as powder samples and also as compacted samples. Results are 
expressed in Table 24. 
Table 24. Binary mixtures of Nicorandil with glidants 
Nicorandil binary mixtures 
Colloidal 
silicon dioxide 
type 1 
Colloidal silicon 
dioxide type 1 
compressed 
Colloidal silicon 
dioxide type 2 
Colloidal silicon 
dioxide type 2 
compressed 
T0 
Assay 101.09% 100.46% 98.37% 92.51% 
Total 
Impurities 0.18% 0.38% 0.17% 0.21% 
25ºC / 60% 
(T= 1W) 
Assay 100.22% 108.34% 95.85% 99.63% 
Total 
Impurities 0.21% 0.99% 0.36% 0.61% 
40ºC / 75% 
(T= 8h) 
Assay 95.24% 93.24% 94.24% 92.24% 
Total 
Impurities 4.50% 6.32% 5.22% 7.37% 
60ºC / 80% 
(T= 8h) 
Assay 19.56% 8.26% 8.83% 6.22% 
Total 
Impurities 75.02% 73.47% 65.79% 55.63% 
Sample were prepared and analyzed only once (n=1). All results from the four 
samples are coherent between themselves and all show high degradation rates. No 
further analysis were done since preliminary results suggest a deleterious effect over 
Nicorandil. Type 1 and type 2 colloidal silicon dioxide should not, therefore, be 
incorporated in the formulation since results seems to indicate an incompatibility with the 
DS. 
1.5.7. Evaluation of diluents 
Pre-gelified starch has been identified as an excipient with a potential stabilization 
effect. Two grades of pre-gelified starch were used: Starch 1500 PG and Starch 1500 PG 
low moisture grade. Reference product uses Starch although it was not possible to know 
which type. To further improve the already mentioned protective effect that Starch 
supposedly might have, binary mixtures were prepared with both types. Results are 
shown on Table 25. 
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Table 25. Binary mixtures of Nicorandil with starch and diluents 
Binary mixtures 
(n > 2) 
Starch 
1500 LM 
Starch 
1500 
Isomalt 
Mannitol 
SD200 
Mannitol 
(powdered) 
MCC 
PH200 
T0 
Assay 
98.44% 
(+ 0.10%) 
101.09% 
(+ 4.87%) 
100.74% 
(+ 0.14%) 
98.78% 
(+ 0.50) 
98.22% 
(+ 0.72) 
99.65% 
(+ 0.72) 
Total 
impurities 
0.17% 
(+ 0.01%) 
0.16% 
(+ 0.13%) 
0.17% 
(+ 0.01%) 
0.14% 
(+ 0.02) 
0.13% 
(+ 0.03) 
0.15% 
(+ 0.02) 
25ºC/60% RH 
(T = 1W) 
Assay 
99.28%  
(+ 1.50%) 
101.36% 
(+ 2.11%) 
100.32% 
(+ 0.10%) 
99.20% 
(+ 0.50) 
100.45% 
(+ 1.30) 
99.64% 
(+ 1.64) 
Total 
impurities 
0.17% 
(+ 0.01%) 
0.48% 
(+ 0.09%) 
0.18% 
(+ 0.01%) 
0.16% 
(+ 0.04) 
0.15% 
(+ 0.05) 
0.16% 
(+ 0.04) 
60ºC / 80% 
(T = 8h)  
Assay 
92.29% 
(+ 1.30%) 
102.36% 
(+ 3.90%) 
97.00% 
(+ 1.37%) 
60.73% 
(+ 1.80) 
62.73% 
(+ 1.50) 
52.32% 
(+ 2.13) 
Total 
impurities 
2.09% 
(+ 0.20%) 
2.52% 
(+ 0.17%) 
1.60% 
(+ 0.34%) 
39.73% 
(+ 0.50) 
37.09% 
(+ 0.76) 
42.35% 
(+ 0.87) 
Results presented on the table are inconclusive on the 25ºC/60% RH after one 
week. There is little difference on the total impurities between samples. Analysing the 
results of total impurities in the 60ºC/80% RH it is possible to distinguish between the low 
moisture grade of starch from the regular grade since the first has a slightly lower total 
impurity value. On the other hand, there is a higher difference on the results of the 
diluents, with Isomalt generating a total impurities results much lower than Mannitol (both 
grades) and microcrystalline cellulose. 
1.5.8. Evaluation of lubricant 
Lubricants on Nicorandil formulations have been described as playing important 
roles mainly in protecting the DS crystal from compression forces (see Patent landscape). 
Two lubricants were selected to perform compatibility studies: glyceryl behenate and 
stearic acid. Results of compatibility studies are shown on Table 26. 
Table 26. Evaluation of lubricants 
Nicorandil binary mixtures 
Glyceryl 
Behenate 
Glyceryl 
Behenate 
compressed 
Stearic acid 
Stearic acid 
compressed 
T0 
Assay 98.02% 102.95% 99.30% 99.80% 
Total impurities 0.22% 0.24% 0.18% 0.19% 
25ºC/60% RH 
(T = 1W) 
Assay 97.20% 100.40% 101.20% 100.24% 
Total impurities 0.31% 0.33% 0.20% 0.21% 
60ºC / 80% 
(T = 8h) 
Assay 75.91% 76.81% 82.81% 95.81% 
Total impurities 22.94% 8.13% 16.80% 6.20% 
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Compatibility studies results were further clarified by increasing the complexity of 
samples by adding more than one excipient to Nicorandl and placing the samples under 
degradation stress. This procedure is justified by the limitations of binary mixtures analysis 
regarding representativity of interactions and ratios in the formulation, therefore, mixtures 
of excipients combined were prepared with Nicorandil to assess chemical compatibility in 
a multi-component prototype formulation. 
Table 27 describes the mixtures prepared by weighing 10g of mixture according to 
the ratios indicated and blending the components. The mixtures were placed on open petri 
dishes inside three climatic chambers at 25ºC/60% HR, 30ºC/65% HR and 40ºC / 75% 
HR respectively. The choice of the degradation conditions was made considering that test 
mixtures composition had similar component ratios to the final formulation and therefore to 
better predict stability the same degradations conditions that would be used in the short 
term stability study were selected. 
Table 27. Composition of the multi component mixtures of Nicorandil 
Composition Mixture A Mixture B Mixture C Mixture D 
Nicorandil 10% 10% 10% 10% 
Isomalt 67% - - 23% 
Microcrystalline Cellulose 
PH 102 
- 67% - 22% 
Mannitol - - 67% 22% 
Starch 1500 LM 10% 10% 10% 10% 
SSG-PSF 8% 8% 8% 8% 
Stearic ac. 50 micronized 5% 5% 5% 5% 
Mixtures A, B and C were prepared to evaluate the effect of the main component on 
the formulation, which is the diluent, together with the remaining potential excipients. To 
gather additional information on Nicorandil stability when in contact with the main 
formulations components and to confirm binary mixtures with diluents results, compatibility 
tests with the three diluents: Isomalt, Mannitol and Cellulose, were done. Mixture D was 
prepared with approximately the same amounts of each excipient and served as control 
for the experiment. These blends were tested in two different stages. 
First stage was done by placing the samples in each of the climate chambers for 
different periods of time according to the condition. After this first degradation time petri 
dishes containing the powder mixtures were closed and hermetically sealed for a period of 
48h after which they were placed back into the climatic chambers for another degradation 
stage. Table 28 summarizes the degradation times and conditions. 
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Table 28. Degradation plan of compatibility study with mixtures 
Time 25ºC/60% RH 30ºC/65% RH 40ºC/75% RH 
First degradation stage 48h 18h 12h 
Hold time 48h 48h 48h 
Second degradation stage 48h 18h 12h 
The total impurity results obtained are shown on Figure 24. 
 
Figure 24. Compatibility of Nicorandil in composite mixtures 
The results suggest that the degradation follows different kinetics on both stages. 
While on the first stage the degradation is not significantly different between all samples 
on the second stage there is a clear difference when samples are degraded in the 
40ºC/75% RH condition. Between all mixtures, mixture A and C were the ones with less 
amount of total impurities generated and Mixture A seems to have an advantage over 
mixture C. 
Considering these results, excipients used in mixutre A will be used for further 
evaluation. 
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1.6. Excipients selection 
The excipients to be included in the final formulation were preliminary selected 
according to a rationale described on Table 29. Optimized qualitative formulation will be 
discussed during formulation development. 
Table 29. List of excipients selected for formulation development stage 
Components Function Rationale 
Isomalt (GalenIQ 721
®
) Diluent / filler 
Formulation main component. Isomalt compatibility results 
suggest that it has the potential to stabilize Nicorandil molecule. 
Sodium Starch Glycolate 
(Vivastar PSF
®
) 
Binder / 
disintegrant 
Starch pregelatinized has a moisture scavenging property and 
low water activity which can be used as an advantage on a 
moisture sensitive formulation.  
Maize starch 
(Starch 1500
®
 low moisture 
grade) 
Disintegrant 
Despite being a hygroscopic excipient this disintegrant could be 
used to accelerate the dissolution profile. A low moisture grade 
will be used. There are no indication of the use of such starch 
grade on the patents. 
Stearic acid 
(Dub Microlub 50
®
 
micronized) 
Lubricant 
This lubricant has been identified as a potential stabilization 
agent to the compaction forces that the Nicorandil crystal suffers 
durint tableting. Additionally, stearic acid has been described as 
a preferred lubricant in formulations containing Starch 1500
®
 
(79). A micronized grade will be used during formulation 
development. Patents describe the use of a non-micronized 
grade of stearic acid. 
1.6.1. Excipients description and characterization 
At this point it was necessary to gather additional information on the excipients 
properties, which is described hereafter. 
 Isomalt - GalenIQ 721® 
Isomalt is the only polyol produced from sucrose and is a mixture of hydrogenated 
mono and disaccharides whose principal components are the disaccharide alcohols 
1-O-α-D-glucopyranosyl-D-mannitol dihydrate and 6-O-α-D-glucopyranosyl-D-sorbitol. 
It appears as a white or almost white powder or granular or crystalline substance 
and has good thermal and chemical stability due to its stable glycosidic bond. It does not 
go through browning reactions and does not possess reducing groups and therefore it is 
not expected to react with other raw materials in a formulation. Isomalt is non-hygroscopic 
and at 25ºC does not significantly absorb additional water up to a relative humidity of 
85%. As an effect of the low hygroscopicity, tablets produced with Isomalt are more stable 
than tablets containing other sugar based diluents. 
This excipient is used in a variety of pharmaceutical preparations including direct 
compression and wet granulation processes for the production of tablets. Several grades 
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of Isomalt marketed under the brand name of GalenIQ® are available, although, type 721 
is an excipient especially designed for direct compression due to its higher solubility which 
produces good disintegration results and has the desirable compaction properties, 
therefore grade 721 is the grade chosen to be used in formulation development. 
Since it is a diluent Isomalt will be the major component therefore it is expected to 
influence the mixture flowability and compaction properties. 
The compaction properties of the different types of Isomalt are described in the 
literature (81-83). Evaluation by Heckel plot analysis showed that Isomalt exhibits plastic 
behavior and undergoes elastic recovery primarily in the die (82). This means that the 
deformation behavior is similar to sorbitol and mannitol, but differs from the deformation 
behavior of other polyols such as xylitol and lactitol, which are mainly brittle materials. It 
has an excellent flowability, does not stick to tableting tools and offers a good 
compactability. 
Compression of Isomalt without lubrication is difficult and may cause die wall 
sticking, capping and lamination. When Isomalt is present in a formulation the addition of 
a lubricant is recommended. 
 Sodium Starch Glycolate - Vivastar PSF® low moisture grade 
Sodium starch glycolate is a substituted derivative of potato starch, rice starch, 
wheat or corn. Sodium starch glycolate is the sodium salt of carboxymethyl ether and 
appears as a fine, very hygroscopic, white to off-white, tasteless, odorless, free flowing 
powder. It can be used in direct compression or wet granulation formulas. Disintegrant 
properties and mechanism of action are widely described in the literature. 
The usual concentration employed in a formulation is between 2% and 8%, with the 
optimum concentration about 4%. SSG has been described as not sensitive to the content 
of lubricant excipients in a tablet formulation and also to the amount of compression force 
applied during tableting. 
Sodium starch glycolate used was Vivastar PSF grade from JRS Pharma which is a 
special grade with low methanol content especially suited for alcohol and moisture 
sensitive actives. 
 Maize starch - Starch 1500®, low moisture grade 
White or slightly yellow, moderately coarse to fine free flowing, odourless and with a 
slight characteristic taste powder. Partial pre-gelatinization provides starch with its unique 
properties. Low moisture grade corn starch has been physically modified with water 
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content below 7% and can be directly compressed into tablets. Starch 1500 LM has 
improved flow and compression characteristics playing multiple functions of binder, 
disintegrant, flow-aid and self-lubricant in direct compression formulations. 
The addition of Starch also helps the mixture flows well and decreases the amount 
of lubricant agents needed due to the self-lubricant properties of pregelatinized starch. 
The low moisture grade is specially designed to be used with moisture sensitive DS which 
helps on the long term product stability (78). 
Besides this characteristic, also showed less absorption rates of moisture compared 
to common disintegrants such as sodium croscarmelose and sodium starch glycolate. In 
this study, it was also suggested that starch 1500 has an inhibiting effect on water activity 
(or equilibrium relative humidity expressed in percentage) within the formulation and 
retarding moisture interaction with the DS. 
The same rationale is used to justify the inclusion of starch 1500 since it should 
preferentially bind moisture and decrease the rate at which the equilibrium relative 
humidity equilibrates with the environment. 
 Stearic Acid - Dub Microlub 50, micronized 
The USP32–NF27 describes stearic acid as a mixture of stearic acid and palmitic 
acid, defining the content of stearic acid as not less than 40.0% and the sum of the two 
acids as not less than 90.0%. Stearic acid is a hard, white or faintly yellow-colored, 
somewhat glossy, crystalline solid with the appearance of leaflets or a white or yellowish 
white powder. It has a slight fat-like odor and taste. Stearic acid is widely used in oral 
formulations as a tablet and capsule lubricant. It is insoluble in water, soluble in alcohols 
and fat solvents. Micronized grade of stearic acid was used to promote an intimate contact 
with remaining particles so that upon tableting compression forces are deviated from the 
Nicorandil crystals.  
1.7. Excipients risk assessment 
The second part of the risk assessment focus on the excipients attributes and was 
performed to evaluate the impact that each component could have on the drug product 
CQA’s. 
Considering the excipients selection following the pre-formulation studies an 
analysis on potential risk that each excipient selected could bring into the formulation and 
process was done and is described on Table 30. The information contained on this table 
lists the formulation components and addresses each one following a procedure that 
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takes into account materials properties, bibliographic research and characteristics that can 
have an impact on the finished product quality attributes. 
Table 30. Risk assessment evaluation on excipients 
Drug Product 
CQAs 
GalenIQ 721
® 
(Isomalt) 
amount 
Maiz starch 
(Starch 1500
®
 LM) 
amount 
Vivastar PSF 
®
 
(Sodium starch glycolate) 
amount 
DUB Microlub 50 
(Stearic acid) 
amount 
Assay Medium Low Low Medium 
Degradation 
Products 
Low Low High Low 
Dissolution Medium Medium Medium High 
Water content Low Medium High Low 
Hardness High Medium Low Low 
The justification of the risk assessment for each excipient is described on Table 31. 
Table 31. Rationale on risk assessment evaluation of formulation excipients 
Drug Product 
CQA’s 
Rationale 
Risk 
evaluation 
Formulation Variables: GalenIQ 721
® 
(Isomalt) amount 
Assay 
Isomalt represents the major portion of the formula, therefore, it can have a strong 
influence on the flow properties of the blend and hence its homogeneity. This, in turn, can 
impact tablet uniformity of dosage and hence tablet assay. On the other hand since this 
particular type of Isomalt is especially designed for direct compression formulations, its flow 
and density properties makes this excipient suitable for this formulation. This variable 
needs further evaluation. 
The risk is 
medium 
Degradation 
Products 
Since Isomalt has a low water content and has low reactivity its influence is not expected to 
be deleterious to the DS as previously suggested by compatibility studies. 
The risk is 
low 
Dissolution 
Isomalt represents the major portion of the formula, which can impact at a great extent the 
compaction properties of the blend. This, in turn, can impact dissolution profile. On the 
other hand since this particular type of Isomalt is especially designed for direct 
compression formulations, its flow and density properties makes this excipient suitable for 
this formulation. This variable needs further evaluation. 
The risk is 
medium 
Water content 
Isomalt represents the major portion of the formula and this can impact at a great extent 
the water content of the formulation. Since Isomalt has a low water content and has low 
reactivity its influence is not expected to be deleterious to the DS as previously suggested 
by compatibility studies. 
The risk is 
low 
Hardness 
Isomalt represents the major portion of the formula and this can impact at a great extent 
the compaction properties of the blend. This, in turn, can impact tablet hardness and cause 
DS instability. This variable needs further evaluation. 
The risk is 
high 
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Table 30. Rationale on risk assessment evaluation of formulation excipients (cont.) 
Drug Product 
CQA’s 
Rationale 
Risk 
evaluation 
Formulation Variable: Starch 1500
®
 LM amount. 
Assay In the recommended amount ranges, starch it is not likely to impact tablet assay. The risk is low 
Degradation 
Products 
Due to starch properties and the demonstrated compatibility, this excipient is expected to 
have a stability promoter effect on Nicorandil DS. 
The risk is low 
Dissolution 
Starch can impact dissolution due to its functional properties. The amount used must be 
evaluated to guarantee dissolution profile similarity to the RP. 
The risk is 
medium 
Water content 
Despite having a water content that can reach 5%, starch properties turns this excipient 
into a water scavenger inside a tablet matrix. Nevertheless, compatibility studies already 
performed suggest low interaction with Nicorandil. 
The risk is 
medium 
Hardness 
Starch is also known for its binding properties. In the range of recommended amounts. 
Compression trials should be performed to evaluate tablet performance. 
The risk is 
medium 
Formulation Variable: Vivastar PSF
® 
(Sodium starch glycolate) amount. 
Assay This excipient is not expected to influence the assay values of the drug product. The risk is low 
Degradation 
Products 
SSG is very hygroscopic which can have a negative impact during processing since it 
has the ability to adsorb moisture from air. Water content is a known factor that 
increases instability of the DS and the drug product. Further studies should be 
performed. 
The risk is 
high 
Dissolution 
SSG level can impact the disintegration time and, ultimately, dissolution profile. Since 
one of the goals is to match as close as possible the RP dissolution profile a disintegrant 
might be needed in the formula. Nevertheless, considering the remaining components 
and the presence of starch, this excipient must be further evaluated. 
The risk is 
medium 
Water content 
SSG has a high water content value. Despite being present in a small amount, its 
hygroscopic nature it is necessary to further evaluate this component. 
The risk is 
high 
Hardness This excipient is not expected to influence the tablet hardness. The risk is low 
Formulation Variable: Stearic acid 50 amount. 
Assay 
In the recommended amount levels and by avoiding over lubrication stearic acid has low 
influence on powder blend flow, therefore it is unlikely to impact tablet assay and CU. 
The risk is 
medium 
Degradation 
Products 
This excipient has been identified as a potential promoter of stability by decreasing the 
compression force on Nicorandil tablets. Compatibility study did not indicate any 
evidence of a possible interaction with the DS. 
The risk is low 
Dissolution Over-lubrication or excessive lubricant may retard dissolution profile. 
The risk is 
medium 
Water content This excipient is not expected to influence total water content of the drug product. The risk is low 
Hardness This excipient is not expected to influence the tablet hardness. The risk is low 
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2. Formulation development 
The goal of this section is to describe the sequence of tests and results that led to 
the production a drug product based on the CQA and TPP defined on the Aims of the 
study section (Table 6). 
The formulation development encompasses the production of powder blend for 
direct compression and the production of 10mg Nicorandil round tablets with 7mm in 
diameter, without scores or embossing. By direct compression it should be understood as 
the process by which tablets are manufactured by directly compressing powder blends of 
the active ingredient and suitable excipients. 
The choice of the manufacturing process is dictated by the stability characteristics of 
Nicorandil. The known stability issues immediately rule out aqueous based wet 
granulation, dry granulation or any other process that induces a physical form change on 
the particles or promotes excessive mechanical stress on its crystalline structure. 
The manufacturing strategy to formulate Nicorandil tablets will be, therefore, the 
production of a powder blend for direct compression. 
Direct compression is a manufacturing process in which a powder blend of the DS 
and adequate excipients is compressed directly after the blending operation. Direct 
compression presents challenges related mainly to the particle size of the several 
components, although shape and density also play important roles (84). If these 
parameters are sufficiently different between each other the powder blend will tend to 
present difficult flow and particle segregation phenomena is likely to occur. This poses a 
threat to the blend homogeneity and tablet content uniformity. Despite being apparently a 
simple and straightforward manufacturing process, formulating a drug product based on 
direct compression requires careful evaluation of DS and excipients physical properties to 
obtain a powder blend with adequate flow properties to allow the powder blend to flow 
uniformly not only into the tableting machine but also into a die cavity where it will be 
compressed into a firm compact, or tablet. 
The tendency of a powder mixture to form a uniform blend or to segregate is also 
dependent on physical properties such as cohesiveness, particle size and shape or 
density (1). The homogeneity of the final blend depends on other parameters such as the 
operating design, DS concentration and raw materials charging sequence as well as 
blender fill level, mixing time and mixing speed. 
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2.1. Manufacturing process risk assessment 
Before starting the formulation development a risk assessment was done 
considering that the final purpose was to produce a powder blend for direct compression. 
The major operations in such manufacturing steps are powder blending, lubrication and 
tableting. Critical points which can have potential impact on finished product CQA’s and 
the corresponding risk assessment are listed on Table 32. 
Table 32. Risk assessment evaluation related with the manufacturing process 
Process step Assessment 
Risk 
evaluation 
Blending 
Loading 
components 
and DS 
sieving. 
Due to PSD of Nicorandil this step should be done with the DS previously sieved 
gently by hand through a 1mm mesh size to scatter larger aggregates. 
The risk is 
low 
Bending step 
Blending with Isomalt should be done in two steps to dilute the blend geometrically. 
Dilution and blending time are critically related to DS homogeneity in the blend. 
The risk is 
medium 
Milling step 
Milling step is done to guarantee that the DS can be properly blended with the 
components. 
The risk is 
high 
Lubrication 
Lubricants are normally used in low amounts and are associated with de-mixing if 
over blended. For the promotion of an adequate lubricant distribution this should be 
sieved by hand through a 0,710mm mesh size partially diluted with a blend portion. 
The risk is 
medium 
Final mixture 
Powder blend will be used to produce 10mg tablets. Blend characteristics must be 
verified before tableting. 
The risk is 
medium 
Tableting 
Compression 
force 
Compression force (main compression and pre-compression) can influence 
product performance since it is related to critical quality attributes of the tablets 
such as resistance to breaking, disintegration, friability and dissolution profile. 
Additionally, compression force has been associated also with increase in product 
instability. 
The risk is 
low 
Tableting 
speed 
Tableting was done considering only one speed. 
The risk is 
low 
Tablet 
characteristics 
Tablets characteristics are an indication of product quality and overall compression 
process efficiency. Characteristics should meet target product profile defined 
initially. 
The risk is 
medium 
2.2. Formulation development studies 
Formulation development was divided in four trials which started by evaluating its 
components. Each of these components are identified as formulation variables with 
potential risk as defined on Table 31. The purpose of the formulation development was to 
define an optimized manufacturing process able to produce a homogeneous powder 
blend for direct compression and to produce 10mg Nicorandil tablets. 
Table 33 summarizes the development process and briefly describes the rationale 
associated with each step.  
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Table 33. Summary of formulation trials 
Trial 
Number 
Number of 
batches 
produced 
Description 
#1 5 
Production of a Nicorandil powder blend to test the influence of sodium starch 
glycolate on the disintegration times of 10mg tablets to assess its relevance on 
the formulation. 
#2 3 
Production of a Nicorandil powder blend using different amounts of Starch 1500 
PG LM grade to evaluate the effect on 10mg tablets properties. 
#3 2 
Development and optimization of the blending process. Introduction and 
evaluation of milling trials. Production and characterization of Nicorandil 10mg 
tablets and evaluation of the compression process. 
#4 1 
Production and characterization of Nicorandil blend and 10mg tablets in a 1kg 
batch size. Production of samples to start a 3 months stability study. Definition 
of the final manufacturing process, critical process parameters, risk assessment 
and final product specifications. 
The amount of excipients to be used was based on technical bibliography (79) 
regarding their commonly accepted amount ranges and is described on Table 34. Test 
regarding changes in the quantitative composition of test formulas will be done inside 
these ranges. 
Table 34. Common amounts of selected excipients  
Component Function 
% in the 
formulation 
Justification 
Nicorandil DS 10% Target profile 
GalenIQ 721
®
 
(Isomalt) 
Diluent, filler > 25% 
Handbook of Pharmaceutical 
Excipients. 
Product technical literature. 
Starch 1500
®
 LM 
(Pregelatinized starch, low moisture) 
Binder, 
disintegrant 
2% - 20% 
Handbook of Pharmaceutical 
Excipients. 
Product technical literature. 
Vivastar PSF
®
 grade 
(Sodium starch glycolate, low moisture grade) 
Disintegrant 2% - 8% 
Handbook of Pharmaceutical 
Excipients. 
Product technical literature. 
Dub MicroLub 50 
(Stearic acid, micronized) 
Lubricant 1% - 3% 
Handbook of Pharmaceutical 
Excipients. 
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2.2.1. Trial #1 
Aim: The purpose of the trial #1 was to assess if sodium starch glycolate (SSG) a 
very hygroscopic excipient is necessary on the formulation and to which extent its 
presence influences the disintegration times and the dissolution profile considering that 
starch, selected to be included on the formulation, also has a disintegrant action on the 
proposed amount. SSG has been identified as a high risk formulation variable and 
requires further evaluation regarding the necessity to be included in the formulation. Trial 
#1 was designed to assess the influence of SSG and is composed of five test mixtures 
with variable SSG amounts. 
Manufacturing process: The selected manufacturing process considers the 
production of five 150g powder blends using a dry blend process for direct compression. 
Blending operation was done manually using a PE plastic bag. The process started by 
mixing the DS with SSG and Starch 1500 LM. This pre-blend was mixed in the bag during 
3 min and sieved by hand through 0,710mm sieve. Isomalt was added and blended for an 
additional 3 min. Stearic acid was diluted with two parts of the mixture and hand sieved 
through a mesh size of 0,5mm and incorporated in the powder blend. The final mixture 
was blended for 1 min. This mixture was used to produce tablets in an 8 stations lab scale 
Ronchi® automatic compressing machine using 7mm round, biconvex punches without 
break line or embossing. 
The composition of the test mixtures is described on Table 35. 
Table 35. Trial #1. Quantitative composition of test mixtures 
Components 
Formulation 
#1 
Formulation 
#2 
Formulation 
#3 
Formulation 
#4 
Formulation 
#5 
Nicorandil 10% 10% 10% 10% 10% 
GalenIQ 721
®
 
(Isomalt) 
75% 73% 71% 67% 63% 
Starch 1500
®
 PG LM 
(Pre-gelelatinized starch) 
10% 10% 10% 10% 10% 
Vivastar PSF
®
 
(Sodium starch glycolate, low 
moisture) 
0% 2% 4% 8% 12% 
Dub MicroLub 50 
(Stearic acid, micronized) 
5% 5% 5% 5% 5% 
Total 100% 100% 100% 100% 100% 
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Variable amounts of SSG were used maintaining fixed the amounts of the remaining 
components except Isomalt which was used to compensate the variable amounts of SSG. 
Test #1 does not contain SSG and serves as control sample. Tests #2, #3 and #4 have 
variable quantities of SSG, 2%, 4% and 8% which are the minimum, optimal and 
maximum recommended amounts in the literature. Test #5 contains 12% SSG-PSF. 
Starch 1500® LM was incorporated in the initial formulation as 10% since it is the 
maximum amount recommended for disintegrant action while maintaining binder 
properties. 
The lubricant agent, stearic acid 50 micronized, was used in the amount of 5% 
based on information retrieved from patent data that indicates stearic acid as an excipient 
that can help to decrease the compression forces over Nicorandil during tableting. 
Results: 
Blending operations were difficult due to the fact that bulk Nicorandil is hard to sieve 
alone. This is due to the large and small aggregates present in the bulk DS that cannot be 
scattered by simple dry blending operations. In fact, using a manual sieving step through 
a 1.0 or 0.710mm mesh sizes, Nicorandil powder alone, without the use of an excipient as 
a sieving adjuvant, re-agglomerates after the sieving. A pre-blend was performed with 
Starch to promote Nicorandil dilution and to aid the subsequent sieving step. 
After the production of the powder blend, the tablets were manufactured by direct 
compression and were characterized. To evaluate the response of the powder blend to 
compaction force, compression trials with increasing forces were performed. Compression 
settings are indicated with values: #150, #125, #100, #75 and #50. Each value represents 
the distance in millimetres between the main compression rolls on the compression 
machine. Lower values mean smaller distances and hence a higher compression force is 
applied between punches. On Table 36 are shown the results (n=20) of hardness testing. 
Table 36. Trial #1. Compression tests results 
Compression setting 
(Main compression force) 
Test #1 Test #2 Test #3 Test #4 Test #5 
Tablet hardness (  + σ) 
#150 27 N (+ 2) 23 N (+ 3) 25 N (+ 2) 20 N (+ 2) 14 N (+ 2) 
#125 46 N (+ 5) 56 N (+ 6) 50 N (+ 8) 44 N (+ 9) 35 N (+ 10) 
#100 115 N (+ 11) 104 N (+ 7) 104 N (+ 4) 89 N (+ 4) 60 N (+ 9) 
#75 120 N (+ 8) 110 N (+ 11) 107 N (+ 6) 97 N (+ 6) 75 N (+ 4) 
#50 127 N (+ 9) 114 N (+ 9) 107 N (+ 9) 102 N (+ 10) 84 N (+ 9) 
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These results are shown on Figure 25. It is possible to observe that there is a more 
linear response to compaction force on test #5 than for the remaining test. Test #1 (0% 
SSG) has the highest change in tablet hardness when the compaction force changes from 
#125 to #100 setting. This might be an indication that the SSG particles are compensating 
the plastic deformation and elastic recovery compaction properties of Isomalt (83) due to 
their predominately elastic deformation (85). 
 
Figure 25. Influence of SSG amounts on tablet hardness 
It is possible to observe that between main compression setting #150 and #125, 
tablets present a hardness value inside the proposed specification range (40N) as 
mentioned in the Aims of the Study section. In this range SSG effect is hardly noticed. 
On Table 37 the results of the characterization of test tablets is summarized. 
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Table 37. Trial #1. Tablet characterization results 
Setting #125. Test mixture # #1 #2 #3 #4 #5 
Number of tablets produced 50 50 50 50 50 
Tablet weight 
(n=10) 
Average 100.1 mg 99.9 mg 98.4 mg 99.8 mg 98.9 mg 
min 98.8 mg 98.8 mg 96.7 mg 98.1 mg 97.1 mg 
max 101.0 mg 102.6 mg 100.1 mg 102.5 mg 100.0 mg 
RSD 0.71% 1.24% 1.16% 1.17% 1.05% 
Tablet thickness 
(n=10) 
Average 
2.59 mm 
(+ 0.02) 
2.60 mm 
(+ 0.03) 
2.62 mm 
(+ 0.03) 
2.63 mm 
(+ 0.03) 
2.65 mm 
(+ 0.02) 
Friability 0.30% 0.32% 0.28% 0.33% 0.38% 
Water content Average (n=2) 1.8% (+ 0.1) 1.9% (+ 0.1) 2.1% (+ 0.1) 2.1% (+ 0.1) 2.2% (+ 0.1) 
Compression 
setting 
Disintegration 
times 
 
#50 
First: 
Last:  
5min 40s 
6min 52s 
5min 07s 
6min 19s 
4 min 34s 
6min 02s 
5min 45s 
6min 10s 
4min 00s 
5min 45s 
#75 
First: 
Last:  
5min 10s 
5min 50s 
3min 43s 
4min 59s 
3min 42s 
6min 30s 
4min 08s 
6min 07s 
3min 38s 
5min 10s 
#100 
First: 
Last:  
4min 40s 
5min 37s 
5min 23s 
5min 46s 
4min 58s 
5min 40s 
4min 52s 
5min 11s 
4min 10s 
4min 27s 
#125 
First: 
Last:  
1min 23s 
3min 20s 
3min 36s 
4min 00s 
3min 47 
4min 19s 
3min 52s 
4min 17s 
3min 12s 
3min 41s 
#150 
First: 
Last:  
1min 00s 
1min 50s 
3min 37s 
4min 03s 
2min 30s 
3min 24s 
3min 00s 
3min 18s 
2min 02s 
2min 30s 
Tablets show acceptable characteristics regarding weight uniformity (max RSD: 
1.24%) and low friability. It is also possible to observe that for higher amounts of SSG 
thickness values increase which might indicate that the compaction efficiency decreases, 
which is in accordance with results on figure 23 and previous published results (86). 
Tablets disintegration times are different and in some circumstances the addition of 
sodium starch glycolate did not lead to shorter disintegration times (Figure 26), which is in 
line with previous work (81). The addition of SSG does not seem to decrease 
disintegration times in the levels normally used (2%-8%), since for the same compression 
setting the formulation without it has equivalent disintegration times as the formulations 
with SSG. 
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Figure 26. Trial #1. Disintegration times vs SSG amounts 
It is possible to observe that hardness decreases with the increase of SSG amount 
(test #2 to test #5), followed up with a coherent response of disintegration times. To 
confirm these results a dissolution test was performed. Dissolution tests were performed 
on trial #1 (0% SSG), #3 (4% SSG) and #5 (12% SSG) since these trials are 
representative. Dissolution test and method is described in the Materials and methods 
section. Figure 27 summarizes the results obtained and compares them with two RP 
batches. 
 
Figure 27. Trial #1. Dissolution tests of formulations #1, #3 and #5 
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All formulations tested release the DS slower than both batches of the RP on the 
same times. At 30min 100% of the DS is solubilized on the dissolution media. Again the 
tests containing SSG had slower results which is in line with results presented on Figure 
26. These results suggest that the addition of SSG is not increasing dissolution rate and 
even formulation #1 (0% SSG) has the fastest dissolution rate of the three tests. 
At this point it seems to be necessary to change formulation composition to 
accelerate dissolution profile and to further evaluate the influence of SSG on the 
formulation if it is intended to develop a new formulation but with an equivalent release 
profile to the RP. 
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2.2.2. Trial #2 
Aim: The purpose of trial #2 was to test reduce the amount of starch 1500 PG LM 
and test different amounts of SSG-PSF to evaluate its effect on the dissolution profile and 
tablets characteristics. 
Manufacturing process: For the production of the three test mixtures of trial #2 the 
same manufacturing process used in trial #1 was followed. For this purpose three test 
mixtures were prepared according to the quantitative composition described in Table 38. 
Mixtures produced in trial #2 were characterized following the methodology 
described in the Materials and Methods section, regarding homogeneity, flowability and 
apparent density while 10mg tablets were characterized regarding weight and dimensions, 
disintegration, hardness, friability, water content and dissolution. 
Blend homogeneity was assessed by collecting 4 samples from approximately 
equidistant points from the powder blend. 
Tablets were produced in an 8 stations lab scale Ronchi® automatic tableting 
machine. 
Table 38. Trial #2. Quantitative composition of test mixtures 
Components 
Test #1 Test #2 Test #3 
Amounts 
Nicorandil 10% 10% 10% 
GalenIQ 721
®
 
(Isomalt) 
80% 76% 72% 
Starch 1500
®
 PG LM 
(Pre-gelelatinized starch) 
5% 5% 5% 
Vivastar PSF
®
 
(Sodium starch glycolate, low moisture) 
0% 4% 8% 
Dub MicroLub 50 
(Stearic acid, micronized) 
5% 5% 5% 
Total 100% 100% 100% 
The results of the pharmacotechnical properties characterization of the powder 
blend mixture are summarized in Table 39. 
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Table 39. Trial #2. Mixture flowability and mixture characterization results 
Test #1 #2 #3 
Apparent Volume 
Bulk density 
0.539 g/mℓ 
(+ 0.05) 
0.532 g/mℓ 
(+ 0.05) 
0.517 g/mℓ 
(+ 0.05) 
Tapped density 
0.636 g/mℓ 
(+ 0.02) 
0.642 g/mℓ 
(+ 0.02) 
0.671 g/mℓ 
(+ 0.02) 
Hausner ratio 1.18 1.21 1.30 
Compressibility 
Index 
15.22% 17.20% 22.90% 
Comments (Ph. Eur. 2.9.36) Good Fair Passable 
Flowability 
(s/100g) 
Nozzle  
25mm:  3.3 s 3.4 s 3.0 s 
15mm:  11.7 s 15.1 s 13.1 s 
10mm:  NP NP NP 
Comments 
25mm:  
Free and steady 
flow 
Free and steady 
flow 
Free and steady 
flow 
15mm:  Irregular flow 
Highly irregular 
flow. Requires aid 
to start flow 
Highly irregular 
flow. 
10mm:  Does not flow Does not flow Does not flow 
NP: Not performed 
The powder blend with best results seems to be the one that does not contain SSG-
PSF. 
Before advancing to compression trials powder blend was tested for content 
homogeneity. Samples were collected from four different points on the powder blend 
approximately at the same distance from each other and prepared according to the 
sample preparation method described in the Materials and Methods section, results are 
summarized in Table 40. 
Table 40. Trial #2. Blend homogeneity 
Sample position min max Average RSD 
Assay 
Test #1 99.84% 102.44% 100.71% 1.17% 
Test #2 98.92% 101.84% 100.96% 1.36% 
Test #3 100.17% 102.60% 101.71% 1.05% 
Results suggest that all powder blends present acceptable homogeneity according 
to the value of the relative standard deviation between the four results (< 2%). 
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Tablets were produced with two different compression forces: setting #125 and #105 
to evaluate target, low and high tablet hardness. Results from tablet characterization are 
presented on Table XX: Trial #2 10mg characterization. Characterization tests were 
performed according to the methodology described in the Materials and Methods section, 
results are summarized in Table 41. 
Table 41. Trial #2. 10mg tablets characterization results 
Mixture number Test #1 Test #2 Test #3 Test #1 Test #2 Test #3 
Compression setting #125 #105 
Hardness 60 N 55 N 29 N 100 N 97 N 85 N 
Friability 0.37% 0.39% 0.40% 0.22% 0.23% 0.36% 
Dissolution (% at 30min) 100.8% 99.7% 100.7% 101.2% 98.5% 99.1% 
Disintegration 
Time (n=6) 
First: 
(mm:ss) 
3:30 3:27 2:40 4:05 4:00 2:40 
Last: 
(mm:ss) 
4:15 3:40 3:10 4:25 4:20 3:10 
Tablet weight 
(n=10) 
Average 99.8 100.5 98.6 100.9 99.5 99.82 
min 97.3 99.5 97.6 98.0 97.9 97.10 
max 102.3 101.3 99.3 102.5 101.2 102.7 
RSD 1.35% 0.62% 0.61% 1.47% 1.28% 2.10 
Tablet 
thickness 
(n=10) 
(mm) 2.59 2.62 2.62 2.51 2.50 2.51 
RSD (%) 0.97% 0.49% 0.39% 1.44% 0.76% 0.75% 
When compared with trial #1, tablets without SSG-PSF (test mixture #1) have higher 
hardness for the same compression force used. The effect on disintegration times when 
SSG PSF increases is evident and it can be concluded that this excipients is accelerating 
as expected the disintegration time.  
Reducing starch from 10% to 5% (from trial #1 to trial #2) seems to produce tablets 
with higher hardness for the same compression force applied. 
On Figure 28 and Figure 29 dissolution profiles are shown and compared with the 
RP. 
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Figure 28. Trial #2. Dissolution profiles of tablets from mixtures 1, 2 and 3 
 
Figure 29. Trial #2. Dissolution profiles of tablets from mixture 1 and RP 
When comparing the dissolution profiles it is possible to observe that tablets 
produced from trial #2 mixture are similar to the dissolution profile of both RP batches 
(Figure 29) and tablets produced from mixture #2 and #3 show slower dissolution rates. 
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2.2.3. Trial #3 
Aim: The purpose of trial #3 was to produce a powder blend using a milling step to 
promote optimal blend homogeneity and to produce and characterize tablet performance. 
During DS characterization it was noticed that bulk Nicorandil presented large, soft and 
sticky agglomerates. Previous trials confirmed that Nicorandil will hardly blend with 
excipients without the use of a mechanical process. Even in a smaller scale, 
agglomeration is present and it is possible to observe small and hard grain like 
agglomerates that would unlikely be scattered by simple dry blending operations. 
Since it became necessary to scatter these agglomerations and microscopic 
aggregates, a milling step was introduced in the manufacturing process. As already 
suggested by pre formulation tests a milling seems to induce less damage on Nicorandil 
crystalline structure than the oscillating bar sieving process which causes more friction 
(Table 21). 
Manufacturing process: The selected manufacturing process considers the 
production of one 500g powder blend using a dry blend process for direct compression. 
Blending operation was done using a double cone blender. The first raw material to be 
added to the bin is Isomalt (10%), next Nicorandil followed by Starch 1500 PG LM grade 
to promote an intimate contact by starch particles. This sequence allows a geometric 
dilution of Nicorandil. This pre-blend was mixed and afterwards the remaining amount of 
Isomalt was added followed by another mixing step. By last, the mixture can be lubricated 
with stearic acid 50 micronized previously diluted with two parts of the mixture and hand 
sieved through a mesh size of 0,5mm. Blend homogeneity was assessed by collecting 4 
samples from approximately equidistant points on the bin using a thief probe in the pre-
blend (before lubrication) an in the final blend. Tablets were produced in an 8 stations lab 
scale Ronchi® automatic compressing machine. 
The composition of the mixture is described on Table 42. 
Table 42. Trial #3. Qualitative composition 
Components Quantitative composition 
Nicorandil 50g 10% 
GalenIQ 721
®
 
(Isomalt) 
375g 75% 
Starch 1500
®
 PG LM 
(Pre-gelelatinized starch) 
5g 10% 
Dub MicroLub 50 
(Stearic acid, micronized) 
2.5g 5% 
Total 500g 100% 
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An optimal blending process can be achieve by testing different blend times and 
sampling powder blend to assess content homogeneity. 
The first blending operation was done in 5 minutes intervals until 15 minutes total 
blending time was reached. At each interval the mixture was inspected for the existence of 
lumps or aggregates. 
The same procedure was repeated after the milling step where different rotor 
speeds were tested. Two additional blending steps following a geometric dilution 
procedure were tested. At this stage, in both steps after milling a mixture homogeneity 
was performed. Lubrication time was also tested with different blending times and at the 
end mixture homogeneity, flow properties, particle size distribution, density and water 
content was determined. 
The tablets obtained from this mixture were also studied regarding physical 
properties and dissolution. 
Manufacturing process sequence, settings, controlling and equipment used are 
described on Table 43: 
Table 43. Trial #3. Process summary table 
Stage Machine/Description Settings Controlling 
Blending 
(Pre Blend) 
Erweka module 
Speed: 34 rpm 
Double cone blender 
Check rotation speed 
Mixing step #1 
5 min 
+ 5 min (total 10min) 
+ 5 min (total 15min) 
Check blending time 
Visual inspection 
Hammerwitt 
Speed: to be defined 
Mesh size: to be 
defined 
Visual inspection 
PSD 
Blending 
(Blend) 
Erweka module 
Speed: 34 rpm 
Double cone blender 
Check rotation speed 
Mixing step #2 
5 min 
+ 5 min (total 10min) 
+ 5 min (total 15min) 
Check blending time 
Mixture homogeneity 
Mixing step #3 
10 min 
+ 10 min (total 20min) 
+ 5 min (total 25min) 
Check blending time 
Mixture homogeneity 
Blending 
(Final Blend) 
Sieve 
(to sieve stearic acid) 
0.500 mm 
Check sieve size and 
integrity 
Erweka module 
Speed: 34 rpm 
Double cone blender 
Check rotation speed 
Mixing step #4 
(lubrication) 
3 min 
+ 2 min (total 5min) 
+ 3 min (total 8min) 
Mixture homogeneity 
Flowability 
Powder density 
PSD 
Compression 
Ronchi 8 station rotary 
press 
Lab scale tableting 
machine 
Main compression: to 
be defined 
Pre-compression: to 
be defined 
Filing: to be defined 
Hardness 
Disintegration time 
Friability 
Dissolution 
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The next flowchart summarizes the manufacturing steps taken. 
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During the initial blending step it was possible to observe larges agglomerates of 
Nicorandil in the powder blend at every 5 minutes interval. At the end of the 15min 
blending time some smaller size agglomerates remained scattered in the powder blend. 
This mixture was milled at different speeds without the use of a mesh. Samples were 
analysed regarding PSD for each speed tested. The results are shown in Figure 30 were it 
is possible to observe the variation on the PSD (micra) with the increase in the milling 
speed (x1000 rotations per minute). 
 
Figure 30. PSD results of milling trials 
Only at higher speeds it is possible to reduce particle aggregates that become 
retained on 1mm sieve (square markers). These aggregates are formed by Nicorandil 
particles and its presence can compromise blend homogeneity. 
Since it is not possible to completely eliminate grain like particles even using 
maximum speed an additional test was performed using this time a mesh size of 0,6mm. 
The results are expressed on Figure 31 using the same representation as in Figure 
30. 
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Figure 31. PSD results of milling trials (with mesh) 
Using a 0,60mm mesh during milling helped to reduce the small Nicorandil 
aggregates even at slower speed (square marker) as is suggested on Figure 31. To this 
milled powder blend Isomalt was added and blended in two steps. This action is done to 
geometrically dilute the initial powder blend according to the manufacturing process 
described. The final mixture was characterized. The results are described on Table 44. 
Table 44. Trial #3. Mixture characterization results 
Test Pre blend Final blend 
Density 
Bulk 0,583 0,570 
Tapped 0,757 0,735 
Hausner 
Ratio 
1,30 1,29 
Compressibility 
Index 
22,92 22,4 
Evaluation Passable Passable 
Flowability 
(Time (s) / 
100gr) 
Nozzle (mm) 25 15 10 25 15 10 
Average (s) 6,5 16,5 NP 6,2 14,5 NP 
St. Dev (s) 0,10 3,42 NP 0,10 3,20 NP 
RSD (%) 1,55% 20,72% NP 1,30% 18,50% NP 
Powder blend presents a passable flow characteristic. Flow through hopper (25mm) 
was constant and steady although when using a 15mm hopper flow was more difficult and 
irregular. When 10mm hopper was used powder did not flow. 
Final mixture particle size distribution by analytical sieving was determined (Figure 
32. 
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Figure 32. Trial #3. Mixture particle size distribution 
This powder blend is characterized by a low particle size with 50% of the particles 
bellow 182micra. 
Blend homogeneity was determined using the in house UV method as described in 
Materials and Methods section. Powder blend was sampled in six points directly into a 
200mℓ volumetric flask according to the diagram on Figure 33. 
 
Figure 33. Trial #3. Mixture sampling diagram 
Each sampling point was measured 4 times. Average and relative standard 
deviation results are summarized in Table 45. 
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Table 45. Trial #3. Mixture homogeneity results 
Stage Time Assay RSD 
Blending step 
#2 
5 min 100.45% 2.64% 
10 min 100.86% 1.30% 
15 min 100.58% 0.98% 
Blending step 
#3 
10 min 99.59% 3.35% 
20 min 101.06% 2.09% 
25 min 99.01% 1.20% 
Final mixture 
3 min 101.19% 1.58% 
5 min 101.56% 0.96% 
8 min 100.16% 0.88% 
Results suggest that homogeneity improves with longer processing times judging by 
the results of relative standard deviation. Lubrication step does not seem to promote de-
mixing with longer blending times. 
The final powder sampled was compressed into 10mg tablets using different 
compression forces. Characterization results are summarized on Table 46. 
Table 46. Trial #3. Tablets characterization results 
Compression setting #105 #115 #125 #135 
Weight (n=10) 100mg 100mg 100mg 100mg 
Hardness 61N 45 N 40 N 18 N 
Disintegration 
time 
First 3min 43s 
4min 15s 
2min 48s 
3min 21s 
3min 30s 
3min 57s 
2min 19s 
3min 16s Last 
Friability 0.23% 0.38% 0.41% 0.59% 
Dissolution (%) 
96.9% 
(0.62%) 
Not performed 
100.5% 
(1.08%) 
Not performed 
Compression setting #125 and #105 produced tablets with an average of 40N and 
61N respectively which were used for a dissolution test (Figure 34). 
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Figure 34. Trial #3. 61N and 40N tablets dissolution test 
Considering the results obtained in this trial, the process parameters included on 
Table 47 will be tested on an increase powder blend amount. 
Table 47. Manufacturing parameters to be tested on trial #4 
Stage Machine/Description Settings 
Blending 
(Pre Blend) 
Erweka module 
Speed: 34 rpm 
Double cone blender 
Mixing step #1 10min 
Hammerwitt 
Speed: to be defined 
Mesh size: to be defined 
Blending 
(Blend) 
Erweka module 
Speed: 34 rpm 
Double cone blender 
Mixing step #2 10min 
Mixing step #3 15min 
Blending 
(Final Blend) 
Sieving step 
(to sieve stearic acid) 
0.500 mm 
Erweka module 
Speed: 34 rpm 
Double cone blender 
Mixing step #4 
(lubrication) 
5min 
Compression 
Ronchi 8 station rotary press 
Lab scale tableting machine 
Main compression: to be defined 
Pre-compression: to be defined 
Filing: to be defined 
Setting for milling and compression force will be defined at the end of Trial #4, 
depending on the outcome. 
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2.2.4. Trial #4 
Aim: The purpose of trial #4 was to scale up the powder blend up to 3kg following 
the same composition and manufacturing process as described in trial #3 to evaluate, on 
a larger scale the blending process and the finished product characteristics. Additionally it 
was intended to define the final manufacturing process and controlling as well as to 
manufacture enough samples to perform a short term stability study of 3 months. 
Manufacturing process: The selected manufacturing process considers the 
production of one 3kg powder blend using a dry blend process for direct compression. 
Blending operation was done using a double cone blender. The first raw material to be 
added to the bin is Isomalt (10%), next Nicorandil followed by Starch 1500 PG LM grade 
to promote an intimate contact by Starch particles. This sequence allows a geometric 
dilution of Nicorandil. This pre-blend was mixed and milled (Hammerwitt®) at 30k rpm/min 
using a 0,60mm mesh size. After the milling step the remaining amount of Isomalt was 
added followed by another mixing step. By last, the mixture can be lubricated with stearic 
acid 50 micronized previously diluted with two parts of the mixture and hand sieved 
through a mesh size of 0,5mm. 
Blend homogeneity was assessed by collecting 10 samples from approximately 
equidistant points on the bin using a thief probe. Mixture homogeneity was assessed 
before lubrication (pre-blend) and again the final blend (after lubrication), which is a 
procedure that allows to confirm that the blending time of the lubricant excipient is not 
promoting de-mixture, which is a common phenomenon when lubricants are over blended 
with the mixture. 
Tablets were produced in an 8 stations lab scale Ronchi® automatic compressing 
machine. 
Table 48 shows the formulation qualitative and quantitative composition. 
Table 48. Trial #4. Quantitative composition 
Components Quantitative composition 
Nicorandil 300g 10% 
GalenIQ 721
®
 
(Isomalt) 
2250g 75% 
Starch 1500
®
 PG LM 
(Pre-gelelatinized starch) 
300g 10% 
Dub MicroLub 50 
(Stearic acid, micronized) 
150g 5% 
Total 3000g 100% 
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The final manufacturing process, settings and controlling is described in the next 
flowchart. 
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Blend homogeneity was determined by in house UV method as described in 
Materials and Methods section. Sampling was done directly into volumetric flasks using a 
thief probe with a 0.6cm3 cell. Sampling diagram which represents the sampling positions 
is described in Figure 35. Each sample was measured three times at 262nm UV. Average 
absorbance was calculated considering the sample weight against a standard solution 
and expressed in percentage of drug substance dissolved. 
 
 
Figure 35. Trial #4. Mixture sampling diagram 
Results from mixture homogeneity are summarized in Table 49. 
Table 49. Trial #4. Mixture homogeneity results 
Sample Content (%) 
T1 101.59% 
T2 101.24% 
T3 101.56% 
T4 101.20% 
T5 98.99% 
M6 102.30% 
M7 99.84% 
M8 101.20% 
B9 99.50% 
B10 99.30% 
Average 100.67% 
SD 1.15 
RSD 1.14% 
Results indicate that the blending process is adequate to obtain a homogeneous 
mixture and that despite the batch size the blend remains homogeneous.  
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The 3kg powder blend was used to produce 10mg tablets with different compression 
force setting (#120, #130, #140 and #150) which characterisation results are described on 
Table 50. 
Table 50. Trial #4. Tablets characterisation results 
Compression setting #120 #130 #140 #150 
Weight (mg) n=20 
(RSD) 
99.9mg 
(0.67%) 
100.9mg 
(0.90%) 
100.2mg 
(0.70%) 
99.0mg 
(0.80%) 
Average hardness (n=20) 64N (+ 3N) 56N (+ 3N) 26N (+ 7N) 13N (+ 3N) 
Disintegration time 
First 3min 52s 
4min 25s 
3min 45s 
4min 02s 
2min 20s 
3min 02s 
1min 16s 
2min 40s Last 
Friability 0.46% 0.45% 0.61% 0.67% 
Dissolution 30min (%) 
(RSD %) 
100.6% 
(1.06%) 
Not performed 
100.5% 
(1.44%) 
Not performed 
Water content (n=2) 
(representative sample) 
2.1% (+ 0.1%) 
These results demonstrate that the compression process produces tablets with a 
good weight homogeneity, which is also an indication of a uniform die filling process. 
Tablets with four different hardness tablets were produced to evaluate the effect of 
different compression forces and to determine which compression setting was necessary 
to produce tablets with hardness approximate to the target. Setting #150 seems to result 
in tablets with very low hardness that showed erosion of the edges during friability test. 
Compression force setting #140 produced tablets with an average of 26N that seem to 
have adequate properties and were used for dissolution testing. For comparison purposes 
tablets produced with maximum hardness were also used for dissolution test, tablets with 
average hardness of 56N and 13N were not used for dissolution test. 
Uniformity of dosage units was assessed to further demonstrate that the blending 
and compression process are adequate to produce tablets with the defined target profile. 
Tablets were sampled (n=10) along the tableting process (beginning, middle and end of 
process) using the #140 compression force setting. Results are shown on Table 51. 
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Table 51. Trial #4. Uniformity of dosage unit 
Sample Assay (%) 
#1 97.99% 
#2 97.41% 
#3 99.52% 
#4 99.45% 
#5 99.38% 
#6 99.26% 
#7 98.40% 
#8 98.50% 
#9 102.10% 
#10 98.86% 
Average 99.09% 
RSD 1.28% 
Acceptance value 3.0 
Low relative standard deviation between samples and an acceptance value (Ph. 
Eur. 2.9.40) AV=3, indicate that tablets present an assay variability complying with 
pharmacopoeial standards and that tableting process is not inducing any particle 
segregation or de-mixing during die filling. 
Dissolution profile of 10mg tablets were tested in two strengths, 26N and 64N. 
Results are shown on Figure 36. 
 
Figure 36. Trial #4. 64N and 26N tablets and RP dissolution profile  
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3. Discussion 
This section addresses the development work final risk assessment and the results 
of the test product characterization and its comparison with the reference product. 
Additionally, the stability results after the 3 months short term stability study are also 
discussed. 
3.1. Final Risk Assessment 
3.1.1. Drug Substance 
Considering the results obtained during pre-formulation and formulations trials the 
reviewed risk assessment can be found on Table 52, Table 53 and Table 54. 
Acceptable data has been gathered supporting the reviewed risk assessment for the 
drug substance and excipients attributes (formulation variables). Based on the results of 
pre-formulation it was possible to identify critical factors that can monitored and controlled. 
Although, due to the nature of the DS, there are still some unavoidable risks when using a 
drug substance such as Nicorandil (Table 52). 
Excipients used were adequate to obtain a drug product complying with target 
critical quality attributes, although, further stability results are necessary to further 
evaluate the effect of total water content on the test formulation. The source of water 
content seems to be Starch, so the risk evaluation has been updated accordingly (Table 
53). 
During formulation development, the high risk steps have been evaluated and 
updated. Results suggest that it is possible to control process variables to reduce the risk 
associated (Table 54). 
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Table 52. Final risk assessment on DS attributes 
Drug Product 
CQA’s 
Rationale 
Risk 
evaluation 
DS Attributes: Particle Size Distribution 
Assay 
Throughout the develppment work all assay results complied with expected results. Milling trials 
performed on powder mixtures also did not indicate any assay problems. The risk was reduced from 
medium to low. 
Low 
Degradation 
Products 
There were no indication that PSD could negatively affect DS stability. The risk was reduced from 
medium to low. 
Low 
Dissolution 
All dissolution tests performed showed fast dissolution profile. These results support the low risk 
assignment relating dissolution and particle size distribution. The risk was reduced from medium to 
low. 
Low 
Water content 
DS PSD is an intrinsic phsical property which is not related with the water content of the drug 
product. During development work described no evidences have been found that could relate this 
two parameters. The risk was unchanged. 
Low 
Hardness 
PSD of the DS does not seem to have relevant influence on tablet hardness results, mainly due to 
the remaning components of the formulatin which characteristics have much more weight on the 
comapction properties of the powder blend. The risk was unchanged. 
Low 
DS Attributes: Solubility 
Assay 
Throughout the develppment work all assay results complied with expected results. Sink conditions 
have been demosntrated to comply with pharmacopoeial standards. The risk was unchanged. 
Low 
Degradation 
Products 
There is no indication that solubility can negatively affect DS stability. The risk was unchanged. Low 
Dissolution 
All dissolution tests performed showed fast dissolution profile. These results support the low risk 
assingnment relating dissolution and solubility. The risk was reduced from medium to low. 
Low 
Water content There is no relationship between solubility and water content. The risk was unchanged. Low 
Hardness 
Solubility of the DS does not seem to have relevant influence on tablet hardness results. The risk 
was unchanged. 
Low 
DS Attributes: Chemical Stability 
Assay Nicorandil stability is a major issue when formulating a drug product with this molecule. A carefull 
monitoring of raw materials properties, manufacturing process and packaging is necessary to avoid 
excessive exposure of the DS and drug product to conditions that can promote degradation 
reactions. The risk was reduced from high to medium. 
Medium 
Degradation 
Products 
Dissolution 
Even at accelerated conditions the Nicorandil tablets maintain a fast dissolution behaviour. 
Nevertheless additional stability data seems to be necessary to further investigate dissolution 
performance. The risk was reduced from high to low. 
Low 
Water content 
Water content and relative humidity must be carefully monitored to avoid excessive exposure to 
water. The risk was reduced from high to medium. 
Medium 
Hardness 
Tablet hardness must be kept at a minimum possible to reduce the a negative effcet on crystalline 
structure of Nicorandil. The risk was reduced from high to medium. 
Medium 
DS Attributes: Flowability 
Assay 
Flow properties do not seem to be influencing assay results. The risk was reduced from medium to 
low. 
Low 
Degradation 
Products 
DS flow properties are not directly related to drug product impurity level. The risk was unchanged. Low 
Dissolution 
Flowability of the DS has been properly compensated during formulation development and had no 
visible impact on dissoloution profile. The risk was reduced from medium to low. 
Low 
Water content DS flow properties are not directly related to drug product water content. The risk was unchanged. Low 
Hardness 
DS flow properties are not directly related to tablet hardness or to an extent that requires further 
evaluation. The risk was unchanged. 
Low 
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3.1.2. Excipients 
Table 53. Final risk assessment on excipients attributes 
Formulation 
Variables 
Drug Product 
CQA’s 
Rationale 
Risk 
evaluation 
GalenIQ 721® 
(Isomalt) 
Assay 
Isomalt seems to be an adequate component (diluent) on the 
formulation. Results do not seem to indicate any negative efefct on drug 
product CQA’s. All paramters risk has been reduced to Low level. 
Low 
Degradation 
Products 
Low 
Dissolution Low 
Water content Low 
Hardness Low 
Starch 1500® 
LM 
Assay 
This excipient does not seem influence the assay results. The risk was 
reduced from medium to low. 
Low 
Degradation 
Products 
A low moisture grade was used on the formulation although it seems 
that additional studies might be necessary to evaluate the effect of 
starch on the proposed concentrations on the formulation. The risk has 
been increased from low to medium. 
Medium 
Dissolution 
Despite the binding / disintegrant properties of starch it seems that 
additional studies might be necessary to evaluate the effect of starch on 
the proposed concentrations on the dissolution behaviour on the long 
term stability. The risk was unchanged. 
Medium 
Water content 
A low moisture grade was used on the formulation although it seems 
that additional studies might be necessary to evaluate the effect of 
starch on the porposed concentrations on the formulation. The risk was 
unchanged. 
Medium 
Hardness 
This componet does not seem to negatively influence tablet hardness. 
The risk was reduced from medium to low. 
Low 
Stearic acid 
50 
Assay 
Stearic acid does not seem to have a negative effecto on any of the 
CQA’s of the drug product. All paramters risk has been reduced to Low 
level. 
Low 
Degradation 
Products 
Low 
Dissolution Low 
Water content Low 
Hardness Low 
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3.1.3. Manufacturing process 
Table 54. Final risk assessment on manufacturing process 
Process step Assessment Control strategy 
Risk 
evaluation 
Blending 
Loading 
components 
and DS sieving. 
Due to PSD of Nicorandil this step should be done 
with the DS previously sieved gently by hand through 
a 1mm mesh size to scatter larger aggregates. 
Nicorandil should be added in between Starch and 
SSG-PSF grade to promote a better DS distribution. 
A simple visual inspection is 
adequate to verify that most of DS 
aggregates have been scattered. 
No impact on final blend 
homogeneity is expected. 
Low 
5 min. bending 
step 
Blending step introduced to prepare the pre-mixture 
for the milling step. 
A simple visual inspection is 
adequate to verify that the 
resulting blend appears to have 
the DS scattered. No impact on 
final blend homogeneity is 
expected. 
Low 
Milling step 
Milling step is done to guarantee that the DS can be 
properly blended with the other components. In the 
settings used. 
Milling speed: 30 to 60rpm 
(x1000). 
Mesh size: 0,60mm. 
Low 
Addition of 
Isomalt and 30 
min blending 
step 
Blending with Isomalt should be done in two steps to 
dilute the blend geometrically. Dilution and blending 
time are critically related to DS homogeneity in the 
blend. 
Mixture homogeneity must be 
performed before lubrication step 
to verify DS homogeneity and the 
need to additional blending time. 
Low 
Addition of 
lubricant and 
5min blending 
step 
Lubricants are normally used in low amounts and are 
associated with de-mixing if over blended. To promote 
an adequate lubricant distribution this should be 
sieved by hand through a 0,710mm mesh size 
partially diluted with a blend portion. 
Mixture homogeneity must be 
performed to verify DS 
homogeneity. 
Low 
Final mixture 
Powder blend will be used to produce 10mg tablets. 
Blend characteristics must be verified before tableting. 
Mixture homogeneity must be 
performed to verify DS 
homogeneity. Additionaly, blend 
characterization must be 
performed. 
Low 
Tableting 
Compression 
force 
Compression force (either main compression and pre-
compression) can influence product performance 
since it is related to critical quality attributes such as 
resistance to breaking, disintegration, friability and 
dissolution profile. Additionaly, compression force has 
been associated also with increase in product 
instability. 
Compression forces must be low 
enough to obtain tablets with 
desirable characteristics. 
Low 
Tableting speed Tableting was done considering only one speed. Check tableting speed. Low 
Tablet 
characteristics 
Tablets characteristics are an indication of product 
quality and overall compression process efficiency. 
Characteristics should meet target product profile 
defined initially. 
IPC should be done at regular 
intervals during manufacturing 
process. 
Low 
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3.2. Similarity assessment 
To assess the influence of stability conditions and time on the dissolution 
performance, results were statistically evaluated at different times (10, 15 and 30min). 
Statistical analysis used is described in the Materials and Methods section. Dissolution 
profiles were plotted by comparing tablets with the same hardness along the time and also 
between different conditions against two batches of the RP, although for the purpose of 
evaluation and to detect differences of performance between the two hardness statistical 
evaluation considers all samples. 
On Figure 37, the dissolution profiles of 30N samples stored at 25ºC/60% RH and 
40ºC/75% RH during the 3 months stability study and two batches of the RP are shown. 
 
Figure 37. Average dissolution profiles of 30N tablets vs RP 
On Figure 38, the dissolution profiles of 60N samples stored at 25ºC/60% RH and 
40ºC/75% RH during the 3 months stability study and two batches of the RP are shown. 
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Figure 38. Average dissolution profiles of 60N tablets vs RP 
Evaluation of the dissolution profiles of 30N tablets samples show that dissolution 
rate decreased in the 40ºC/75% RH after 1 month (T1M) and 3 months (T3M) and the 
dissolution profile in these two conditions is very approximate. As for the 25ºC/60% RH 
condition, profiles seem to be also very similar and almost match the initial time (T0). 
Considering that the product still exhibits a fast dissolution profile it might be possible to 
assume that all DS is released and solubilized before the stomach emptying time (30min). 
Evaluation of the dissolution profiles of 60N tablets samples show that dissolution 
rate decreased after 1 month (T1M) in both degradation conditions. After 3 months (T3M) 
at 40ºC/75% RH the profile is equivalent to the one at T1M in the same condition. 
Nevertheless, the product still shows a fast dissolution profile so it might be possible to 
assume that all DS is released and solubilized before the stomach emptying time (30min) 
even at the end of the short term stability study. 
To evaluate similarity of dissolution profiles a statistical comparison of the results of 
dissolved amounts at 10, 15 and 30min was done. These results allow to conclude that 
there are some statistical differences in the comparison times although in terms of 
pharmaceutical performance these differences are not likely to have an impact on the 
biological availability of the DS in the bloodstream. 
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Considering that the disintegration times are under 5min and to discard the 
variability induced by this physical phenomenon, dissolution profiles were compared at 
10min, 15min and 30min. At 10min, tablets are fully disintegrated so we assume that 
performance is now dictated by dissolution behavior only, which is influenced, on its turn, 
by the solubility of the DS. Dissolution at 15 minutes was also used for comparison 
purposes to evaluate differences for the RP which demonstrates a very fast dissolution 
profile (87). 
At 10 minutes the samples can be divided in four groups with statistical differences 
between them (subsets 1 to 4) as described in Table 55. To evaluate these differences a 
box plot representation is shown, where it is possible to observe that all samples at 
40ºC/75% RH stand aside the remaining samples (Figure 39). When comparing with both 
batches of the RP it is possible to conclude that dissolution data at 10min is statistically 
similar to the 30N tablet values in the 25ºC/60% RH in all time points, while the remaining 
samples present significate differences from the RP. 
 
Figure 39. Box plot of dissolution results at 10min 30N and 60N vs RP 
Table 55. 10min dissolution Tukey HSD results 
Samples 
Subset for alpha = 0.05 
1 2 3 4 
Lt#2 60N T1M 40_75 65.0897    
Lt#2 30N T3M 40_75 69.2589 69.2589   
Lt#2 60N T3M 40_75 69.5887 69.5887   
Lt#2 30N T1M 40_75  70.7537   
Lt#2 60N T1M 25_60   81.8686  
Lt#2 60N T0M   84.6200  
Lt#2 60N T3M 25_60   85.5925  
Lt#2 30N T1M 25_60    90.6523 
Lt#2 30N T3M 25_60    91.5079 
Lt#2 30N T0M    93.2803 
RP 54599 20    94.3667 
RP 54372 34    95.0167 
Significance 0.063 0.994 0.233 0.081 
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The next critical point analyzed was at 15minutes. In this time the samples can be 
divided in five groups with statistical differences between them (subsets 1 to 5) as 
described in Table 56, although more samples are statistically similar to the RP. To 
evaluate these differences a box plot representation is shown, where it is possible to 
observe that all samples at 40ºC/75% RH still stand aside the remaining samples (Figure 
40). When comparing with both batches of the RP it is possible to conclude that 
dissolution data at 15min is statistically similar to the 30N and 60N tablet values in the 
condition 25ºC/60% RH in all time points, while the remaining samples present significate 
differences from the RP. This suggest that the differences caused in the dissolution profile 
by increased hardness are fading away. 
 
Figure 40. Box plot of dissolution results at 15min 30N and 60N vs RP 
Table 56. 15min dissolution Tukey HSD results 
Samples 
Subset for alpha = 0.05 
1 2 3 4 5 
Lt#2 60N T1M 40_75 77.9595     
Lt#2 30N T3M 40_75 
 
82.1284    
Lt#2 60N T3M 40_75 
 
83.9882 83.9882   
Lt#2 30N T1M 40_75  
 
85.9201 92.3188  
Lt#2 60N T1M 25_60   
 
94.4833 94.4833 
Lt#2 60N T0M   
 
94.9304 94.9304 
Lt#2 60N T3M 25_60   
 
95.5000 95.5000 
Lt#2 30N T1M 25_60    95.5478 95.5478 
Lt#2 30N T3M 25_60    
 
96.9107 
Lt#2 30N T0M    
 
97.7784 
RP 54599 20    
 
98.0175 
RP 54372 34     99.0234 
Significance 1.000 0.872 0.842 0.165 0.087 
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The last time point analyzed was at 30minutes. In this time the samples can be 
divided in three groups with statistical differences between them (subsets 1 to 3) as 
described in Table 57. 30min dissolution Tukey HSD resultsThe graphic representation of 
these differences is shown on a box plot, where it is possible to observe that RP samples 
are different from all other samples except for 30N tablets at 3 months in the 40ºC/75% 
RH samples. 
This is due to the fact that the RP does not reach 100% dissolution at 30 minutes 
dissolution time and instead has 95% (Figure 41). 
 
Figure 41. Box plot of dissolution results at 30min 30N and 60N vs RP 
Table 57. 30min dissolution Tukey HSD results 
Samples 
Subset for alpha = 0.05 
1 2 3 
RP 54599 20 94.4833   
Lt#2 30N T3M 40_75 95.4480   
RP 54372 34 95.5333   
Lt#2 60N T3M 40_75 97.1925 97.1925  
Lt#2 60N T1M 40_75  99.0176 99.0176 
Lt#2 30N T1M 40_75  99.1605 99.1605 
Lt#2 30N T3M 25_60  99.9335 99.9335 
Lt#2 60N T1M 25_60  99.9547 99.9547 
Lt#2 60N T3M 25_60   100.3397 
Lt#2 30N T0M   100.4654 
Lt#2 60N T0M   100.6020 
Lt#2 30N T1M 25_60   100.9409 
Significance. 0.141 0.124 0.615 
As mentioned before these differences have less importance since all dissolution 
profiles are still very fast which means that DS is completely dissolved before 30min. In 
practical terms, these results suggest that the bioequivalence between test tablets should 
be the same as the RP. 
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3.3. Stability assessment 
Concerning the short term stability the selected tests to evaluate product stability 
and pharmaceutical performance were: DS assay, impurity assessment (single known and 
total), dissolution, disintegration time, hardness and water content (KF). Table 58 
summarizes the results obtained at each time and in each condition. 
Dissolution and Water Content (KF) were not performed for the intermediate 
condition at 1 month and 3 months since the information gathered from these two points 
was not considered necessary taking into account the drug product performance 
characteristics. 
It is assumed that long term (25ºC/60%RH) and accelerated conditions 
(40ºC/75%RH) are representative of drug product stability and the results obtained at 
those time points can be used to assess performance in intermediate conditions, 
according to international guidelines on stability (16) and matrixing and bracketing (88). 
In case of any odd results in disintegration times and water content at extreme 
conditions, intermediate samples would be analyzed. 
Table 58. Tests performed during stability study 
Tests to 
perform 
T0 
T1M T3M 
25ºC/60%RH 30ºC/65%RH 40ºC/75%RH 25ºC/60%RH 30ºC/65%RH 40ºC/75%RH 
Assay Yes Yes Yes Yes Yes Yes Yes 
Impurities Yes Yes Yes Yes Yes Yes Yes 
Disintegration Yes Yes Yes Yes Yes Yes Yes 
Dissolution Yes Yes No Yes Yes No Yes 
Water content Yes Yes No Yes Yes No Yes 
Resistance to 
crushing 
Yes Yes Yes Yes Yes Yes Yes 
Stability testing was performed on 10mg Nicorandil tablets packed in Alu-Alu blister. 
This packaging material is a special designed multilayered ultra-high barrier laminate film 
with a polyolefin sealant layer incorporating moisture scavenging agent / desiccant in the 
inner layer of the aluminum foil. Tablets in the blister are therefore in contact with a 
surface that adsorbs moisture from the air inside the pocket. 
Table 59 and Table 60 presents the overall results for 30N and 60N test product, 
correspondingly. Parameters evaluated were assay, known and unknown impurities, total 
impurities, disintegration, dissolution, water content (KF) and tablet hardness. 
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Table 59. Summary of stability results of test formulation (30N) 
Parameter 
Testing point (month) / results 
T0 T1M T3M 
RP 30N 
25ºC/60% RH 30ºC/65% RH 40ºC/75% RH 25ºC/60% RH 30ºC/65% RH 40ºC/75% RH 
RP 30N RP 30N RP 30N RP 30N RP 30N RP 30N 
Assay 96.9% 101.05% 98.7% 101.21% 96.9% 100.25% 88.60% 94.01% 96.3% 100.44% 94.70% 103.81% 85.80% 85.36% 
Nicotinic acid ND ND ND ND ND ND ND < 0.1% ND ND ND ND ≤ 0.1% < 0.1% 
N-(2 hydroxyethyl) 
Nicotinamide 
ND < 0.1% ND < 0.1% ND < 0.1% ≤ 0.1% < 0.1% ND ND ND ND ≤ 0.1% < 0.1% 
Imp A ≤ 0.1% < 0.1% ≤0.1% < 0.1% ≤ 0.1% < 0.1% 0.16% 0.1005% ≤ 0.1% 0.1507% ≤ 0.1% 0.1123% 0.32% 0.0221% 
Imp B 0.20% < 0.1% 0.37% 0.2547% 0.45% 0.3702% 0.68% 1.0113% 0.42% 0.4657% 0.47% 0.5530% 0.53% 1.3454% 
Imp C 0.21% < 0.1% ≤0.1% < 0.1% 0.29% 0.1331% 0.55% 0.6055% 0.26% 0.0331% 0.35% 0.3292% 0.58% 1.1240% 
Nitrate NP 0.0903% NP 0.1348% NP 0.2116% NP 1.2876% NP 0.3833% NP 0.7985% NP 4.2523% 
Single unknown imp. ≤ 0.1% 0.03% ≤0.1% 0.02% ≤ 0.1% 0.03% 0.30% 0.64% ≤ 0.1% 0.07% ≤ 0.1% 0.25% 0.36% 0.68% 
Total impurities 
(except Nitrate) 
0.41% 0.23% 0.37% 0.43% 0.74% 0.67% 1.90% 2.93% 0.68%  0.83% 0.82% 1.35% 2.60% 3.91% 
 
Disintegration 
2min 50s 
3 min 15s 
3min 05s 
3min 30s 
2min 00s 
2min 29s 
3min 10s 
3min 30s 
1min 00s 
1min 18s 
NP 
1min 25s 
1min 42s 
3min 55s 
4min 35s 
1min 10s 
1min 33s 
2min 55s 
3min 45s 
1min 20s 
1min 45s 
3min 59s 
4min 43s 
2min 35s 
2min 56s 
4min 09s 
4min 50s 
Dissolution 98% 100.6% 98% 98.6% 98% NP 97% 97.9% 99% 98.5% 98% NP 95% 93.7% 
Water content (KF) 0.3% 2.1% 0.2% 2.2% 0.2% 2.5% 0.2% 2.8% 0.3% 2.0% 0.3% 2.0% 0.3% 1.9% 
Resistance to 
crushing 
61 N 29N 56 N 30N 66 N 34N 64 N 45N NP 31N NP 37N NP 46N 
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 Table 60. Summary of stability results of test formulation (60N) 
Parameter 
Testing point (month) / results 
T0 T1M T3M 
RP 60N 
25ºC/60% RH 30ºC/65% RH 40ºC/75% RH 25ºC/60% RH 30ºC/65% RH 40ºC/75% RH 
RP 60N RP 60N RP 60N RP 60N RP 60N RP 60N 
Assay 96.9% 99.79% 98.7% 99.02% 96.9% 99.86%% 88.60% 93.56% 96.3% 100.31% 94.70% 98.40% 85.80% 86.26% 
Nicotinic acid ND ND ND ND ND ND ND < 0.1% ND ND ND ND ≤ 0.1% 0.0394% 
N-(2 hydroxyethyl) 
Nicotinamide 
ND < 0.1% ND < 0.1% ND ND ≤ 0.1% < 0.1% ND ND ND ND ≤ 0.1% ND 
Imp A ≤ 0.1% < 0.1% ≤0.1% < 0.1% ≤ 0.1% < 0.1% 0.16% 0.1272% ≤ 0.1% 0.1075% ≤ 0.1% 0.1527% 0.32% 0.2950% 
Imp B 0.20% < 0.1% 0.37% 0.4129% 0.45% 0.5432% 0.68% 1.1412% 0.42% 0.5857% 0.47% 0.5801% 0.53% 1.4509% 
Imp C 0.21% < 0.1% ≤0.1% < 0.1% 0.29% 0.1400 0.55% < 0.1% 0.26% 0.2127% 0.35% 0.2953% 0.58% 0.1149 
Nitrate NP 0.0832% NP 0.0288% NP 0.3123% NP 1.7602 NP 0.4697% NP 0.8717% NP 4.3576% 
Single unknown imp. ≤ 0.1% 0.02% ≤0.1% 0.03% ≤ 0.1% 0.26% 0.30% 0.93% ≤ 0.1% 0.14% ≤ 0.1% 0.27% 0.36% 0.96% 
Total impurities 
(except Nitrate) 
0.41% 0.21% 0.37% 0.62% 0.74% 1.26% 1.90% 3.56% 0.68%  1.11% 0.82% 1.38% 2.60% 3.44% 
 
Disintegration 
2min 50s 
3 min 15s 
3min 30s 
4min 00s 
2min 00s 
2min 29s 
4min 05s 
5min 25s 
1min 00s 
1min 18s 
NP 
1min 30s 
1min 42s 
5min 00s 
5min 40s 
1min 15s 
1min 33s 
4min 15s 
4min 58s 
1min 30s 
1min 45s 
4min 17s 
5min 12s 
2min 45s 
2min 56s 
4min 52s 
5min 03s 
Dissolution 98% 101.4% 98% 100.0% 98% NP 97% 99.0% 99% 101.6% 98% NP 95% 99.0% 
Water content (KF) 0.3% 2.0% 0.2% 2.2% 0.2% 2.1% 0.2% 2.0% 0.3% 2.2% 0.3% 2.0% 0.3% 1.9% 
Resistance to 
crushing 
61 N 52N 56 N 56N 66 N 58N 64 N 70N NP 54N NP 58N NP 73N 
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Test formulation was compared with Nicorandil reference product using a cluster 
analysis technique, or clustering, to compare multiple characteristics that all together can 
be used to describe the drug product in terms of performance and stability. Details on this 
statistical evaluation is described in the Materials and Methods section. 
When evaluating test formulation and the RP results (Table 59 and Table 60) using 
the clustering technique, three types of evaluations were done: the first one used all the 
parameters to evaluate samples and the relationship between them; the second 
evaluation used assay and impurities results only and the third evaluation used the 
impurities results only. 
For each one of these three studies, the evaluation was always the same with the 
generation of only one cluster of data, which is an indication that the results of parameters 
evaluated fall inside one common group where they are assumed as similar, 
independently of the study done. This suggests that results obtained are similar between 
samples and no samples can be described as different from the others at the end of the 3 
months stability study. 
In detail, it is possible to say that in terms of chemical stability and physical 
performance there is not a relevant difference between test formulation and the RP at the 
end of the short term stability study, with the products packed in their primary packaging 
materials. 
On the other hand, the effect of the physical parameters on the performance 
indicators (disintegration times, dissolution water content and resistance to crushing) was 
done using the clustering technique. 
In this case two groups were generated with a clustering classification of “Good”, 
which is an indication of the fitness of the clustering technique (Figure 42). This means 
that using the physical parameters to assess stability, it is possible to obtain two groups of 
results showing significant differences between each other. 
To illustrate the results, the dendogram obtained from the Hierarchical Cluster 
Analysis is shown to elucidate the structure of the clusters Figure 43. 
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Figure 42. Dendogram using Average Linkage Between Groups 
One of the clusters includes all the results related to the RP (Batch A) and the other 
group includes all the results of test formulation (both hardness in all conditions). This 
means that there is a difference of performance between RP and test formulation. 
 
Figure 43. Two cluster analysis summary 
Therefore this analysis suggests that mechanical properties are closely related with 
performance of the composition of the dosage form. The major factor contributing to this 
distinction was the water content (Figure 44). 
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Figure 44. Cluster analysis predictor importance 
On Figure 45, a PXRD analysis of samples after 3 months 40ºC/75% RH is 
presented. It is possible to observe unchanged crystalline structure in 30N and 60N 
samples which is suggestive of less damage to the crystalline structure of higher 
compaction forces during tableting. 
Additionally, it might be possible to assume that the crystalline structure is not 
affected by the higher temperatures and relative humidity levels or that at least they are 
not accelerating the loss of structural integrity. 
 
Figure 45. PXRD analysis after 3 months stability  
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In general terms after the 3 months stability study under the ICH long-term 
(25ºC/60% RH), intermediate (30ºC/65% RH) and accelerated conditions (40ºC/75% RH), 
tablets did not show any alteration of color or aspect, or any surface defects on the 
tablets, which indicates that the finished drug product did not show evidences of physical 
instability during this period. 
The results also suggest that tablet hardness has low impact on chemical stability of 
the drug product, hence formulation components seems to withstand compaction forces 
away from the crystalline structure. 
Overall, the finished product obtained comply with the pharmacopoeial standards 
and enough data has been gathered to support the demonstration of a manufacturing 
process which is adequate to produce a homogeneous mixture suitable to be used to 
produce 10mg Nicorandil tablets by direct compression. 
Regarding stability results and despite the statistical analysis performed an 
extension of the stability study is necessary to gather additional data to evaluate chemical 
stability of the formulation in the long term. 
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1. General conclusions 
The present work described the pre-formulation and formulation development that 
led to the production of 10mg tablets of Nicorandil by direct compression of a 
homogeneous powder blend. The manufacturing process has been demonstrated to be 
able to produce a finished product that presents adequate pharmacotechnical 
characteristics and presents performance characteristics similar to the reference product. 
Nicorandil is highly sensitive to moisture and compaction forces, reaching high 
degradation rates when included in a formulation, which is potentiated at increased 
temperatures.  
A three months short term stability study was performed. Various critical properties 
were assessed and compared to the reference drug product. Evaluation of the results of 
the tested parameters suggest that over the time period of the study, no relevant 
differences in terms of performance and stability between the test product and the 
reference drug product were observed. Despite this analysis, it is clear that due to the 
unstable nature of Nicorandil, ICH accelerated conditions might not be adequate to 
support expiry date of the finished product. Nevertheless, results obtained on the RP also 
indicate the same degradation trend. 
 
The main principles that guided this work were: 
1. Detailed research on available scientific bibliography and patents in order to 
collect information that could be used to optimize the development process. 
2. Definition of a Target Product Profile and the Critical Quality Attributes of the 
drug product to define a development strategy. 
3. Application of a risk management tool during the development process. 
4. Characterization and evaluation of the DS properties before manufacture. 
5. Careful selection and characterization of excipients in order to maximize 
Nicorandil stability. 
6. Selection of adequate process parameters to avoid unnecessary risks linked 
to stability issues of the DS. 
7. Selection of a packaging material constituting an effective barrier against 
moisture. 
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The main achievements of this work can be summarized as the following: 
1. A simple and robust manufacturing process, advantageous for industrial 
production, was designed and it was demonstrated that it allows the 
production of a homogeneous powder blend with adequate flowability and 
compressibility. 
2. Tablets with adequate pharmacotechnical properties and content uniformity 
can be obtained by direct compression of the powder blend. 
3. Formulation seems to protect Nicorandil within an interval of compression 
forces (up to 60 N). 
 
This work also demonstrated that the control strategy applied on the manufacturing 
process was adequate to guarantee the compliance with the quality targets defined. 
It is possible to conclude also that specific control strategies must be followed, such 
as: 
1. The initial properties of the DS must be carefully evaluated. Characteristics such 
as water content, initial impurity levels and PSD must be specified and batches 
not complying with specifications must be rejected for manufacture. 
2. Excipients must be also controlled regarding critical parameters, like water 
content and PSD. 
3. Environmental conditions on manufacture areas must be adjusted, meaning that 
it is recommended that temperature should be kept at least bellow 25ºC and 
relative humidity levels should be as low as possible. 
4. Tablets should have a storage conditions restriction considering the sensitivity of 
Nicorandil. It can be recommended that tablets should be stored bellow 25ºC 
and protected from moisture sources. 
 
From the initial target product profile it is possible to conclude that all requirements 
have been achieved. Table 61 presents the initial TPP and compares each parameter with 
the obtained drug product. 
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Table 61. TPP of test product conclusion 
Parameter TPP Conclusion 
Dosage form and route of 
administration 
Oral tablet 
Pharmaceutical development achieved the 
production of oral tablets. 
Dosage design Immediate release. 
Dissolution results demonstrate an immediate 
release profile. 
Dosage strength 10mg 
Assay and content uniformity demonstrate 
compliance with target strenght. 
Assay 100% w/w label claim. Complies. (Table 59) 
Impurity level 
Known impurities: NMT 0.5% 
Unknown impurities: NMT 0.2% 
Stability has been demonstrated to be 
statistical similar with RP in the end of the 
short term stability study. Accelerated 
conditions revealed to be unadequate for the 
establishment of an expiry date due to out of 
specification results, although the RP exhibited 
the same trend. 
Dissolution 
Very fast dissolution profile 
(Q +5%) > 85%, 15min. 
Dissolution results showed that more than 85% 
of DS is solubilized after 15minutes. (Figure 
36) 
Water content As low as possible. 
Test product exhibits higher water content that 
RP probably due to starch. (Table 50) 
Hardness 
(Resistance to crushing) 
As low as possible maintaining 
minimum compendial standards 
for oral tablet dosage form. 
Proposed specification is  
20N – 60N 
10mg tablets have been produced with 
adequate pharmacotechncal properties. (Table 
50) 
Tablet shape Round, biconvex 
Complies 
Tablet dimensions 7 mm 
Score and embossing None Complies 
Colour and appearance White Complies 
Weight 100mg Complies (Table 50) 
Friability NMT 1.0% w/w Complies (Table 50) 
Disintegration 
Tablets should disintegrate in 
more than 20s and less than 10 
min. 
Complies (Table 50) 
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Specifications for the validation methods are based on in-house limits 
PARAMETER Dissolution UV 
HPLC 
Assay Impurities 
SELECTIVITY 
Excipients 
Interference in the 
blank: NMT 2% 
Excipients 
Interference in the 
Reconstituted 
Formula: NMT 2% 
% interference: 
NMT 2% 
Presence of excipients 
and impurities should not 
interfere with 
Nicorandil peak. 
Interference ≤ 2.0% 
The impurity tested has no 
interference from the DS, other 
impurities and excipients. Peaks 
are completely separated from 
each other and from any 
unknown peaks due to the 
excipients or solvent. 
LINEARITY 
y-intercept: ≤3% 
R ≥ 0.990 
Slope deviation: ≤3% 
y-intercept: ≤3% 
r ≥ 0.997 
Slope deviation: ≤3% 
y-intercept  ≤3% r ≥ 0.997 
Slope deviation ≤3% 
y intercept (%) should be ≤ 10%; 
correlation coefficient should be 
≥ 0,99; 
RSD of slope should be ≤ 3%; 
RSD of the RRF for each 
impurity at selected 
concentration levels used for the 
calculation must be ≤ 7% (intra-
day); 
RSD of the average RRF 
(selected concentration levels 
only) determined for each 
impurity on each day must be ≤ 
10% (inter-day); 
ACCURACY 
Recovery = 95-105% 
Report Confidence 
Interval at 95% 
97% ≤ Recovery ≤ 
103% 
RSD ≤ 3% 
97%≤Recovery ≤103% 
RSD ≤ 3% 
Recovery must be between 90% 
and 110% for all concentrations 
tested; 
The RSD between recovered 
values (at each level) should be 
≤ 7%. 
REPEATABILITY Intra-day RSD ≤ 5% RSD (intra-day) ≤ 3% RSD (intra-day) ≤ 3% 
Recovery (when applicable): 
between 90% and 110%; 
Intra-day RSD must be ≤ 7%; INTERMEDIATE 
PRECISION 
Difference between 
mean dissolution 
results ≤ 5% for time 
points above (or 
equal) 85% 
dissolved 
Difference between 
mean recovery 
values 
≤ 3% 
Difference between mean 
assay values ≤ 3% 
SYSTEM 
PRECISION 
RSD ≤ 2% 
RSD (intra-day) ≤ 2% 
RSD (inter-day) ≤ 3% 
RSD (intra-day) ≤ 2% 
RSD (inter-day) ≤ 3% 
RSD intra-day must be ≤ 5.0% 
for the concentration level of 0.1 
and 0.3%; 
RSD intra-day must be ≤ 3.0% 
for the concentration level of 
0.5%. 
Stability 
Standard solution: 
RF deviation 
from t=0 ≤ ±2% 
Sample Solutions: 
RF deviation to 
10min dissolution ≤ 
±2% 
- influence of 
robustness 
parameters variations 
must be minimal; 
- RF deviation from 
standard conditions 
≤±2%; 
- p-value >0.05 
(confidence 
level=95% in t-test 
evaluation) 
RF and RT deviation from 
standard condition ≤ 2%;                  
t-test evaluation (CI 95%); 
evaluation should allow 
the confirmation of peak 
purity (PDA) 
The solutions are considered 
stable if there is no statistically 
significant difference between 
the average values, for a 
confidence level of 95%, or 
when the difference exists, this 
is not higher than 0.1%. 
Filtration 
t-test evaluation and 
RF deviation 
(for each filter) ≤ 
±2%; 
Interference in blank 
solution ≤ ±2% 
There is no influence of the filter 
if the difference is NMT 5% of 
the specification level 
(<>0.025% difference). 
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Statistical evaluation data 
All parameters 
  
Assay and impurities 
  
Impurities only 
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Calculation formulas used 
Mixture homogeneity 
Calculations are done according to the following equation: 
100
2
20
20
200
 %content  Nicorandil  H
T
T
R
R T
W
A
A
C
 
Formula 1. Mixture homogeneity calculation formula 
Legend: 
CR = Concentration of Nicorandil in reference 
solution (mg/ml) 
WT = Weight of sample (mg) 
AR = Absorbance of Nicorandil reference 
solution 
TH = Theoretical mass of the mixture (mg) 
AT = Absorbance of Nicorandil in test solution 20/2 = dilution of the stock test solution 
Dissolution 
Drug substance dissolved is calculated according to the formula: 
)10**)(
*100*900*)(
 % dissolved Nicorandil
mgSTDvolBlankS
STDweightmlBlankS
absabs
absabs



 
Formula 2. Dissolution calculation formula 
Legend: 
Sabs = Standard absorbance 900ml = Dissolution volume 
Blankabs = Blank absorbance STDvol: Standard volume 
STD weight: Standard weight 10mg: tablet potency 
Acceptance Value (AV) 
Calculation according to the formula: 
 
Formula 3. Acceptance value calculation 
In order to comply with specification for uniformity of dosage units acceptance 
criteria is AV < 15. 
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Legend: 
M: 
if 98.5% < X > 101.5%, then M = X (AV = ks) 
if X < 98.5%, then M = 98.5% (AV = |98.5% - X| + ks) 
if X > 101.5%, then M = 101.5% (AV = |101.5% - X| + ks) 
X: mean of individual contents 
expressed as a percentage of the 
label claim 
K: acceptability constant. For n=10 tablets k= 2.4 S: sample standard deviation 
Content Uniformity 
Content uniformity is calculated according to the following equation: 
100
4
20
_% 
L
V
A
A
C
tabletsCU TT
R
R
 
Formula 4. Content uniformity formula 
Legend: 
CR = Concentration of Nicorandil in reference 
solution (mg/ml) 
20/4 = dilution of the stock test 
solution 
AR = Absorbance of Nicorandil reference 
solution 
VT = Volume of stock test 
solution 
AT = Absorbance of Nicorandil in test solution L = Label claim (mg): 10 (10mg 
tablets) 
Water content 
Water quantification expressed in percentage was calculated according to the 
following formula: 
)(_
)(**100
 (%)Water 
mgsizeSample
KFRVolFactor

 
Formula 5. Water content calculation 
Flowability and powder flow 
The formulas used to calculate Compressibility Index and Hausner ratio are: 
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Formula 6. Compressibility and Hausner ration formulas 
Where V0 and Vf are the unsettled apparent volume and final tapped volume of 
powder respectively. Alternatively, the compressibility index and Hausner ratio may be 
calculated using measured values for bulk density ( bulk) and tapped density ( tapped) as 
follows: 
For the Compressibility Index and the Hausner ratio, the generally accepted scale of 
flowability is the following: 
Compressibility Index (%) Flow Character Hausner Ratio 
 10 Excellent 1.00 – 1.11 
11 – 15 Good 1.12 – 1.18 
16 – 20 Fair 1.19 – 1.25 
21 – 25 Passable 1.26 – 1.34 
26 – 31 Poor 1.35 – 1.45 
32 – 37 Very poor 1.46 – 1.59 
> 38 Very, very poor > 1.60 
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